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Abstract  
Schizophrenia and major depressive disorder (MDD) are disabling, poorly understood 
conditions with inadequate diagnostic and therapeutic technologies. They are characterized 
by clinical and epidemiological heterogeneity between male and female patients. Females 
have a higher prevalence of MDD, and in schizophrenia males have a higher incidence, 
earlier onset, more negative symptoms, and a worse prognosis and response to 
antipsychotic medication in schizophrenia. A better understanding of sex differences in these 
patients is needed to provide insight into biological mechanisms in these conditions and 
develop better diagnostic tools and therapies for males and females.  
This thesis sought to examine molecular sex differences in control subjects and in 
schizophrenia and MDD patients by profiling serum and prefrontal cortex (PFC) brain tissue. 
Multiplex immunoassay and microarray technologies were used to measure concentrations 
of proteins and small molecules in serum and gene expression in brain, respectively. 
Extensive differences in serum molecular concentrations were found between males and 
females experiencing a menstrual cycle, using oral contraceptives, and after menopause. 
These were involved in immune, metabolic, and endocrine processes and may play a role in 
driving sex differences in susceptibility and other characteristics of mental disorders. 
Furthermore, the hypothalamic-pituitary-gonadal (HPG) axis was altered in MDD and first 
onset, antipsychotic naive schizophrenia patients. Biological processes involving response to 
steroid hormone stimulus and estradiol were enriched among differentially expressed genes 
in the PFC in schizophrenia. However, investigation of sex-dependent differences in PFC 
gene expression in schizophrenia was limited by the small number of female samples 
available. Finally, higher serum concentrations of a number of immune and inflammatory 
molecules were associated with MDD and schizophrenia in males only and this may have 
consequences for immune hypotheses of these disorders.  
The research undertaken in this thesis has advanced the understanding of the mechanisms 
potentially involved in schizophrenia and MDD in males and females. Furthermore, sex and 
female hormonal status should routinely be taken into account during design and analysis of 
psychiatric molecular data to increase the reproducibility of such studies. This research 
shows that failing to consider these in biomarker studies can result in a high proportion of 
false positive findings and obscure important sex-dependent markers of mental disorders.  
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Chapter 1 Introduction 
1.1 The burden and challenges of mental disorders 
A mental disorder is ‘a syndrome characterized by clinically significant disturbance in an 
individual’s cognition, emotion regulation, or behaviour that reflects a dysfunction in the 
psychological, biological, or developmental processes underlying mental functioning’, 
according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 (1). They 
include schizophrenia spectrum and psychotic disorders, bipolar disorders, depressive 
disorders (e.g., major depressive disorder), anxiety disorders, neurodevelopmental disorders 
(e.g., autism spectrum disorders), and a number of others. Heterogeneous in nature, they 
are characterized by a spectrum of distinct and often overlapping symptoms. These 
disabling and stigmatized conditions have a global lifetime prevalence of 18-36%, are 
associated with largely unsatisfactory diagnostic and therapeutic technologies (2), and are 
expected to cause an estimated cumulative global loss in economic output of US$ 16.3 
trillion between 2011 and 2030 (3). The biological bases for these disorders have not yet 
been elucidated, though genetic and environmental, neurotrophic, neurochemical, 
endocrine, and infectious and immune factors have been implicated. However, a number of 
challenges hinder progress, including: the subjective basis for the diagnosis of mental 
disorders; use of different diagnostic manuals or other criteria frequently revised over time; 
inaccessibility of the brain; confounding with psychiatric medication use; high comorbidity 
with other mental disorders and physical illnesses; misdiagnosis and changes in diagnosis 
over time; ethical considerations; lack of validated animal models; and heterogeneous 
clinical presentation, epidemiology, and biological findings.  
An important component of heterogeneity within mental disorders are sex and gender 
differences (defined in Sections 1.2 and 1.3) in prevalence and incidence, age of onset, 
symptoms, course, treatment response, and other clinical characteristics. A summary of 
differences between males and females in a subset of the major mental disorders can be 
found in Table 1.1. The importance of studying sex and gender differences in health is 
increasingly recognized in policy and health programming, and in the social and biomedical 
sciences (4–6). Initiatives to include them in research have taken place in Canada, the 
United States, and the European Union. Novel insights have been gained into disease 
mechanisms and treatment by considering sex and gender in research of neurological, 
cardiovascular, pulmonary, and autoimmune diseases that show prominent differences 
between men and women (7, 8). Exploration of sex-based heterogeneity in the biological 
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underpinnings of mental disorders could yield novel insights into aetiology, pathophysiology, 
and treatment options, and provide new personalized medicine approaches. The limited 
research done in this field has found estrogen to be a promising treatment for female 
schizophrenia patients (9) and has discovered sex-specific biomarker profiles for Asperger 
syndrome (10). This thesis will focus on sex-dependent molecular differences in the serum 
and brain tissue of patients with schizophrenia and major depressive disorder (MDD), mental 
disorders with well-characterized and profound sex and gender differences. A more detailed 
discussion of these disorders and sex and gender differences in them is given, following a 
short introduction to biological and socio-cultural differences between men and women.  
Table 1.1. Summary of differences between males and females in mental disorders. 
Mental disorder Sex and gender differences 
Autism spectrum disorders 
(Fombonne, 2005) (11) 
 Higher prevalence in males (~4:1) 
 Lower cognitive abilities in females 
Schizophrenia (Abel et al, 
2010) (12) 
 Higher incidence in males (~1.4:1) 
 Later female age of onset 
 Better premorbid function, social course, prognosis, and 
response to antipsychotic medication in females 
 More affective symptoms in females; more negative symptoms 
in males 
Major depressive and anxiety 
disorders (Bromet et al, 2011 
(13); Hawton, 2000 (14))  
 More prevalent in females (~2:1) 
 Higher suicide rate in depressed males 
Posttraumatic stress disorder 
(Tolin and Foa, 2006) (15) 
 Higher risk to females following traumatic experience, especially 
after assault 
 Differences in vulnerability to types of trauma 
Obsessive-compulsive 
disorder (de Mathis et al, 
2011) (16) 
 Earlier onset in males 
 More chronic course of illness in males, greater social 
impairment 
 Differences in symptoms and psychiatric comorbidities 
Bipolar disorder (Kawa et al, 
2005) (17) 
 Later female age of onset 
 Higher prevalence of bipolar disorder II, rapid cycling, and mixed 
mania in females 
Anorexia and bulimia nervosa 
(Hudson et al, 2007) (18) 
 Higher prevalence in females (~3:1) 
Substance use disorders 
(Becker and Hu, 2007) (19) 
 Higher prevalence in males (~2:1) 
 Differences in drug abuse initiation, escalation of use, addiction, 
and relapse 
Personality disorders (PDs) 
(Cale and Lilienfeld, 2002 
(20); Sansone and Sansone, 
2011 (21); DSMs IV/5  (1, 22); 
Corbitt and Widiger (2006) 
(23)) 
 Higher prevalence of antisocial PD in males (~3:1) 
 Schizoid, schizotypal, paranoid, narcissistic, obsessive-
compulsive PDs may be more prevalent in males 
 Borderline personality, histrionic, dependent PDs may be more 
prevalent in females 
 Differences in personality traits, psychiatric comorbidity, and 
treatment of borderline PD 
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1.2 Sex  
Sex refers to the biological and physiological attributes that characterize males and females. 
Sex differences in humans are present throughout life and range from obvious dichotomous 
characteristics to more subtle and less observable sexual dimorphisms. These emerge 
either as a direct result of sex chromosome effects or from indirect effects through levels of 
sex hormones, which influence growth, development, maintenance, and function of body 
systems (8, 24).  A summary of factors influencing biological expression of sex differences 
can be seen in Figure 1.1. Sex differences in a number of body systems and cellular 
processes relevant to mental disorders are described briefly in the following sections. These 
biological differences interact with socio-cultural factors to produce complex differences 
between men and women (8).  
 
 
Figure 1.1. A unified model of sexual differentiation of mammalian tissues, adapted from Arnold (2009) 
(25). Reprinted with permission. 
1.2.1 Endocrine and nervous systems 
Glands comprising the endocrine system secrete signalling molecules called hormones into 
the circulatory system, which regulate physiology and behaviour. Reproductive functions are 
controlled by complex feedback loops between the hypothalamus, pituitary, and gonads, 
referred to as the hypothalamic-pituitary-gonadal (HPG) axis and illustrated in Figure 1.2. 
Gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates production of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in the anterior pituitary. 
Their release into the bloodstream influences male and female reproductive function, 
including production of sex steroids. Sex steroids include androgens, estrogens, and 
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progestogens, which are secreted from the gonads or adrenal glands or are converted from 
other sex steroids.  
 
 
Figure 1.2. The female (left) and male (right) HPG axes, from Hiller-Sturmhӧfel and Bartke (1998) (26). 
Abbreviations: HPG (hypothalamic-pituitary-gonadal); GnRH (gonadotropin-releasing hormone); LH (luteinizing 
hormone); FSH (follicle-stimulating hormone). Reprinted with permission. 
The effects of sex steroids can generally be classified as organizational or activational (24) 
and occur through genomic and non-genomic mechanisms. Non-genomic effects cause 
rapid activation or repression of cell function when sex steroids modulate regulatory proteins 
on the cell membrane or in the cytoplasm (27). Genomic effects, on the other hand, affect 
medium- and long-term function and programming of cells and regulate gene expression and 
protein synthesis (27). In the male foetus, the Sry gene on the Y chromosome causes testes 
to grow and secretion of testosterone from them permanently affects brain and genital 
development. A female foetus develops without Sry, and a female brain and genitals 
develop. These permanent, differentiating effects constitute the organizational effects of sex 
steroids. Activational effects of sex hormones can be reversed and occur at puberty 
(together with further organizational effects) (24), during which time GnRH stimulates 
production and release of LH and FSH to in turn produce sex steroids. Sex steroids cause 
the genitals and other secondary sexual characteristics to develop. At this time, males begin 
to produce sperm and females begin menstruation.  
Hormonal variations occur within the menstrual cycle and across the female lifespan, 
affecting many aspects of brain and body function. In the female menstrual cycle, as shown 
in Figure 1.3, an ovary releases an egg and the uterus is prepared for pregnancy in a 
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process that repeats approximately every 28 days (28). During the follicular phase 
(approximately days 1-14), ovarian follicles develop with elevated FSH. An estrogen-
stimulated surge in LH, which occurs around day 12 and lasts 36-48 hours, causes the egg 
to be released from the follicle (called ovulation). In the luteal phase (approximately days 15-
28), the follicle is transformed to a corpus luteum, which secretes progesterone and 
degenerates in the absence of pregnancy. Changes in body temperature and the uterine 
endometrium occur during the menstrual cycle. Hormonal contraception is used by a 
substantial number of reproductive-aged females in the developed world and can prevent 
ovulation, thicken cervical mucus, and may thin the endometrium. The most popular of these 
is the combined oral contraceptive pill (OC), containing estrogen (mostly ethinyl estradiol) 
and progestin. Pregnancy is marked by increases in estrogen and progesterone, which drop 
postpartum. Menopause marks the end of menstruation and generally occurs around age 
51. Estrogen and progesterone ovarian production largely stops, while FSH and LH levels 
remain high.  
 
Figure 1.3. The female menstrual cycle. Image courtesy of Isometrik; reprinted with permission. 
Abbreviations: LH (luteinizing hormone); FSH (follicle-stimulating hormone).  
In addition to their role in reproduction, sex hormones are important in a number of other 
physiological processes. The HPG axis interacts with other hormone systems, including the 
hypothalamic-pituitary-adrenal (HPA) axis (29). The HPA axis plays a key role in maintaining 
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homeostasis in the presence of physical and psychological stress and is illustrated in Figure 
1.4 (30). Altered activation of this network  has been implicated in schizophrenia, depression 
and anxiety disorders, bipolar disorder, autism, and others (31–34). Sex differences in HPA 
axis development and functional cross-talk with the HPG axis may result in sex-dependent 
reactions to stress in systems regulated by these axes, including reproductive, nervous, 
musculoskeletal, cardiovascular, and immune systems, in addition to metabolism and 
electrolyte and water balance (29, 35–37).  
 
Figure 1.4. The HPA axis, from Hiller-Sturmhӧfel and Bartke (1998) (26). Abbreviations: HPA (hypothalamic-
pituitary-adrenal); CRH (corticotropin-releasing hormone); ACTH (adrenocorticotropic hormone). Reprinted with 
permission. 
The influence of sex hormones on brain and behaviour is well documented. In addition to 
sex differences in mental disorders and neurological conditions, sex dimorphisms occur in 
memory, cognition, emotion, vision, hearing, face processing, pain perception, and other 
behaviours (38). Perinatal secretion of testosterone in males causes the brain to develop 
differently from females, and sex hormone receptors distributed throughout the brain 
influence neural function over the lifespan of an individual (39). Sex differences in humans 
and other species have been found in the volumes of certain brain areas, the number, 
architecture and activity of cells, neurochemical make-up, stress hormone action, and 
synaptic connectivity (38, 39). Neurotransmitter systems like γ-aminobutyric acid  (GABA), 
glutamate, acetylcholine, opioids, vasopressin, and monoamines differ between males and 
females (38, 40, 41). For instance, serotonin synthesis is more than 50% higher in human 
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males (42) and estradiol has antipsychotic effects in rats treated with amphetamine, which 
increases dopaminergic activity (43). In the hippocampus, vital for memory formation and 
recollection, glucocorticoid receptor affinity is reduced in females and sex hormones 
influence excitability of cells, dendritic structure, N-Methyl-D-aspartic acid (NMDA) receptor 
binding, and memory and learning processes (38). Studies in rats and monkeys have found 
chronic stress to cause more hippocampal damage to males (38) and estrogen has been 
found to be neuroprotective in vivo, mediated by its ability to reduce oxidative stress and 
neurotoxicity (27). The prefrontal cortex is involved in cognitive control and has a high 
concentration of sex hormone receptors and differences between males and females have 
been observed in brain activation during working memory tasks (38). Though much of the 
research on sex differences in neuroscience has focused on sex hormones, increasingly 
effects of the sex chromosomes are being investigated (44). X-chromosome genes influence 
development of intelligence, social cognition, and emotional regulation (45). X-linked 
intellectual disability (ID) is thought to account for 5-10% of ID in males (46).   
1.2.2 Other systems 
Sex differences exist in the functioning of other body systems and processes relevant to 
mental illness. Studies have suggested that immune and cardiovascular systems and 
metabolic processes are involved in mental disorders, often in a bi-directional manner (47–
52).  
1.2.2.1 Immune response 
Females generally have a more robust immune response, which may be responsible for the 
higher prevalence of a number of autoimmune diseases and lower risk for many types of 
infection in females (53). The hormones progesterone, testosterone, and estrogens account 
for many of the observed sex differences in immune response. Though androgens largely 
suppress immune function, the role of estrogens in inflammation is complex and hormonal 
fluctuations in females can influence production of cytokines and chemokines, chemotaxis of 
cells to sites of inflammation, and development and function of immune cells (53), as 
illustrated in Figure 1.5. Females have more CD4+ T cells and estrogen increases the 
regulatory T-cell population, survival of autoreactive B-cells, and increase differentiation of 
dendritic cells from bone marrow (53). On the other hand, estrogen reduces the cytotoxicity 
of natural killer cells and has anti-inflammatory effects on monocytes, macrophages, and 
neutrophils (53). 17β-estradiol has been found to mediate anti-inflammatory pathways in 
microglial cells, which are brain macrophages that are necessary for early sexual 
differentiation and development (54). Estradiol reduces their activation, superoxide release, 
phagocytic activity, and recruitment of peripheral monocytes (55, 56). Furthermore, sex 
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differences have been found in the number of microglia in developing brain regions, their 
morphology, and in their ex vivo inflammatory signalling responses in rodents (54).   
 
Figure 1.5. The role of 17β-estradiol in immune function, from Fish (2008) (53). Abbreviations: IL 
(interleukin); IFN (interferon); Reg (regulatory); CCR (CC-chemokine receptor); TNF (tumour-necrosis factor); 
BMDC (bone-marrow-derived DC precursor); cDC (conventional dendritic cell); DC (dendritic cell); CCL (CC-
chemokine ligand). Reprinted with permission.  
1.2.2.2 Metabolism 
Sex differences have been reported in glucose, lipid, and drug metabolism. Males are more 
sensitive to central insulin while females are more sensitive to leptin that control glucose 
metabolism and energy balance (57). Insulin-like growth factor type 1 receptor (IGF-1R) 
regulates blood glucose regulation, oxidative stress, and longevity in a sex dimorphic 
manner, with heterozygous knockout Igf1r+/- female mice showing increased lifespan and 
stress resistance and male mice showing a stronger glucose response than controls (58). 
Female rats are protected against mitochondrial oxidative stress, with lower oxidative 
damage and higher gene expression of antioxidant enzymes compared to males (59). Lipid 
metabolism differs greatly between the sexes, with human females generally having a higher 
percentage of body fat, greater oxidation of fat during exercise, and different fat mobilization 
and body fat distribution compared to males (60). While females have a greater tendency to 
deposit fat subcutaneously and in the gluteal-femoral region, males are more likely to build 
visceral fat, associated with increased risks for hypertension, cardiovascular disease, type 2 
diabetes, and other disorders (57). Gonadal hormones play key roles in these sex 
differences, with testosterone increasing lipolysis and estradiol enhancing production of 
preadipocytes (57). Hormonal changes in menopause have been associated with increased 
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deposition of visceral fat and use of OCs have been shown to cause increased levels of 
serum triglyceride, low-density lipoprotein cholesterol, and insulin (57, 61). Adipose tissue 
itself is also a source of leptin, adiponectin, resistin, cortisol, estradiol, testosterone, and 
inflammatory cytokines (57). In the brain, sex differences in glucose metabolism have been 
found to vary with brain region, with males having higher metabolism in temporal-limbic 
regions and the cerebellum and lower metabolism in cingulate regions (62). Estrogen and 
progesterone are believed to be protective and beneficial in recovery after brain injury and 
stroke, in part due to their capacity to reduce lipid peroxidation (63). Substantial sex 
differences in drug pharmacokinetics and pharmacodynamics have also been found and can 
be influenced by pregnancy, hormonal contraceptive use, menopause, and menstrual cycle 
(64). In particular, differences in hepatic enzymes between males and females are thought to 
be of great importance to pharmacokinetic differences (64). 
1.2.2.3 Cardiovascular function 
Estrogen is reported to have favourable effects on vascular function, with a better prognosis 
for most cardiovascular diseases and reduced incidence of atherosclerosis, coronary artery 
disease (CAD), and ischemic stroke in premenopausal women compared to men (48, 65). 
However, estrogen replacement has also been shown to increase the risk of coronary heart 
disease in postmenopausal women, and combined OCs are associated with increased risk 
for venous thrombosis, myocardial infarctions, and ischemic strokes (66–68). In periphery 
and brain, estrogen affects vascular reactivity, promoting vasodilation and thereby increasing 
blood flow (65, 69). Testosterone, on the other hand, promotes vasoconstriction (65, 70). 
Consequently, blood pressure is higher in men than in premenopausal women, and 
increases after menopause (69). Estrogen has also been found to reduce oxidative stress 
and blood-brain barrier permeability, increase neurogenesis and angiogenesis, and inhibit 
formation of atherosclerotic plaques (65, 69, 71–73).  
 
1.3 Gender 
Gender refers to the socially constructed roles filled by men and women. While these roles 
may differ between cultures, biological attributes do not. A number of gender-based factors 
influence the differences in mental disorders between men and women. Gender inequalities 
in social status are highly prevalent, with larger gaps in developing countries. In general, 
women have lower levels of economic participation and opportunity, educational attainment, 
health and survival, and political empowerment, as quantified by the Global Gender Gap 
Index (74). However, men are more likely to engage in novel or intense activities (75) and 
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are less likely to seek help for health problems (76). Gender differences are present in 
vulnerabilities to different types of traumatic events (77), and perception of stress and coping 
style (78). The magnitude of gender differences in personality traits has been reported to 
vary across cultures and is greater in European and American cultures. Women were 
generally higher in neuroticism, agreeableness, warmth, and openness to feelings using the 
Revised NEO Personality Inventory, while men were higher in assertiveness and openness 
to new ideas (79).  Social structural and behavioural determinants of health are also often 
different in men and women, adding to the complexity of gender differences in disease and 
disorders (80). Gender and sex are intricately tied and are both important in the emergence 
of differences between men and women in mental disorders.  
 
1.4 Diagnosis of mental disorders  
Mental disorders are currently diagnosed by interview carried out by a psychiatrist or other 
health or mental health professional. The majority of psychiatrists (approximately 80%) often 
or always use a formal classification system for diagnosis of patients (81). A 2010/2011 
World Psychiatric Association (WPA)-World Health Organization (WHO) global survey of 
psychiatrists in 44 countries reported that Chapter V of the International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10; produced by 
the WHO) was most widely used (70%), followed by the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV; produced by the American Psychiatric Association; 
23%), with the remainder using another classification system (81). The DSM has recently 
been revised and the 5th edition was released in May 2013 (1). A number of sources of 
variation can often reduce diagnostic reliability, and various methods have therefore been 
developed for clinical research and post-mortem studies. The Composite International 
Diagnostic Interview (CIDI) assesses mental disorders according to ICD and DSM criteria in 
a highly standardized way across various settings and cultures (82). The CIDI was intended 
for epidemiological studies, but is also used widely in the clinic and in research (82). 
Nevertheless, the issue of classification of mental disorders is contentious, with some 
arguing a dimensional approach is preferable to a categorical one (83). Evidence from 
clinical neuroscience and genetics suggests that diagnostic categories in the DSM and ICD 
may not align with pathophysiological mechanisms in mental disorders (84). The Research 
Domain Criteria (RDoC) project launched by the US National Institute of Mental Health 
(NIMH) conceptualizes mental disorders as brain disorders and aims to incorporate 
pathophysiological data into future classification schemes to improve patient outcomes (84). 
It defines five domains representing functional dimensions of behaviour and several units of 
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analysis, including genes, circuit, behaviour, and other measurements in psychopathology 
research (85). White et al (2012) (86) also argue that current scientific evidence supports the 
reclassification of mental and neurological illnesses as disorders of the central nervous 
system in diagnostic manuals.  
 
1.5 Research tools in mental disorders 
A number of tools and technologies are used to study biological psychiatry. Post-mortem 
brain studies are used to detect abnormalities in function and structure, including brain 
volume and cell size, density, and distribution. Structural neuroimaging is used to study 
structure of the brain in living patients and controls, while functional neuroimaging is used to 
investigate aspects of brain function (87). Brain activity can be measured using electrical 
currents, magnetic fields, regional cerebral blood flow and metabolism, and blood 
oxygenation. Neurotransmitter activity can also be studied using functional neuroimaging.  
Genomic and transcriptomic studies can reveal risk genes and altered gene expression 
important in the aetiology and pathophysiology of mental disorders. Study of the functional 
products of genes (proteins) provides direct insight into the cellular mechanisms underlying 
mental disorders. Elucidating abnormalities in protein expression, structure, and function 
(proteomics) is needed to establish common pathways to the behavioural and psychological 
dysfunction in mental disorders caused by genetic vulnerability and environmental factors 
(88). Metabolic studies (metabolomics) can quantify perturbations in the cellular products of 
biochemical reactions that may underlie dysfunction in mental disorders. Central and 
peripheral omics studies have revealed a number of abnormalities in mental disorders (89). 
Peripheral studies allow easier and less invasive access to tissue from living patients and 
can mirror aspects of brain function. 
In addition to direct patient measurements, cellular and animal models of mental disorders 
have been investigated. Fibroblasts from patients can be reprogrammed into human induced 
pluripotent stem cells and differentiated into neurons to study aspects of their function (90). 
Animal models of mental disorders can be used to study the physiological underpinnings of 
behaviours caused by specific environmental and biological manipulations.  
A better understanding of mental disorders is imperative to improving patient diagnosis, 
therapy, and outcome. A clinical need has been identified for tools to prevent misdiagnosis, 
aid early diagnosis, and predict response to treatment (91). These may be achieved by a 
number of technologies and their translation into clinical practice, as seen in Figure 1.6. 
Increasingly, a need to address the heterogeneity in mental disorders is recognized, with an 
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emphasis on providing personalized care. The vision for schizophrenia in Figure 1.6 was put 
forth by the director of the NIMH (92), but is also relevant for other mental disorders.  
 
Figure 1.6. A vision for schizophrenia; from Insel (2010) (92). Reprinted with permission.  
 
1.6 Major depressive disorder (MDD) 
Major depressive disorder (MDD) is a mental disorder characterized by heterogeneous 
symptoms including chronic low mood, loss of pleasure or interest in activities, and other 
physical and psychological symptoms. MDD is a highly prevalent and disabling condition 
with poor recognition in primary care settings (93, 94). The average lifetime prevalence of 
MDD was 14.6% in high-income countries and 11.1% in middle- and low-income countries in 
a WHO World Mental Health survey published in 2011, with considerable variation between 
countries (13). The WHO predicts that by 2030 MDD will be the leading cause of disease 
burden worldwide, accounting for 6.2% of all disability-adjusted life years (DALYs), which 
measure years of healthy life lost due to disability and premature mortality (95). In Europe 
this has already occurred and annual costs of MDD have been estimated at €92 billion (59% 
direct costs, 41% indirect costs), accounting for approximately 12% of the cost of all brain 
disorders (96).  
Other mental disorders share features of MDD. Dysthymia is a milder, chronic form of MDD 
now consolidated with chronic MDD as persistent depressive disorder in the DSM-5 (1). 
Bipolar disorder is characterized by episodes of depressed and elevated mood (mania or 
hypomania). Negative symptoms of schizophrenia may resemble depressive symptoms, 
while psychotic features may be present in severe MDD. MDD is frequently accompanied by 
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anxiety disorders, characterized by excess fear, anxiety, and associated behaviours (1). 
Anxiety disorders include social and generalized anxiety disorders, panic disorder, and 
phobias, such as agoraphobia and specific phobias. They are highly comorbid with each 
other and have different physical and psychological symptoms. MDD is also often comorbid 
with alcohol use disorders, eating disorders, borderline personality disorder, schizophrenia, 
and physical illnesses such as cardiovascular disease and type 2 diabetes  (1, 48, 52, 97, 
98). A relative risk of incidence of 1.5 for coronary artery disease is conferred independently 
by depression (48, 50). 
1.6.1 Criteria for diagnosis 
The DSM-IV criteria for diagnosis of MDD (22) are presented in Table 1.2. The work in this 
thesis and most other published research has not been carried out with the most recent 5th 
edition.  
Table 1.2. DSM-IV criteria for diagnosis of MDD. 
A. At least 5 of the following, during the same 2-week period, representing a change from 
previous functioning: at least one symptom is either (a) or (b) 
a. Depressed mood most of the day 
b. Diminished interest or pleasure in all, or almost all, activities 
c. Significant weight loss or gain 
d. Insomnia or hypersomnia 
e. Psychomotor agitation or retardation 
f. Fatigue or loss of energy 
g. Feelings of worthlessness or guilt 
h. Diminished ability to think or concentrate, or indecisiveness 
i. Recurrent thoughts of death, suicidal ideation, suicide attempt, or a specific plan for 
committing suicide  
B. The symptoms cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning. 
C. The episode is not attributable to the physiological effects of a substance or to another 
medical condition. 
D. The occurrence of the major depressive episode is not better explained by schizoaffective 
disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and 
unspecified schizophrenia spectrum and other psychotic disorders. 
E. There has never been manic episode or a hypomanic episode. 
F. Symptoms are not better accounted for by bereavement. 
 
Single or recurrent episodes are diagnosed with additional specifiers including severity, 
remission, chronic status, psychotic features (mood-congruent or mood-incongruent), 
atypical features, melancholic features, catatonia, postpartum onset, and seasonal pattern.  
Changes in the DSM-5 include removal of the bereavement exclusion for a diagnosis of 
MDD and addition of specifiers, “with anxious distress” and “with mixed features”. 
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Premenstrual dysphoric disorder and disruptive mood disorder were also added in the DSM-
5 and chronic MDD and dysthymia were combined as persistent depressive disorder, as 
stated above (1).  
1.6.2 Course and treatment 
The risk of MDD increases substantially with puberty, with peak incidence occurring in the 
20s and 30s. Length of episode and course of illness varies considerably. In 40% of patients, 
recovery starts within three months of onset, and within one year 80% of patients will have 
begun to recover (1). Comorbid anxiety disorders are present in more than half of those 
suffering from depression, typically preceding development of MDD and associated with 
poorer psychiatric outcomes (99, 100). Other factors associated with lower rates of recovery 
include psychotic features, personality disorders, substance use disorders, severe 
symptoms, and length of current episode (1). MDD is a highly recurrent condition with the 
risk of another episode at least 50% for individuals who have had one and 80% for those 
who have had two prior episodes (101). Certain patients may infrequently or never 
experience remission, while others may experience partial or complete recovery between 
episodes. MDD patients have high rates of attempted and completed suicides (102, 103).   
Pharmacological and other interventions are used in the treatment of MDD. The first 
generation of antidepressant medications were monoamine oxidase inhibiters (MAOIs) and 
tricyclic antidepressants (TCAs) that had several side effects. Selective serotonin reuptake 
inhibitor (SSRI) and serotonin and noradrenalin reuptake inhibitor (SNRI) antidepressant 
medications were developed later and have fewer adverse effects and better safety profiles. 
However, the effectiveness of antidepressant medication does not differ from placebo in 
cases of mild and moderate depression (104, 105) and several weeks of treatment are 
required for therapeutic benefit to be seen. Psychological and psychosocial interventions are 
also commonly used to treat MDD, and combined with antidepressant therapy they can lead 
to higher improvement in depressive symptoms and better adherence to treatment (106). 
Other options include electroconvulsive therapy (ECT), transcranial magnetic stimulation, 
vagus nerve stimulation, and neurosurgical procedures (107–109).      
1.6.3 Risk factors  
A number of biological, psychological, and environmental risk factors influence the 
occurrence of MDD. Neuroticism, adverse childhood events, stressful life events, and low 
socioeconomic status all increase the risk of the disorder (1, 110–113). Chronic medical 
conditions, female gender, and a family history of MDD also increase risk, with a heritability 
of approximately 37% (1, 114). Substantial cultural differences exist in the prevalence and 
symptom presentation of depression (93).  
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1.6.4 Pathology 
Central and peripheral abnormalities are reported in MDD and are tied to hypotheses of 
MDD. Additional pathological findings are described in the context of specific hypotheses of 
MDD following this section. 
1.6.4.1 Central  
Anatomical and blood flow abnormalities have been found in a number of brain regions in 
MDD, including the prefrontal and cingulate cortex, hippocampus, striatum, amygdala, and 
thalamus (115). Gray matter reductions have been observed in a number of brain regions 
(116). The left subgenual cingulate cortex, involved in regulation of emotional behaviour, 
shows volume reduction early in MDD, in young adults with high familial risk, and lesions in 
the area are associated with perturbed autonomic responses to social stimuli (117). 
Hippocampal atrophy occurs in recurrent MDD and is correlated with total duration of MDD 
(118), while reduced cortical thickness, neuronal size, and neuronal and glial densities have 
been found in areas of the prefrontal cortex (119). Findings from gene expression and 
proteomic studies of the brain in MDD include alterations in oligodendrocyte structure and 
function, synaptic neurotransmission, energy metabolism, and cell proliferation (120, 121). 
1.6.4.2 Peripheral 
A number of peripheral disturbances have been found in MDD involving immune and 
inflammatory, oxidative stress, metabolic, neurotrophic, and endocrine factors.  Elevated 
peripheral (blood/urinary) markers of oxidative stress have been found in depression 
together with perturbed antioxidant superoxide dismutase and glutathione activity, though 
these findings are inconsistent (122). Markers of inflammation, including erythrocyte 
sedimentation rate and blood levels of C-reactive protein (CRP), cytokines, and neopterin, 
are also higher in depression patients (122–124). Furthermore, interleukin (IL)-1β, IL-6, and 
CRP are reduced after antidepressant treatment (125, 126). In drug naive MDD patients, 
higher peripheral leukocyte messenger ribonucleic acid (mRNA) levels of vascular 
endothelial growth factor (VEGF) have been found, and reductions were correlated with 
clinical improvement after antidepressant treatment (127). On the other hand, serum levels 
of brain-derived neurotrophic factor (BDNF) are reduced in depression and increase after 
antidepressant treatment (128). A serum proteomic study of first onset, antidepressant naive 
MDD patients found evidence for concurrent elevations in pro-inflammatory and oxidative 
stress response, HPA axis hyperactivity, and growth factor disruptions (129). A plasma 
biomarker panel has produced good sensitivity and specificity in separating MDD patients 
from controls and has implicated altered insulin, acute phase proteins, and matrix 
metalloproteinases in MDD (130). Another set of nine serum analytes involved in 
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inflammation, metabolism, and neurotrophic and HPA systems separated patients from 
controls with approximately 92% sensitivity and 81% specificity (131). A number of studies 
have reported insulin resistance in depression consistent with an increased risk for CAD, 
type 2 diabetes, stroke, and hypertension (132). Dysfunction of the HPA axis under stress 
been investigated through peripheral measurements and is discussed in the next section.   
1.6.5 Hypotheses  
Little is known about the aetiology and pathophysiology of MDD and other mental disorders. 
However, a number of hypotheses for depression have emerged and are briefly outlined 
below.  
1.) Genetic and environmental factors are thought to interact in MDD. The inherited 
personality trait neuroticism is a considerable, but not the only, component of this 
genetic vulnerability (133). However, the heterogeneity of MDD and insufficient 
sample sizes have prevented discovery of strong, consistent genetic risk factors 
(134). Multiple genes may be involved in developing MDD, with each gene 
contributing a small effect (115). Epigenetic modifications may also alter gene 
expression and explain the high discordance rates between monozygotic twins, 
greater female prevalence, and other aetiological complexities (135). 
 
2.) Little is known about the impairment of neural circuitry in MDD, including brain 
reward pathways and regulation of mood and emotion. The prefrontal cortex and 
hippocampus are implicated in the cognitive dysfunction of depression, the striatum 
and amygdala in anhedonia and anxiety, and the hypothalamus in neurovegetative 
symptoms of depression (115, 136).  
 
3.) The monoamine hypothesis proposes that reduced monoamine function in the 
brain leads to MDD. This hypothesis was generated by studying the mechanisms of 
antidepressant medications, which increase monoamine transmission (136). 
Glutamatergic and GABAergic neurotransmitter system disturbances may also be 
involved in MDD (117). 
 
4.) Involvement of neurotrophic factors and neurogenesis in MDD is hypothesized 
from observations of decreased volumes of some brain regions in depression. BDNF 
is thought to be of particular importance and has been implicated in stress response 
and antidepressant action (136).  
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5.) Dysregulation of the HPA axis may result from chronic stress and be involved in 
the pathophysiology of MDD. Excesses in the levels of cortisol have been found in 
MDD patients at baseline and during recovery from stress (136–139). Metabolic 
abnormalities and hippocampal volume reductions in MDD may be partly explained 
by excess glucocorticoid (140). However, HPA axis dysfunction may depend on MDD 
type. Hyperactivity of the axis is associated with severe episodes, psychotic 
symptoms, and melancholic depression, while hypoactivity is associated with atypical 
depression, characterized by lethargy and hypersomnia (141).  
 
6.) The cytokine hypothesis of depression posits that peripheral proinflammatory 
cytokines are responsible for the behavioural, neuroendocrine, and neurochemical 
changes in MDD (142, 143). Cytokines activate the HPA axis and may contribute to 
dysregulation of the axis. Mechanisms have been identified that allow peripheral 
cytokines to infiltrate the brain through the blood-brain-barrier (BBB) or to indirectly 
signal the brain, resulting in production of cytokines by migroglia (142, 143). 
Systemic administration of cytokines affects monoaminergic neurotransmission in 
animals and induces ‘sickness behaviour’ similar to depression (136, 142, 143). 
Alternatively, chronic psychological stress may impair glucocorticoid regulation of the 
immune system and result in higher cytokine levels (144). A recent study 
demonstrated that microglial function is disturbed in chronic stress-induced 
depression in rodents (145).   
 
7.) The vascular depression hypothesis posits that cerebrovascular disease is linked 
to late-life depression (146). This subtype has been characterized by executive 
dysfunction and/or white matter hyperintensities and has a poor response to 
antidepressant treatment (147). 
 
8.) Diurnal changes in symptoms, antidepressant effects on circadian rhythms, and 
shorter REM latency in MDD patients suggest that abnormalities in circadian 
rhythm may be associated with MDD. However, genetic and molecular evidence for 
this hypothesis is lacking (117).  
 
Hypotheses of depression continue to evolve to account for and encompass all pathological 
findings.  
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1.7 Sex and gender differences in MDD 
Women have a higher prevalence of MDD, a phenomenon that has been observed 
consistently across several countries and cultural settings from late adolescence onwards 
(148, 149). Puberty marks the emergence of this trend, with childhood depression equally 
prevalent in boys and girls (150). In the United States, lifetime prevalence is estimated to be 
17% for women and 9% for men, with similar rates observed in Europe (151, 152). Suicidal 
behaviour shows considerable differences between men and women (14), with higher 
suicide rates for men in most countries (China being a notable exception), and trends toward 
further increases in this difference. On the other hand, attempted suicide and deliberate self-
harm is more common in women (14). Women and men may also differ in their presentation, 
aspects of course of the disorder, and response to treatment, but there is conflicting 
evidence for this (153).  
Anxiety disorders and comorbid MDD and anxiety disorder(s) (CMA) also have a higher 
prevalence in women (154). Data from the Collaborative Psychiatric Epidemiology Studies 
(2002-2003) (154) in the United States revealed anxiety disorders affected 28% of 
individuals, with higher female lifetime (odds ratio 1.7) and past-year prevalence rates (odds 
ratio 1.8) and a higher comorbidity with MDD in women with lifetime anxiety (odds ratio 
1.38). This was concurrent with a greater illness burden for women with anxiety disorders. 
Simonds and Whiffen (2003) (155) also assessed seven studies (published 1990-1997) and 
concluded that women had a higher prevalence of pure anxiety or depressive and comorbid 
disorders. On the other hand, the prevalence of bipolar disorder has not been found to differ 
between men and women (149).      
1.7.1 Hypotheses and pathology 
Current explanations proposed for the marked gender difference in prevalence of MDD 
include artefactual and genuine biological, psychological, and social determinants (156, 
157). These will be discussed in more detail in this section. 
1.7.1.1 Artefactual hypotheses 
A greater female tendency to report more and different depressive symptoms, seek help for 
depression more frequently, and recall more past depressive events than men have been 
hypothesized as artefacts explaining the greater preponderance of women with MDD (157). 
Mixed evidence has been reported for these hypotheses. However, two large multicentre 
studies showed comparable gender differences in prevalence of MDD in the community and 
primary care setting and studies have shown no evidence for gender differences in recalling 
severity of depressive symptoms (156, 157). Men and women may differ in types of 
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symptoms expressed in MDD, but this does not fully account for the difference in prevalence 
(157). 
1.7.1.2 Psychological and social hypotheses 
The roles of childhood abuse and adverse experiences, social roles and cultural norms, 
adverse life events, personality traits and coping strategies, prior anxiety, and others have 
been explored. Section 1.3 outlines gender differences in some of these factors. Mixed 
evidence has been presented for social and other psychological factors causing more MDD 
in women, including chronic strain resulting from female social status, role limitation, use of 
rumination as a coping strategy, and greater vulnerability and/or sensitivity to different 
stressors, life events, and major traumas, in particular sexual abuse (156–158).  
1.7.1.3 Biological hypotheses  
1.7.1.3.1 Sex hormones 
Sex hormones have been implicated in the emergence of higher rates of female depression 
during puberty and rising hormonal levels during this time have been linked to affective 
disturbances in girls (156). Hormones may influence gene expression and interact with 
negative life events to produce the gender difference in MDD prevalence at puberty (159). 
Fluctuating hormone levels associated with the female cycle and other reproductive events, 
such as pregnancy and menopause, cause disturbances in neurochemical pathways (160). 
A cycle-dependent vulnerability for affective symptoms in the premenstrual phase has been 
found in approximately 1% of women (156). The postpartum period is a period of increased 
risk for depression and may be associated with the abrupt change in hormone levels at this 
time, though rates vary considerably across cultures (160). Similarly, the incidence of 
depression in women is higher during perimenopause (160).  
1.7.1.3.2 HPA axis dysfunction 
Animal studies of HPA axis activity have found lower basal and stress-induced glucocorticoid 
and adrenocorticotropic hormone (ACTH) levels in males, but these findings have not been 
upheld in human studies (29, 161). Most acute real-life and laboratory studies of HPA axis 
response to psychological stress have found no sex differences or a higher cortisol response 
in young men, but results vary with stressor protocol, population studied, female hormonal 
status, and other factors (161). Females have been reported to have greater cortisol 
responses after social rejection, while males were found to have greater cortisol responses 
to achievement challenges (162). Cortisol response to stress is affected by female hormonal 
status, with smaller responses to the Trier Social Stress Test in the follicular phase 
compared to the luteal phase and severely blunted responses in OC users (158). 
Chapter 1 | 
20 
 
Menopause is associated with increased dexamethasone resistance compared to 
premenopausal women (158). Some evidence suggests that depressed females may show 
greater HPA axis dysregulation (161, 163, 164), while others have found the reverse, with 
higher baseline levels of salivary cortisol only in medication-free depressed males (165) and 
in adolescent males who later developed clinical depression (166). Goldstein et al (2014) 
(164) suggested study inconsistencies may be due to the timing of cortisol measurement, 
patient age and hormonal status, genetic factors, chronicity of MDD, or low statistical power.  
1.7.1.3.3 Inflammation and immune function 
Recent studies of depression have found sex-dependent differences in inflammation. 
Several large studies have found an association between elevated levels of CRP and 
depression in males only, though this finding is not entirely consistent (124, 167–172). 
Furthermore, a 2009 meta-analysis of inflammatory markers in depression showed that 
samples consisting only of men showed a significant increase in CRP while samples of only 
women did not (124). However, IL-1 and -6 were also increased in depression with no 
evidence of sex differences, while another large meta-analysis of cytokine levels in 
depression did not investigate sex differences  (123, 124). A study by Toker et al (2005) 
(169) also found that the association between burnout, depression, and anxiety and levels of 
CRP and fibrinogen varied in a sex-specific manner across these states and speculated that 
stress pathways may influence inflammatory processes differently in males and females. 
1.7.1.3.4 Other hypotheses 
Other hypotheses implicate genetic factors, the hypothalamic-pituitary-thyroid (HPT) axis, 
and aspects of brain function (156, 157). A genotype-stress interaction involving 5-HTTLPR 
in MDD has been demonstrated for female adolescents only and there is evidence that 
MAOA polymorphisms on the X-chromosome produce more vulnerability to depression in 
females (159). Skewed (non-random) X-chromosome inactivation has also been proposed 
as an epigenetic process that could contribute to higher rates of MDD in females (135). 
Alternatively, affective disorders in subgroups of females may be caused by subclinical 
hypothyroidism, which is associated with reduced central serotonergic activity (156). 
However, subsequent studies have failed to confirm this. Sex differences in brain 
development and function, discussed in Section 1.2.1, are also hypothesized to play a role 
(159).  
1.7.1.4 Integrated models 
No single explanation for the preponderance of depression in females has been found. 
Affective and cognitive factors are thought to interact with biological factors to contribute to 
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the greater female prevalence of MDD (157, 159). Models integrating these factors to 
influence the female preponderance in MDD have been proposed, as seen in Figure 1.7. 
 
Figure 1.7.  An affective, biological, and cognitive model explaining gender differences in prevalence for 
MDD from Hyde et al (2008) (159). Reprinted with permission. 
 
1.8 Schizophrenia 
Schizophrenia is a chronic, severe psychotic disorder with heterogeneous symptoms 
impairing cognition, behaviour, emotions, and social and occupational functioning. 
Symptoms are positive (hallucinations, delusions, thought and movement disorders) and 
negative (flat affect, poverty of speech, avolition, anhedonia, asociality). Cognitive deficits 
(impaired executive functioning, working memory, attention) are also common. 
Schizophrenia has a lifetime prevalence of approximately 0.7% (173). Though rare, it is a 
severely debilitating and costly disorder with poor outcome. Sufferers are often incarcerated, 
homeless, or unemployed (92) and their lifespan is shortened by 13-30 years (174). 
Schizophrenia is the 5th and 6th leading global cause of years lost to disability for men and 
women, respectively, and 8th leading cause of DALYs in the 15-44 years age group (175, 
176). Psychotic disorders account for annual estimated direct and indirect costs of €94 billion 
in Europe and are considered the most expensive mental illness per patient treated (96, 
177).  
Other mental disorders may be associated with psychosis or share similar symptoms with 
schizophrenia. These include schizoaffective, schizophreniform, brief psychotic, schizotypal 
personality, delusional, obsessive-compulsive, body dysmorphic, posttraumatic stress, and 
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autism spectrum disorders. MDD, bipolar disorder, and other mental disorder may also have 
psychotic or catatonic features. Substance abuse is prevalent in schizophrenia, both before 
and after diagnosis (178, 179), and this is associated with young age, earlier onset, violent 
crime, less education, male gender, and a worse outcome in patients (178–180). Tobacco 
smoking is also more common in schizophrenia patients, particularly in males (181). 
Physical illness is more common in schizophrenia, due in part to lifestyle and antipsychotic 
side effects.  Schizophrenia carries an increased risk for the metabolic syndrome together 
with cardiovascular disease and type 2 diabetes (182).    
1.8.1 Criteria for diagnosis 
The DSM-IV criteria for diagnosis of schizophrenia (22) are again presented in Table 1.3, as 
this work and most other published research has not been carried out with the most recent 
5th edition.  
Table 1.3. DSM-IV criteria for diagnosis of schizophrenia. 
A. Two (or more) of the following, each present for a significant portion of time during a 1-month 
period: 
a. Delusions 
b. Hallucinations 
c. Disorganized speech 
d. Grossly disorganized or catatonic behaviour  
e. Negative symptoms 
 
Note: Only one Criterion A symptom is required if delusions are bizarre or hallucinations consist of a 
voice keeping up a running commentary on the person’s behaviour or thoughts, or two or more voices 
conversing with each other. 
B. For a significant portion of the time since the onset of the disturbance, one or more major 
areas of functioning such as work, interpersonal relations, or self-care are markedly below the 
level achieved prior to the onset. 
C. Continuous signs of the disturbance persist for at least 6 months. This 6-month period must 
include at least 1 month of symptoms that meet Criterion A and may include periods of 
prodromal or residual symptoms. 
D. Schizoaffective Disorder and Mood Disorder With Psychotic Features have been ruled out 
because either (1) no Major Depressive Episode, Manic Episode, or Mixed Episode have 
occurred concurrently with the active-phase symptoms; or (2) if mood episodes have occurred 
during active-phase symptoms, their total duration has been brief relative to the duration of 
the active and residual periods. 
E. The disturbance is not due to the direct physiological effects of a substance or a general 
medical condition. 
F. If there is a history of Autistic Disorder or another Pervasive Developmental Disorder, the 
additional diagnosis of Schizophrenia is made only if prominent delusions or hallucinations 
are also present for at least a month. 
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Five subtypes of schizophrenia are defined in the DSM-IV based on the predominant 
symptomatology at clinical presentation. These include paranoid, disorganized, catatonic, 
undifferentiated, and residual types.  
Changes in the DSM-5 include removal of the exception to Criterion A requiring only one 
symptom for bizarre delusions or hallucinations of voices (1). However, one of the core 
positive symptoms (a, b, or c in Criterion A) is still required for a diagnosis of schizophrenia. 
Subtypes of schizophrenia were also removed because they were found to inadequately 
represent the heterogeneity of the illness, showing instability over illness course, lack of 
clinical value, and poor reliability and validity (183). These have been replaced with a rating 
scale for the severity of the core symptoms (1).  
1.8.2 Course and treatment 
Psychotic symptoms of schizophrenia usually manifest between late adolescence and the 
mid-30s, while childhood and late-onset (after 40 years) are rarer. Onset of psychosis is 
most often preceded by signs and symptoms in the prodromal stage, including poor 
functioning, low-grade psychotic symptoms, depression and anxiety, and disorganization 
(184). A premorbid phase may occur prior to this prodromal phase in which early-stage 
dysfunction manifests. The course of schizophrenia is highly variable, favourable in 
approximately 20% of patients, with the majority requiring substantial daily support, 
experiencing relapses and remission of psychotic symptoms, and some progressively 
deteriorating (1). About 5% of schizophrenia patients commit suicide and more will attempt 
suicide or have suicidal ideation (185). While the psychotic symptoms of schizophrenia are 
generally reduced over the course of illness, cognitive and negative symptoms persist. Late-
onset schizophrenia has more positive symptoms, less family history, and a higher female 
incidence (186).   
From the mid-1950s, antipsychotic medication has been used for treatment and 
maintenance of positive symptoms in schizophrenia. First-generation antipsychotics (FGAs) 
include chlorpromazine, haloperidol, and perphenazine and act by blocking dopamine D2 
receptors (187). However, FGAs cause extrapyramidal symptoms and second-generation 
antipsychotics (SGAs) were introduced in the 1980s. SGAs include clozapine, olanzapine, 
quetiapine, and risperidone, and block both dopamine D2 and serotonin 2A (5-HT2A) 
receptors (187). These SGAs increase the risk of metabolic side effects, including weight 
gain, hyperglycemia, dyslipidemia, and type 2 diabetes. FGAs and SGAs have not been 
found to differ in their efficacy or tolerability (188). However, lack of response to 
antipsychotics, poor adherence, and lack of effective treatment for negative symptoms and 
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cognitive deficits continue to cause severe impairment in schizophrenia. Psychological and 
psychosocial interventions are also used to improve outcome in schizophrenia (189).    
1.8.3 Risk factors 
A number of biological, psychological, and environmental risk factors influence the 
occurrence of schizophrenia. Babies born in late winter and early spring in the Northern 
Hemisphere, to older fathers, and who are exposed to hypoxia and maternal infection, 
stress, and malnutrition are more prone to later develop schizophrenia (190, 191). Children 
diagnosed with schizophrenia in adulthood are also more likely to have poor social 
functioning, emotional and behavioural disturbances, intellectual and language impairments, 
and motor delays (191). Growing up in an urban environment, immigrant status in certain 
ethnic groups, male gender, cannabis use, and social disadvantage are also associated with 
a higher risk for schizophrenia (173, 191). Family history increases the risk of schizophrenia 
and it has a high heritability of approximately 80% (191). However, prevalence varies 
considerably between sites and diagnostic criteria affects incidence estimates differently in 
men and women (173, 191). 
1.8.4 Pathology 
Both central and peripheral abnormalities have been found in schizophrenia and are 
discussed below. Studies of the pathology of schizophrenia and hypotheses for its aetiology 
and pathophysiology are intimately linked. A number of additional pathological findings are 
also discussed in Section 1.8.5 in the context of specific hypotheses of schizophrenia. 
1.8.4.1 Central 
Studies have found structural and functional brain abnormalities in schizophrenia together 
with altered gene and protein expression. A large meta-analysis of structural magnetic 
resonance imaging (MRI) studies found that the mean volume of the cerebrum was 
decreased (98% of control volume) and ventricular volume was increased (126%) in 
schizophrenia (192). Decreased amygdala, hippocampus, and parahippocampus volumes 
were found in excess of the global difference. This may be due to decreased size of 
neuropils and neurons (193). Reduced gray and white matter volume and increased sulcal 
and ventricular cerebrospinal fluid (CSF) have also been reported in schizophrenia (194). A 
number of these abnormalities have been observed in first onset, unmedicated patients, 
though they may progress over time (195) and be influenced by long-term antipsychotic use 
(196). Functional imaging data points to dysfunction of the activity and integration of circuits 
in the prefrontal cortex, hippocampus, and subcortical structures (193). The dorsolateral 
prefrontal cortex (DLPFC) is thought to be important to the cognitive deficits in schizophrenia 
and a number of abnormalities have been found in this region, including reduced metabolism 
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and blood flow and other disruptions in neurotransmission and cortical connections (197). 
Studies of gene expression and proteomic investigations have found a number of biological 
processes altered in schizophrenia post-mortem brains, including oligodendrocyte function, 
energy metabolism, oxidative stress, myelination, inflammation, synaptic transmission, cell 
communication, and signal transduction (51, 198–204).   
1.8.4.2 Peripheral 
Peripheral metabolic, neurotrophic, endocrine, and immune abnormalities have been found 
in schizophrenia and many of these may reflect central disturbances. Altered lipid 
metabolism has been found, with evidence for an association between peripheral membrane 
abnormalities and perturbed brain phospholipid metabolism in schizophrenia (89, 205). 
Additionally, eicosapentaenoic acid may be beneficial in schizophrenia and omega-3 fatty 
acids are reported to reduce conversion to psychosis in high-risk individuals (89, 206). 
Impaired fasting glucose tolerance and more insulin resistance has also been reported in 
first-episode, drug naive schizophrenia patients (207). Cerebral glucose metabolism 
abnormalities have been associated with peripheral platelet mitochondrial complex I activity 
(208). Furthermore, increased serum insulin, chromogranin A, pancreatic polypeptide, 
prolactin, progesterone, and cortisol levels, and decreased growth hormone levels found 
concurrently in first and recent onset patients have implications for dysfunction of 
neuroendocrine systems (209). Reduced blood concentration of BDNF (210) has been 
reported in schizophrenia and elevated levels of inflammatory markers in blood are a robust 
finding (211) in the disorder. A biological signature for schizophrenia comprised of ten 
plasma analytes has distinguished schizophrenia patients from controls with a sensitivity and 
specificity of over 90% and 95%, respectively (130), while another panel of 51 serum 
inflammatory and metabolic molecules, hormones, and others has yielded 83% sensitivity 
and 83% specificity in separating patients from controls in an independent cohort (212). This 
multiplex immunoassay panel has also been used to identify 21 analytes differentially 
expressed in schizophrenia in post-mortem brain tissue, nine of which were altered at the 
transcriptional level in the same patients, and another nine of which were reproducibly 
altered in serum of first onset patients (213). Another approach has uncovered six genes 
differentially expressed in both blood and brain (214). 
1.8.5 Hypotheses  
Remarkably little is known about the aetiology and pathophysiology of schizophrenia. 
Nevertheless, current hypotheses of schizophrenia are briefly outlined below. Many of these 
hypotheses are not necessarily mutually exclusive and may work at different levels.  
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1.) Schizophrenia is highly heritable and it is hypothesized that genetic vulnerability 
interacts with environmental factors to influence its development. Multiple genes are 
thought to be involved, each conferring a small risk (215). A 2014 meta-analysis of 
genome-wide association studies (GWAS) identified 128 associations in 
schizophrenia for 108 genetic loci, including the dopamine D2 receptor and genes 
involved in glutamatergic neurotransmission and synaptic plasticity (216). Findings 
were enriched for genes expressed in brain and tissues important for immunity. In 
particular, strong enrichment was found for the mid-frontal lobe, angular gyrus, and in 
B-lymphocyte lineages (CD19 and CD20 lines). Altered gene expression in 
schizophrenia is implicated from these GWAS results, rather than altered protein 
structure. Copy number variants may account for 2% of cases (217) and epigenetic 
factors may play a role in schizophrenia (218).  
 
2.) Neurotransmitter dysfunction has long been implicated in schizophrenia.  
a. The dopamine hypothesis proposed that schizophrenia was due to an 
excess of dopamine in the brain after it was found that FGAs blocked 
dopamine D2 receptors. Subsequent findings lead to a revision of the 
hypothesis and proposed that prefrontal hypodopaminergia results in 
subcortical hyperdopaminergia to cause schizophrenia. The current 
hypothesis posits that presynaptic dopamine dysregulation is the final 
common pathway to psychosis in schizophrenia (219).  
b. Evidence of NMDA receptor (NMDAR) hypofunction in schizophrenia has 
come from animal and clinical studies (220). Chronic use of phencyclidine 
(PCP), a noncompetitve NMDAR antagonist, induces schizophrenia-like 
positive, negative, and cognitive symptoms. Trials with glycine modulatory 
site agonists on the NMDAR have yielded reduced negative symptoms of 
schizophrenia (220).  
c. The GABAergic origin hypothesis of schizophrenia pathophysiology 
suggests that GABAergic interneurons mediate symptoms caused by NMDAR 
hypofunction (221).  Schizophrenia-like phenotypes can be generated using 
transgenic mice with selectively removed NMDARs from GABAergic 
interneurons in the cortex and hippocampus (221).  
d. The neurotransmitter serotonin is also implicated in schizophrenia. Chronic 
serotonergic overdrive in the cerebral cortex caused by stress may cause 
disrupted glutamatergic signalling, cortical atrophy, and peripheral 
phospholipid abnormalities in schizophrenia (222). 
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e. The cholinergic system may play a role in schizophrenia, suggested by the 
high prevalence of smoking in schizophrenia patients (223). 
 
A circuit-based framework has been developed by Lisman et al (2008) (223) to 
model how risk genes and neurotransmitters in schizophrenia interact, and our 
understanding of these systems will no doubt continue to evolve.    
 
3.) A number of observations, including the increased risk for schizophrenia after 
maternal infection and elevated peripheral and central markers of inflammation, have 
lead to immune hypotheses of schizophrenia, including the macrophage-T-
lymphocyte (224, 225), cytokine (226), microglia (227), Th2 (228), fetal brain cytokine 
imbalance (229), genetic-inflammatory-vascular (230), and mild encephalitis (231) 
hypotheses of schizophrenia. A 2011 meta-analysis (211) of blood levels of cytokines 
found support for the macrophage-T-lymphocyte and microglia hypotheses of 
schizophrenia. The macrophage-T-lymphocyte theory of schizophrenia (224, 225) 
proposes that chronically activated macrophages and T-lymphocytes are essential 
mediators of schizophrenia and suggests the gastrointestinal tract as the potential 
cause of immune activation. Release of cytokines and free radicals by activated 
microglia are thought to be important in the microglia hypothesis of schizophrenia 
(227). Findings from the meta-analysis were less consistent with the Th2-hypothesis 
that posits a shift to Th2-like immune reactivity in schizophrenia. Low-level 
neuroinflammation is an important part of the pathophysiology of schizophrenia and 
affective disorders according to the mild encephalitis hypothesis, caused by 
autoimmunity, infection, trauma, or toxicity (231). In this context, a higher prevalence 
of NMDA receptor antibodies have been found in serum of patients with an initial 
diagnosis of schizophrenia (232). Alternatively, cytokine signalling from peripheral to 
immature brain tissue during development may result in abnormal brain development 
in schizophrenia (cytokine hypothesis) (226) or elevated maternal cytokines may 
influence neurodevelopment through an imbalance in pro- and anti-inflammatory 
cytokine signalling in the fetal brain (fetal brain cytokine imbalance hypothesis) (229). 
A genetic-inflammatory-vascular theory of schizophrenia further proposes that a 
genetic predisposition to exaggerated inflammatory response damages the brain’s 
microvascular system, causing metabolic disturbances (230). Recent GWAS results 
discussed above were enriched for genes expressed in tissues important for 
immunity, providing further evidence for involvement of the immune system in 
schizophrenia. 
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4.) The diathesis-stress model proposes that schizophrenia is caused by a biological 
vulnerability together with exposure to stress. Stressful life events can increase the 
severity of schizophrenia symptoms (233) and higher post-dexamethasone 
suppression test cortisol levels are associated with poor prognosis, greater 
premorbid impairment, and ventricular enlargement in schizophrenia (233). 
 
5.) The neurodevelopmental hypothesis of schizophrenia posits that abnormalities in 
brain development cause schizophrenia in adulthood and is illustrated in Figure 1.8. 
The two-hit model further proposes that these abnormalities occur during critical 
developmental time points early in life and during adolescence. This hypothesis is 
supported by genetic and early risk factors that affect development, congenital 
anomalies, brain pathology (234), and disturbed neurotrophic factors (235) in 
schizophrenia.  
 
Figure 1.8. Neurodevelopmental model of schizophrenia; from Insel (2010) (92). (A) illustrates normal 
cortical developmental processes, while (B) illustrates neurodevelopmental processes that may occur in 
schizophrenia. Reprinted with permission. 
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As with MDD, hypotheses of schizophrenia are constantly developing in order to account for 
all pathological findings.  
 
1.9 Sex and gender differences in schizophrenia 
A higher male incidence of schizophrenia has been found in a number of recent studies, 
despite a similar prevalence in males and females (12, 236). A risk ratio of 1.4:1 for male 
compared to female incidence was reported in a 2003 meta-analysis, with more restrictive 
definitions of schizophrenia yielding higher ratios (237). Several studies have shown that 
males have more negative symptoms while females have more affective symptoms (238), 
although some have not found sex differences in symptomatology (236). Females have also 
been found to suffer from more atypical and cyclical psychoses, which together with more 
affective symptoms reduce diagnostic concordance for women under different systems 
(238).   
Studies have also consistently shown that females typically have an older age of 
schizophrenia onset (12, 236). A mean age of onset of 30.1 years in females and 26.7 years 
in men was found in the WHO Determinants of Outcome Study (239), which began in the 
1980s and examined patients aged 15-54 from centres in 10 countries. Whereas the male 
age-at-onset distribution showed a single peak in the early twenties across countries, the 
female distribution showed a broad peak in the twenties with a second peak after age 40, 
illustrated in Figure 1.9 (239). Similar results were found in the ABC Schizophrenia Study 
(1987-1989) in Germany (239). Evidence for an additional female peak after age 60 was 
also found in a study by Castle, Sham, and Murray (1998) (240) that included older subjects. 
Sex differences in age of onset are consistent across cultures, definitions of onset, and 
diagnostic criteria of illness, and cannot be accounted for by gender differences in patient or 
family help-seeking behaviour (238). Studies have shown that the older female age of onset 
may occur only in the paranoid subtype of schizophrenia (241, 242) and that it dissipates in 
patients with a family history of schizophrenia (238). Together with better premorbid 
functioning, the older female age of onset is thought to account for the better social course 
and short- to medium-term prognosis of illness in women compared to men (12, 236, 243, 
244). Greater rates of substance abuse are present in men with schizophrenia, which are 
associated with poor adherence to treatment, more severe psychotic symptoms, violence, 
and homelessness (179, 236). Premenopausal women have also been reported to respond 
better to treatment with antipsychotic medication and require lower doses compared to their 
male counterparts (243, 245, 246). Postmenopausal women require higher antipsychotic 
doses and may develop more severe symptoms (12, 243).  
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Figure 1.9. Male and female age-at-onset distributions for schizophrenia in the WHO Determinants of 
Outcome 10-country Study (239). 
1.9.1 Pathology 
Despite the evidence for sex-based heterogeneity in schizophrenia, many studies do not 
report whether the results of analyses differed for males and females. Nevertheless, sex 
differences in brain abnormalities, HPG axis involvement, and genetic risks in schizophrenia 
provide evidence for differences in aetiology and/or pathophysiology between males and 
females. In general, a greater number of structural brain abnormalities have been found in 
male compared to female schizophrenia patients, including enlarged ventricles and smaller 
temporal and frontal lobes (247), though a meta-analysis in 2000 of regional brain volumes 
did not find evidence for this (248). A MRI study conducted by Goldstein et al (2002) (249) 
found disruptions in normal sexual dimorphisms in cortical brain volumes in schizophrenia, 
including sex-specific abnormalities in frontomedial cortex, basal forebrain, and planum 
temporale volumes and planym temporale asymmetry. Similarly, the orbitofrontal cortex to 
amygdala ratio was reported to be feminised in males with schizophrenia and masculinised 
in females (250). Other functional MRI (fMRI) studies have found reversals of normal sexual 
dimorphisms in cerebral activation during processing of aversive stimuli (251) and during 
mental rotation (252). A more prominent increase in hypothalamic volume has been found in 
female schizophrenia patients and non-psychotic first-degree relatives compared to controls 
(253). The magnitude of overall and region-specific reduced gray matter volume and their 
correlation with clinical variables in schizophrenia may be mediated by sex (254–257). Sex-
specific differences in cerebral asymmetry and craniofacial shape asymmetries may also 
occur in schizophrenia (258, 259). However, some of these findings are inconsistent and 
many require replication (238).   
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A number of studies have investigated the role of estrogen in schizophrenia. Psychosis has 
been associated with reduced estrogen levels after menopause and postpartum (260), while 
pregnant females experience fewer relapses and symptoms of schizophrenia are improved 
during the higher estrogen phase of the menstrual cycle (260–263). Hyperprolactinemia 
induced by typical and some atypical antipsychotics (264) is thought to contribute to 
menstrual disturbances, sexual dysfunction, and reduced fertility in female patients (265). 
However, studies dating from before the introduction of antipsychotic medication have found 
hypoestrogenism in female schizophrenia patients (266) and more recent studies have 
confirmed these findings in all phases of the menstrual cycle in patients who were using both 
typical and prolactin-sparing atypical antipsychotic medication (263, 267). A 2012 meta-
analysis concluded that estrogen treatment improved total, positive, and negative symptom 
severity in females with schizophrenia (9). Evidence of further gonadal dysfunction in 
schizophrenia has been found, though findings vary with chronicity of illness and treatment 
with antipsychotic medication. In treated patients, Bergemann et al (2005) (267) found low 
serum LH and progesterone and high testosterone levels. On the other hand, studies of 
male and female recent and first onset, antipsychotic naive schizophrenia patients have 
found elevated serum progesterone, prolactin, FSH, and LH (209, 268). Studies of 
testosterone and other androgens in men with schizophrenia have produced conflicting 
results, but some have found an inverse correlation between testosterone levels and 
negative symptom severity (269, 270).   
 Sex-specific and sex-dependent genetic risks may contribute to the heterogeneity of 
schizophrenia in males and females, but these require confirmation (271). These include 
genes with roles in dopaminergic metabolism catechol-O-methyltransferase (COMT) and 
monoamine oxidase (MAO) (272). Furthermore, three single-nucleotide polymorphisms 
(SNPs) on the X-chromosome were associated with schizophrenia in the most recent GWAS 
meta-analysis (216).  
1.9.2 Hypotheses  
A number of hypotheses have been proposed to explain the sex-based heterogeneity in 
schizophrenia, and these are described below. 
1.) Differences between male and female schizophrenia patients have lead to 
speculation that the sexes are differentially predisposed to subtypes of the 
disorder (273–276). Males may be more prone to schizophrenia caused by early 
environmental insults with a neurodevelopmental basis of illness. The late-onset form 
of schizophrenia more common in females may be aetiologically more similar to 
affective psychosis.  
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2.) Several neurodevelopmental theories of sex differences have been proposed.  
a. An early neurodevelopmental model of sex differences proposes that sex 
steroid hormones in males and females during pre- and neonatal 
development mediate susceptibility to brain lesions that later cause 
schizophrenia (238). Greater male brain lateralization may also reduce their 
ability to compensate for left brain injury. 
b. A late neurodevelopmental model posits that sex hormones influence 
excessive synaptic pruning in the prefrontal cortex that may cause 
schizophrenia (238). 
c. Neuroimaging and clinical data have lead to the hypothesis that 
schizophrenia is characterized by a reversed or disturbed cerebral sexual 
dimorphism (277). Sex hormone imbalances present during organization 
and activation may cause female masculinisation/un-feminisation and male 
feminisation/un-masculinisation of the brain in schizophrenia, leading to 
onset.  
3.) The estrogen hypothesis of schizophrenia proposes that estrogen is responsible for 
the reduced incidence, delay in female onset, more favourable course, and better 
response to treatment with antipsychotic medication in premenopausal women (260). 
Clinical, epidemiological, and animal studies have provided evidence for this 
hypothesis. In addition to its role in the brain, summarized in part in Section 1.2.1, 
estrogen also plays an important role in immune and inflammatory, cardiovascular, 
and metabolic processes implicated in schizophrenia. 
4.) Sex differences in genetic risk, or gene-sex interactions, may account for sex 
differences in schizophrenia (272). However, exploration of this topic is relatively 
new.  
 
1.10 Study aims and outline 
Despite much research, the aetiologies and pathophysiologies of schizophrenia and MDD 
have not been elucidated. New diagnostic and therapeutic technologies are needed to 
facilitate care of patients with these disabling conditions. Sex- and gender-based differences 
in incidence, prevalence, age of onset, symptoms, course of disorder, and response to 
antipsychotic medication have been found, the causes and mechanisms of which have also 
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remained elusive. The main aim of this thesis is to explore molecular sex differences and 
sex-dependent molecular differences in schizophrenia and MDD and their potential 
implications for pathophysiological mechanisms and biomarker studies and technologies. 
This will be accomplished by molecular profiling of serum and brain tissue using multiplex 
immunoassay and microarray technologies, respectively.  
The remaining chapters of this thesis will be organized as follows: 
 Chapter 2 explores the experimental and statistical methods used to obtain the 
findings presented in subsequent chapters. This includes an outline of the multiplex 
immunoassay and microarray technologies used for molecular profiling of serum and 
brain tissue. Data pre-processing and analysis methods for the data are also 
described.   
 
 Chapter 3 assesses variation in serum concentrations of proteins and small 
molecules in males and females in the follicular and luteal phases of the menstrual 
cycle, using OCs, and after menopause not affected by MDD or other mental 
disorders. It discusses the potential implications of these findings for schizophrenia 
and MDD and assesses the importance of recording sex and hormonal status for 
future biomarker studies. 
 
 Chapter 4 investigates sex differences in serum biomarkers of MDD and their 
potential relevance to diagnostic technologies. It tests whether these sex-dependent 
markers are present in CMA and persist in remitted MDD. Finally, it explores HPG 
axis function in females with current and remitted MDD and CMA compared to 
controls by assessing variations in the serum concentrations of reproductive 
hormones across follicular and luteal phases of the menstrual cycle, OC use, and 
after menopause.  
 
 Chapter 5 explores differences in the levels of serum proteins and small molecules 
between first onset, antipsychotic naive schizophrenia patients and controls and their 
modification by sex. Sex differences in the associations of these serum molecules 
with positive, negative, and general symptoms of schizophrenia are further 
investigated together with changes in their concentrations after six weeks of 
treatment with antipsychotic medication.  
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 Variations in gene expression in post-mortem prefrontal cortex tissue with 
schizophrenia diagnosis, sex, and sex-diagnosis interactions are explored in Chapter 
6. These are compared to serum findings from Chapters 3 and 5. Potential 
confounding with suicide status and lifetime antipsychotic, alcohol, and drug use are 
also evaluated. 
 
 Finally, Chapter 7 provides an integrated summary of the findings from Chapters 3-6 
and their implications, discusses limitations of the work in this thesis, and provides an 
outlook on future studies needed to improve and build upon this research.
 
  
Chapter 2 | 
35 
 
Chapter 2 Methods 
2.1. Human DiscoveryMAP® multiplex immunoassay 
The Human DiscoveryMAP® is a multiplex immunoassay from Myriad-RBM (Austin, TX, 
USA) that measures high and low abundance proteins and small molecules. It uses Luminex 
xMAP technology, which combines multiplexed microsphere-format enzyme-linked 
immunosorbent assays (ELISAs) with flow cytometry. Polystyrene microspheres measuring 
5.6 μm are coated in a primary antibody to capture a specific protein of interest. Different 
types of antibodies are used to coat the microspheres, each of which can be identified by an 
internal dye composed of a unique ratio of red to infrared fluorophores. A mixture of 
antibody-coated microspheres is combined with serum in a 96-well plate and incubated for 
one hour, during which time target proteins/molecules bind to the antibodies coating the 
microsphere. Detection antibodies, which are labelled with a fluorescent dye reporter signal, 
are then added and incubated for another hour. They bind to a specific part of the protein of 
interest and a flow cytometer then funnels the microspheres single-file into a detection 
chamber, where they are identified and quantified. A red laser is used to identify the 
microsphere by exciting the internal dye, while a green laser excites the fluorescent dye on 
the detection antibodies to quantify the amount bound. Multiplexing capabilities come from 
the use of flow cytometry and the unique internal dyes identifying each type of antibody-
coated microsphere. An overview of this process is shown in Figure 2.1. 
In this work, the protocol for the study participants, collection and storage of clinical samples, 
and test methods were carried out in compliance with the Standards for Reporting of 
Diagnostic Accuracy (STARD) initiative. Blood samples were collected following strict 
standard operating procedures in the morning, with no systematic differences between 
patients and controls. Venous puncture into S-Monovette 7.5 mL serum tubes (Sarstedt; 
Numbrecht, Germany) was used, and serum was prepared using standard protocols, leaving 
samples at room temperature for two hours to allow blood to coagulate. They were then 
centrifuged for five minutes at 4,000×g to remove particulate material and supernatants and 
stored at –80 ºC in LoBind Eppendorf tubes (Hamburg, Germany). Samples (250 μL) were 
shipped on dry ice and the assay procedure was carried out in a Clinical Laboratory 
Improvement Amendments (CLIA)-certified laboratory at Myriad-RBM (Austin, TX, USA). 
Samples were blinded to analysts until all assays are completed. Assays were calibrated 
using duplicate 8-point standard curves and raw intensity measurements were converted to 
absolute protein concentrations using proprietary software. Performance of the instrument 
was verified using low, medium, and high concentration quality control samples for each 
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analyte. Concentrations were reported as ng/mL, pg/mL or mIU/mL, as appropriate. Samples 
with insufficient volumes and analytes above or below the concentrations on the calibration 
curves were labelled accordingly. 
The panel of proteins and molecules was selected based on prior knowledge of peripheral 
biomarkers of disease and is not specific to mental disorders, constituting a semi-hypothesis 
driven approach. The panel focuses largely on metabolic and immune response functions 
and includes cytokines, chemokines, hormones, growth factors, transport proteins, acute 
phase response proteins, and other analytes important in mental disorders and other 
diseases. The specific molecules assayed vary between versions of the DiscoveryMAP®. 
The 95/171 analytes from the panels analysed in this work are listed in the Appendix (Table 
A.1). Measured proteins and steroid hormones important in reproductive function include 
testosterone, prolactin, FSH, LH, sex hormone-binding globulin (SHBG) and progesterone. 
The DiscoveryMAP® has been used to explore molecular changes in mental disorders, 
cancer and autoimmune, cardiovascular, and various other diseases (10, 278–284).   
 
Figure 2.1. Overview of Luminex xMAP technology used to quantify serum concentration of proteins and 
small molecules. Image courtesy of Viktoria Stelzhammer; reprinted with permission.  
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2.1.1 Advantages 
Proteomic methods provide an advantage over gene expression by directly measuring the 
functional components of cells. This results in a more straightforward determination of 
dysfunction in cellular mechanisms that underlie mental disorders. Compared to other 
technologies, the high dynamic range and throughput are key advantages of the multiplex 
immunoassay platform. These advantages reduce measurement variability and deterioration 
caused by lengthy individual experiments and allow simultaneous measurement of high and 
low abundance proteins. Furthermore, the required sample volume is relatively low, enabling 
valuable samples to be conserved.  
2.1.2 Disadvantages   
Incorporating new assays into the platform is expensive and costly. Therefore, relatively few 
proteins and molecules are measured and these are biased toward particular biological 
pathways and functions. Optimising signal intensity in the multiplex immunoassay requires 
compromise to minimise cross reactivity of detection antibodies with non-specific antigens 
and balance dilution ranges. Additionally, assays do not distinguish between post-
translational modifications, alternative splicing, and cleaved proteins. Plate and batch effects 
can also cause large-scale variation in concentration measurements. These factors need to 
be taken into consideration when analysing and interpreting data from this multiplex 
immunoassay platform.  
2.1.3 Clinical samples 
Psychiatric diagnoses were made as described in individual chapters. Recruitment, inclusion 
and exclusion criteria, and demographic information are also listed in separate chapters. The 
ethical committees of all participating universities approved the protocols of the studies and 
informed written consent was obtained. Where it was required, local ethical approval for use 
of human serum samples was granted by the Cambridgeshire Local Research Ethics 
Committee. Further details about the clinical samples can be found in individual Chapters 3-
6. Differences in demographic and other variables between groups to be compared in each 
chapter were assessed using Fisher’s exact test for categorical variables and a t-test or 
analysis of variance (ANOVA) for continuous variables using the statistical programming 
software R (v3.1.2) (285) and p<0.05 to indicate significance. 
2.1.4 Multiplex immunoassay data  
Data pre-processing for all samples was first carried out to remove assays with more than 
30% missing values using R. Lists of analytes present after this step, their abbreviations and 
UniProtKB accession or PubChem compound identifiers, and the percentage of missing 
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values for each assay can be found in the Appendix (Table A.1) for individual studies. 
Following removal of these assays, samples with more than 30% missing values were 
removed where these occurred. Missing values for the remaining assays were replaced by 
the minimum or maximum analyte level for measurements below or above the limit of 
quantitation, respectively. Analyte values missing due to low sample volume were replaced 
by the mean concentration for that analyte. Missing demographic or lifestyle variable values 
were also replaced by the mean (continuous) or most frequent (categorical) value when they 
were used in the analysis. Analyte values were log2-transformed to stabilize variance and 
improve normality. Multivariate outliers were assessed based on robust measures of the 
Mahalanobis distance (see Section 2.3.2). Logistic, linear, and robust regressions and other 
analyses (see Section 2.3) were then carried out as described in individual chapters.     
 
2.2 Affymetrix GeneChip® DNA microarrays 
Affymetrix GeneChip® single-channel DNA microarrays were used in this work to study 
gene expression by measuring levels of messenger ribonucleic acid (mRNA). Single strands 
of deoxyribonucleic acid (DNA) are built in situ on a quartz wafer by photolithography with 
combinatorial chemistry (286). Unique targets are chosen from the 3’ end of the transcript 
using various public databases (287). These probes are 25 bases in length, built and 
arranged such that each 8-11 μm square on the chip is composed of a specific type of probe 
(288). Features consist of either complementary perfect match (PM) probes or mismatch 
(MM) probes, illustrated in Figure 2.2. These differ from PM probes by one base at the 
centre base position and are designed to evaluate non-specific hybridization and 
background signal. Each sequence is interrogated with 11 probe pairs making up a probe 
set. The Affymetrix HG-U133A and HG-U133 Plus 2.0 chips used in this thesis measure 
47,400 transcripts (from 38,500 genes) and 18,400 transcripts (from 14,500 genes), 
respectively (288). 
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Figure 2.2. Illustration of a single Affymetrix GeneChip® feature. Image courtesy of Affymetrix; reprinted with 
permission. 
RNA samples are extracted and purified from the tissue of interest, and the quantity and 
quality of the extracted RNA are assessed. RNA samples then undergo reverse transcription 
to yield complementary DNA (cDNA) followed by transcription, amplification, and 
fragmentation to produce biotin-labelled complementary RNA (cRNA) fragments that are 
hybridized to arrays in batches (214). Following hybridization, staining takes place with a 
fluorescent molecule that binds to the biotin. They are then scanned with a laser and the 
fluorescence intensity of the spots is quantified. A summary of this process is shown in 
Figure 2.3. Data processing is then needed for background correction, normalization, 
summarization, and logarithmic transformation prior to further analysis. More details on this 
are found in Section 2.2.4 below. 
2.2.1 Advantages 
Although gene expression does not interrogate proteins directly, the high-throughput 
technology used to measure mRNA expression is technically simpler and more advanced 
than technology used to quantify protein abundance (289). The number of genes 
investigated in the DNA microarray is over 100 times the number of proteins measured with 
multiplex immunoassay in this thesis. Statistical methods and tools to examine quality and 
analyse microarray data have been developed, evaluated, and are widely available. 
Microarray experiments are numerous and public repositories of data have been created to 
store them. Measuring mRNA levels has proved useful for diagnosis and classification of 
cancers and other applications.  
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Figure 2.3. Summary of the steps performed during an Affymetrix GeneChip® DNA microarray 
experiment. Image courtesy of Affymetrix; reprinted with permission. 
2.2.2 Disadvantages 
Although proteins are translated from mRNA, a number of post-transcriptional processes 
may interfere with translation. This may in part cause poor correlation between levels of 
mRNA and protein, hindering interpretation of findings. Schwanhӓusser et al (2011) (290) 
found that mRNA expression explained approximately 40% of the variability in the levels of 
proteins for 5000 genes in mammalian cells. High experimental noise occurs in microarray 
experiments due to sample preparation and hybridization processes. 
2.2.3 Clinical samples 
Five microarray datasets of schizophrenia and control prefrontal cortex (Brodmann area (BA) 
9, 10, 46) were obtained from public repositories. All used Affymetrix (Santa Clara, CA, USA) 
HG-U133A or HG-U133 Plus 2.0 GeneChips®. Specific information for each cohort was 
obtained from the data repository or from articles published on the individual datasets 
[Maycox et al (2009) (291); Narayan et al (2008) (198); Glatt et al (2005) (214); Iwamoto, 
Bundo, and Kato (2005) (292); Torrey et al (2000) (293); the Stanley Medical Research 
Institute Online Genomics Database (www.stanleygenomics.org, accessed December 2014); 
and the Harvard Brain Tissue Resource Centre (Mclean66 collection, 
national_databank.mclean.harvard.edu, accessed December 2014)]. Further information is 
found in Chapter 6. Differences between groups for these variables were evaluated using 
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Fisher’s exact test for categorical variables and a t-test for continuous variables, with p<0.05 
considered significant. 
2.2.4 Microarray data 
2.2.4.1 Array quality 
Array quality can be assessed in a variety of ways, including measurement of RNA 
degradation; average, minimum, and maximum background levels; percentage of genes 
present; scale factors; 3’/5’ ratios for beta-actin and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH); and spike-in hybridization controls; and inspection of Relative Log 
Expression (RLE) and Normalized Unscaled Standard Error (NUSE) plots and spatial 
distribution of feature intensities. These array quality assessments were carried out here by 
using Bioconductor (v3.0) (294) arrayQualityMetrics (295), affy (296), and simpleaffy (297) 
packages with the statistical programming software R (v3.1.2) (285). Poor quality arrays 
were assigned lower weights in downstream analyses, as described in Section 2.2.4.3 
below. 
2.2.4.2 Pre-processing 
After array quality assessments, pre-processing reduces microarray data from the probe to 
the gene level. Robust multi-array average (RMA) is a widely used microarray pre-
processing procedure and performs background correction, normalization, and 
summarization using only PM probes. In this thesis, the methodologically similar frozen RMA 
(fRMA) was used to pre-process microarray data (298). RMA and fRMA use an exponential-
normal convolution model for background correction. This adjusts the signal for sources of 
noise in each array by modelling the observed PM intensity as      , where   (signal) 
follows an exponential distribution and   (background) follows a normal distribution 
truncated at zero (299). Background correction is performed separately for each array. 
Following this step, quantile normalization is used to give each array the same empirical 
distribution of intensities, removing technical variation and making arrays comparable. 
Quantile normalization requires a reference distribution, which in fRMA is provided by a 
“frozen” database of samples from public repositories (298). Probe intensities are 
summarized into measures of gene expression using median polish. Pre-processing of 
microarray data with fRMA was carried out using the Bioconductor fRMA package (298).    
2.2.4.3 Analysis 
Linear models were used to find differentially expressed genes using the limma package in 
Bioconductor (300, 301). With the approach in limma, estimated residual sample variances 
for each gene are shrunk towards a pooled estimate (301). A moderated t-statistic can then 
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be used for inference (see Section 2.3.4 for more on linear regression), thereby moderating 
standard errors for regression coefficients and increasing inference stability.  
Array quality weights were used in the analysis to down-weight observations with lower 
quality arrays. For this, variance factors are modelled from the data, array weights are 
determined, and these are used to calculate a weighted least squares estimate of regression 
coefficients for each gene (302). The arrayWeight function in the R Bioconductor limma 
package was used to find array weights (300, 302) and these were checked to ensure that 
low quality arrays (determined from findings in Section 2.2.4.1) received low weights. 
 
2.3 Statistics  
All data pre-processing, analysis, and plotting was carried out in this work using the 
statistical programming software R (v3.1.2) (285) and Bioconductor (v3.0) (294).This section 
describes most of the statistical procedures carried out in this work. Other procedures used 
are described in individual chapters. Procedures specific for multiplex immunoassay or 
microarray data are described above in Sections 2.1.4 and 2.2.4, respectively. 
2.3.1 ComBat 
ComBat is a method to eliminate batch effects across experiments (303) and was used in 
Chapter 6 for microarray data and in Chapters 3-4 for multiplex immunoassay data. It works 
by borrowing information across genes or proteins to calculate and adjust for additive and 
multiplicative batch effects. The adjusted data were then used in subsequent analyses. 
ComBat is implemented using the sva package in R (304). Principal component analysis 
(PCA) plots (Section 2.3.3 below) and boxplots of individual analytes were used to assess 
unadjusted and batch-adjusted data. 
2.3.2 Mahalanobis distance  
Mahalanobis distance was used to detect multivariate outliers in Chapters 3-5. The 
Mahalanobis distance for each sample    is defined as                     , where   
is a measure of location and   is an estimate of the covariance matrix (305). The sample 
mean and covariance are sensitive to outlying points, and therefore robust estimates of 
these were used (306, 307). The classic and robust squared Mahalanobis distances have   
  
and asymptotic   
  distributions for multivariate normal data, respectively (where   is the 
number of variables). In Chapters 3 and 4, the Maronna and Zamar (2002) (306) reweighted 
orthogonalized Gnanadesikan-Kettenring (OGK) robust estimates of location and dispersion 
were used to compute robust Mahalanobis distances, as implemented in covRob of the 
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robust package in R (308).  In Chapter 5, the Filzmoser, Maronna, and Werner (2006) (305) 
Sign procedure, designed for data with more dimensions than the number of observations, 
was used as implemented in sign1 of the mvoutlier package in R (309).  
2.3.3 Principal component analysis (PCA) 
Principal component analysis (PCA) was used in Chapters 3-6 to reduce the dimensionality 
of the data in order to facilitate visualization of patterns, including plate/batch effects, in the 
data. PCA converts correlated variables into sets of uncorrelated linear combinations of 
these variables (called principal components, PCs) that capture as much information as 
possible about the data. Geometrically, for the first PC, PCA finds the vector (called the 
loading vector) that is the direction along which the greatest variation occurs in the data in 
the space of the original variables. Scores are the projections of the data points onto this 
vector. The second PC is found in the same way with the constraint that the loading vector 
for the second PC is orthogonal to the loading vector for the first PC (the scores are 
uncorrelated with those of the first PC). Subsequent PCs are found such that the     PC 
loading vector is the direction of maximum variance, subject to being orthogonal to all 
previous loading vectors. PCA assumes that large variances have important structure, that 
PCs are orthogonal, and linearity (310). The PCA function in the R package FactoMineR 
was used for PCA analysis (311). 
2.3.4 Linear regression 
Linear regression models a linear relationship between a dependent variable and one or 
more explanatory variables in Chapters 3-6 of this thesis. This model is represented as: 
                                                            
where    is the dependent variable for observation  ;            are the   independent 
variables for observation  ;          are regression coefficients;   is the number of 
observations; and    is an unobserved random variable representing noise added to the 
linear relationship. An intercept is included by setting       for          and is the 
predicted value of the dependent variable when the values of all independent variables are 
zero. Coefficients for independent variables can be interpreted as the predicted change in 
the dependent variable for a one unit change in the independent variable, holding all other 
independent variables constant (i.e., the value of the partial derivative of the dependent 
variable with respect to that independent variable). When multicollinearity is present among 
the independent variables, the regression coefficient of each independent variable 
represents its additional contribution on the dependent variable after it has been adjusted for 
the remaining independent variables (312).  
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Categorical independent variables can be included in the regression by recoding to a set of 
new variables, with the number of new variables equal to one less than the number of 
categories. Dummy coding was used in Chapters 3-6, in which one category is chosen as 
the reference and indicator variables represent remaining categories. Each new variable is 
coded as 1 to indicate membership in a particular category and 0 otherwise (312). 
Coefficients for dummy coded categorical variables can be interpreted as differential 
intercept coefficients, whereby the intercept for the regression is shifted between categories. 
In Chapter 3, contrasts were set manually to compare categories.  
Ordinary least squares (OLS) estimates of  , found by minimising the sum of squares of the 
residuals, have the smallest variance amongst unbiased linear estimates according to the 
Gauss-Markov theorem (assuming linearity, constant error variance, independence, and lack 
of linear dependence in the independent variables). The lm function in the stats package in 
R (285) was used to carry out OLS linear regression and hypothesis testing for regression 
coefficients. 
2.3.4.1 Assumptions of OLS 
The following assumptions should be met in order to guarantee the validity of OLS estimates 
and other desirable properties described below (313–315): 
1. Correct specification: the model should be correctly specified with linear parameters. 
2. Measurement error: independent variables are measured without error. 
3. The expected value of errors in the regression is 0, conditional on the independent 
variables           : on average the model is exactly linear and errors are not 
correlated with independent variables.  
4. Spherical errors                :  
a. Homoskedasticity      
                : constant error variances. When 
heteroskedasticity is present, OLS estimates will not be efficient and 
inaccurate standard error calculations will result (315). 
b. No serial correlation                            : error terms of 
observations are uncorrelated.  
5. No linear dependence in the independent variables. Strong collinearity with other 
independent variables will cause the coefficient to be highly unstable and inflate its 
variance.  
6. Normality of errors                : this assumption is required for hypothesis 
testing and construction of confidence intervals. In large samples the levels of 
hypothesis tests and confidence intervals are approximately correct even with non-
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normal errors (315). However, particularly with heavy-tailed error distributions, OLS 
will be inefficient (315).  
In this thesis, these assumptions were verified by: examining residual regression plots to 
check for normality, heteroskedasticity, and examine influential points; checking for duplicate 
samples; and computing correlations between independent variables. As mentioned 
previously, analyte levels were log2-transformed to stabilize variance and improve normality. 
2.3.5 Robust regression 
Unusual data can heavily influence OLS. Regression outliers are observations with unusual 
values conditional on the independent variable. These were identified in this thesis as 
Studentized regression residuals with Bonferroni-corrected p-values < 0.05 (used to control 
the probability of making one or more false discoveries), calculated using the outlierTest 
function in the car package in R (316). When outliers occur at high leverage points, they 
have a substantial influence on the regression coefficients (315). Robust regression was 
performed as an alternative to OLS in this case in Chapters 3, 5, and 6. MM-estimators for 
regression were used, implemented in lmrob (robustbase package) in R (317), as they have 
a 50% breakdown point and 95% efficiency relative to OLS (318, 319).  The following 
procedure is used to find an MM-estimator of regression: 
1. Regression coefficients are found first using a high breakdown, consistent, but not 
necessarily efficient estimator. In this thesis, S-estimators are used, which find 
regression coefficients that minimise a robust estimate of the scale of the residuals. 
Regression residuals from the S-estimator are calculated. 
2. These residuals are used to compute a robust estimate of scale with a breakdown 
point of 50%.  
3. Finally, regression coefficients are computed using an efficient, robust estimator (M-
estimator) with the computed estimate of scale from the second step.  
MM-estimates of regression coefficients are asymptotically normal, enabling hypothesis 
testing, conducted using lmrob (robustbase package) in R (317).  
2.3.6 Generalized least squares (GLS)  
GLS was used in Chapter 4 to account for heteroskedasticity (non-constant error variance). 
Regression coefficients are found by solving a weighted ordinary least squares problem, as 
implemented using the gls function in the nlme package in R (320). Hypothesis tests were 
conducted using a likelihood ratio test (see Section 2.3.7 below).  
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2.3.7 Logistic regression 
Logistic regression models the relationship between the probability of an event       
            and the independent variables in Chapter 4. The logistic function is (321, 322): 
      
                          
                            
                 
where observations are indexed with subscript  ;   is the number of observations; and 
         are regression coefficients for   explanatory variables. This model can be 
manipulated to yield a function that is linear in the independent variables, with the left-hand 
side termed the logit: 
    
     
       
                                            
Parameters for this model are found using maximum likelihood estimation, a general method 
for estimating model parameters. Regression coefficients are interpreted as the change in 
log-odds associated with a one unit change in the independent variable, holding 
constant/adjusting for all other independent variables in the model.  Exponentiating the 
coefficient gives the odds ratio (OR) associated with a one unit change in the independent 
variable: 
       
               
             
                  
for   explanatory variables. A likelihood ratio test was conducted to compare the fit of the full 
model with the reduced model (322). Logistic regression and hypothesis testing was carried 
out using the glm function in the stats package of R (285). 
2.3.7.1 Assumptions of logistic regression 
Violation of logistic regression assumptions can have consequences for bias, efficiency, and 
statistical inference of estimates (321). The following assumptions are made: 
1. Correct specification: The logistic model should be correctly specified, with the 
binomial distribution appropriate for the response variable. The relationship described 
by the model should be linear in the logit (321).  
2. No linear dependence in the independent variables. Strong collinearity with other 
independent variables will cause the coefficient to be highly unstable and inflate its 
variance (321).  
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3. No overdispersion or underdispersion.  These occur when the observed variance is 
smaller or greater than the expected variance, respectively (321). However, in 
Bernoulli (binary response) data used in this thesis, there is no overdispersion or 
underdispersion.    
4. Independence of errors (323).  
As in linear regression, regression outliers at high leverage points can heavily influence 
model fit. In this thesis, assumptions were verified by examining residual plots for outliers, 
checking for duplicate samples, and computing correlations between independent variables. 
2.3.8 Interactions 
Interactions between variables occur in regression analyses when the relationship between 
the dependent variable and an independent variable is modified by one or more independent 
variables.  Here, the relationships between sex, schizophrenia or MDD diagnosis, and 
analyte levels were explored in linear and logistic regression. In linear regression, the model 
evaluated (Chapters 5 and 6) was: 
                                                                           
                         
where     is the log2-transformed concentration of analyte   for observation  ;     , 
          , and                 represent these variables;            are     additional 
explanatory variable vectors;           are regression coefficients;     is an unobserved 
random variable representing noise;  is the number of analytes;   is the number of 
explanatory variables; and   is the number of observations. Sections 2.3.4 and 2.3.5 above 
provide more details on linear regression (OLS and robust).  
Main effects of sex and diagnosis (    and    , respectively) are the predicted differences in 
log2-transformed analyte levels between males and females (   ) and between 
schizophrenia patients and controls (   ), adjusted for/holding constant other variables in the 
model. Their interaction,    , is the predicted change in the relationship between the log2-
transformed analyte level and diagnosis in females compared to males. Since analyte values 
are log2-transformed, testing whether the interaction coefficient       is equivalent to 
testing whether      
       . This can be interpreted as assessing whether the 
proportional impact of schizophrenia diagnosis on the raw, untransformed serum 
concentration of analyte   is the same in males and females (adjusted for/holding constant 
other variables in the model) (324): 
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where        is the untransformed concentration of analyte  ,     is schizophrenia, and    
is control. When this was significant, differences in analyte levels between schizophrenia 
patients and controls were investigated separately for males and females (i.e., separate 
estimation of           
       for males and females): 
        
                
              
                           
                  
                
                        
 
Example plots of potential main effects and interactions between sex and schizophrenia 
diagnosis in linear regression are in Figure 2.4. 
 
Figure 2.4.  Illustration of main effects and interactions. (A) shows a main effect of diagnosis on log2-
transformed concentration of analyte   on the left, and main effects of both diagnosis and sex on the right. (B) 
shows examples of possible interactions between sex and diagnosis. Abbreviations: NC (control); SCZ 
(schizophrenia). 
In logistic regression, the model evaluated (Chapter 4) was: 
    
      
        
                                                       
                         
Section 2.3.7 above provides more details on logistic regression. Testing the hypothesis 
      assesses whether the relationship between the log odds of MDD and the log2-
transformed concentration of analyte   differs between males and females (again, adjusted 
for/holding constant other variables in the model). When this occurred, inference and 
estimation on     was conducted for males and females separately: 
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Since analytes are log2-transformed, the exponentiated regression coefficient gives the odds 
ratio associated with a two-fold increase in the untransformed analyte concentration (again, 
adjusted for/holding constant other variables in the model). 
Interactions were also used to assess heterogeneity in effects between cohorts in Chapters 
5 and 6, where multiple studies were pooled together. This involved testing for an interaction 
between the cohort variable and the variable of interest (diagnosis or sex-diagnosis 
interaction term). 
2.3.9 Model selection 
In order to avoid overfitting and to clarify interpretation, variable subset selection can be 
used in regression (325). Analysis of variance (ANOVA) compares nested linear models in 
Chapter 3 and tests the null hypothesis that new variables do not add explanatory value 
over the reduced model. This was carried out using the aov or anova functions in the stats 
package in R (285). ANOVA for robust regression was also used, as implemented in the 
robustbase package in R (317).   
Stepwise variable selection was used in Chapters 3-5 for model building. Forward-stepwise 
selection was used, which sequentially adds independent variables to the model to improve 
the fit until a stopping criterion is reached, as well as mixed (or backward- and forward-) 
stepwise selection, which considers removing or adding a variable at each step. Bayesian 
information criterion (BIC) was used to select the most parsimonious model (325), which 
provides an indirect estimate of the test error of the model by adjusting the training error to 
account for the number of parameters in the model. BIC generally penalizes larger models 
more heavily than other criteria and is asymptotically consistent, selecting the correct model 
as     (312). The step function in the stats package of R (285) was used to perform 
stepwise regression.    
2.3.10 False discovery rate (FDR) 
Performing multiple statistical hypothesis tests simultaneously increases the chances of 
incorrectly rejecting a null hypothesis. In the microarray and proteomic experiments 
performed in this work, hundreds or thousands of hypothesis tests are performed. False 
discovery rate (FDR) procedures were therefore used in Chapters 3-6 to control the 
expected proportion of false positive findings. The method of Benjamini and Hochberg 
(1995) (326) assumes independent tests and defines the false discovery rate: 
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where   and   are given in Table 2.1 below, which describes the outcomes of testing   
hypotheses: 
Table 2.1. Results of performing  hypothesis tests: correct and incorrect rejections or failures to reject 
the null hypothesis.  
 Do not reject the 
null hypothesis 
Reject the null 
hypothesis Total 
Null hypothesis true        
Alternative hypothesis true        
       
 
The Benjamini and Hochberg FDR controlling procedure is performed by first ranking the   
obtained p-values in order of significance. Then   is the largest   for which 
     
 
 
  
where   is the index of the ranked p-value and   is the level at which FDR is controlled. Then 
all hypotheses         are rejected and         . A FDR analogue of the p-value, 
called the q-value, is the expected proportion of false positives among the list of results up to 
that finding, or the minimum FDR that can be attained where the finding will be called 
significant. These are calculated from the ordered p-values: 
              
 
 
                        
          
       
The p.adjust function in the stats package in R was used to compute q-values in this work 
(285).  
2.3.11 Random forests 
Random forests were used in Chapter 3 to classify observations using analyte 
concentrations and other demographic variables. This ensemble method constructs many 
classification trees and classifies new observations based on the majority decision (majority 
vote) of these trees (327). Each tree in the forest is grown from   random cases sampled 
with replacement (from   observations) by recursively splitting observations until the terminal 
node contains data purely from one category (328, 329). The maximum decrease in the Gini 
impurity criterion, a measure of node homogeneity, determines the best way to split the data 
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at each node from     (of   total) randomly selected variables (328, 329). The Gini impurity 
criterion is (312): 
        
 
 
   
 
where    is the fraction of observations with label   in the set, of a total of  possible labels. 
Greater node homogeneity occurs with smaller values of   , which reaches zero when the 
node contains observations from only one category. Figure 2.5 shows a simulated example 
of a single decision tree for classifying an observation as either disease or control based on 
log2-transformed analyte concentrations. Random forests were composed of 5000 trees and 
built using the randomForest function in the R package of the same name (329). Variable 
importance was assessed by adding the decreases in Gini impurity resulting from a split on a 
particular variable and averaging over the number of trees (328).  
 
Figure 2.5. Simulated decision tree for classifying an observation as either disease or control based on 
log2-transformed analyte concentrations. For each node, the top line shows the enriched class; the middle line 
shows the proportion of each class; and the bottom line shows the percentage of observations. The decision 
boundary is shown below each node. Only part of the decision tree is shown (terminal nodes are not shown). 
2.3.12 Classification performance 
In order to assess the performance of the MDD classifications in Chapter 4, a repeated ten-
fold cross-validation procedure was performed, followed by plotting the receiver operating 
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characteristic (ROC) curve and measuring the area under the ROC curve (AUC). For the 
ten-fold cross-validation, the data was randomly divided into ten partitions, stratified by sex 
and MDD diagnosis using the sample function in the base package in R. Nine of these 
partitions were used to create a logistic model that was used to estimate the probability of 
MDD diagnosis for the observations in the last partition. This was then repeated for each of 
the remaining partitions. The entire process of randomly dividing into stratified partitions, 
building the model using nine partitions, and evaluating in the last was done 50 times.  This 
provides a better estimate of the complete cross-validation (or leave-10-out cross-validation), 
the average of all possible different splits into ten partitions (330). The average ROC curve 
can be generated by first merging all test sets into one large set (331). The true and false 
positive rates are then found and plotted for each classification threshold. A classifier with a 
ROC curve along the line     represents the performance expected by randomly guessing 
a class, with curves above this line representing better classifier performances. The AUC of 
the ROC curve is a single measure of classifier performance and is the probability that a 
randomly chosen subject with MDD will be ranked higher than a randomly chosen control 
subject (331, 332). Examples of possible ROC curves and AUCs for classifiers are shown in 
Figure 2.6.  In this thesis, ROC curves were generated and AUCs were calculated using the 
ROCR package in R (333).  
 
Figure 2.6. Examples of ROC curves to assess classification performance and their AUCs.  
2.4 Gene Ontology (GO) terms 
The Gene Ontology (GO) Consortium provides a dynamic, controlled vocabulary for 
annotating genes based on three independent ontologies: cellular components, molecular 
functions, and biological processes (334). Chapters 3-6 investigated the biological 
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processes of genes and proteins found to be involved in sex and mental disorders using GO 
terms and manual searches of the literature. UniProtKB accession (proteins) and Affymetrix 
3’ IVT array identifiers (genes), were used in the Uniprot.ws (335) and biomaRt (336, 337) 
packages in Bioconductor, respectively, to find biological process GO terms associated with 
lists of genes or proteins. These were mapped to ancestor terms using the GOSim package 
in Bioconductor (338). In Chapters 3 and 6, summaries of GO terms for significant genes or 
proteins were prepared, with selected terms based on the number and relevance of 
annotated proteins. The European Bioinformatics Institute (EBI) browser for GO annotations, 
QuickGO (http://www.ebi.ac.uk/QuickGO/, accessed March 2015) and the UniProt website 
(www.uniprot.org; accessed March 2015) were also used to investigate GO terms for 
individual genes or proteins. 
2.4.1 GO term enrichment 
GO biological process term enrichment of significant genes was examined in Chapter 6. 
Affymetrix 3’ IVT array identifiers were mapped to Entrez Gene identifiers using biomaRt  
(336, 337) and overrepresented biological process (BP) terms were evaluated using GOstats 
in Bioconductor (339). GOstats uses a hypergeometric test to evaluate enrichment of terms. 
However, the hierarchical structure of GO ontologies often means many directly related GO 
terms are identified as being enriched. For this reason, a conditional test was used in which 
genes with significantly enriched terms are removed when testing the parent term (339). 
Here, at least ten annotated genes for the term were required and p<0.001 was considered 
statistically significant.
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Chapter 3 Variations in serum 
molecular concentrations associated 
with sex and female hormonal status 
 
3.1 Introduction 
Sex and gender differences are an important component of the heterogeneity of mental 
disorders and can include differences in prevalence, incidence, age of onset, symptoms, 
course of the disorder, and treatment response (17, 154, 157, 236, 340). Some of these may 
be explained by sex-dependent regulation of biological pathways. Endocrine, nervous, 
immune, metabolic, and cardiovascular function all show substantial variation between 
males and females and are important in mental disorders (see Chapter 1). However, many 
of these processes and the changes that may accompany variations in the levels of sex 
hormones after menopause, during oral contraceptive (OC) use, and within the menstrual 
cycle are poorly understood.  
Important insights into sexually dimorphic disease mechanisms have been gained by 
studying sex differences in control populations. Research into sex differences in immune, 
metabolic, and cardiovascular function has benefitted understanding of the higher 
prevalence of most autoimmune diseases in females, better prognosis for cardiovascular 
diseases in premenopausal females, sex differences in pharmacological response, and 
others (see Chapter 1). The study of nervous system development and function in males 
and females has also lead to a better understanding of possible mechanisms for sex 
differences in mental disorders, though many other potentially important sexually dimorphic 
biological processes remain to be elucidated.  
Investigations of sex differences at the molecular level carried out so far have largely been 
limited to the study of only a few molecules and mechanisms. A previous study by Ramsey 
et al. (2012) (341) evaluated sex differences in 174 serum molecules in a meta-analysis of 9 
independent cohorts comprising 392 subjects free of mental disorders and other chronic 
conditions (196 males/196 females). They found 40 analytes elevated in females and 37 
elevated in males. Clusters of molecules enriched in fatty acid oxidation/hormone regulation, 
immune cell growth and activation, and cell death processes were elevated in females, while 
clusters of molecules enriched in immune cell chemotaxis and other indistinct functions were 
elevated in males. However, demographic and lifestyle information was limited and hormonal 
status of females (phase of menstrual cycle, menopausal status, use of OCs, etc.) was 
unavailable. Furthermore, although the Ramsey et al (2012) (341) study found sex 
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differences in a large proportion of serum molecules, the potential consequence of these 
differences for biomarkers studies was not evaluated. Although many studies now record 
and some also match for sex, female hormonal status is typically not assessed. This 
includes recent biomarker studies of schizophrenia and major depressive disorder (MDD) 
(129, 278). The result of ignoring sex and female hormonal status in these and other studies 
has not been assessed.  
3.1.1 Aims and objectives   
The work presented in this chapter had the following aims and objectives: 
1.) To investigate differences in biological processes between males and females by 
determining serum analyte concentrations that vary with sex and female hormonal 
status (OC use, phase of menstrual cycle, and menopausal status). This was done in 
a cohort of subjects free of mental disorders using a Human DiscoveryMAP® 
multiplex immunoassay panel of 243 molecules. Agreement with the Ramsey et al 
(2012) (341) meta-analysis was evaluated and the potential relevance of the results 
to schizophrenia and MDD was assessed by comparing them to reported peripheral 
(serum/plasma) markers of these disorders. 
2.) To evaluate the possible effect of ignoring sex and female hormonal status on the 
number of false positives obtained in biomarker studies comprising these analytes. 
This was assessed through simulations of group imbalances in these variables. 
3.) To construct and evaluate algorithms for classifying sex and female hormonal status 
of samples. Classification tools were constructed using both the full set of analytes 
and demographic, lifestyle, and health variables available in the current study and 
also using a reduced set that was available in previous studies. Performance of the 
classification tool was evaluated on subjects with current and/or past depressive and 
anxiety disorder episodes. The goal of this was to assess whether sex and/or female 
hormonal status of samples from prior investigations could be evaluated where this 
had not been recorded.       
In order to accomplish these aims and objectives, samples from the Netherlands Study of 
Depression and Anxiety (NESDA) were used. NESDA is a well characterized and ongoing 8-
year longitudinal, multi-site naturalistic cohort study with participants recruited from the 
general population, general practices, and mental health organizations in the Netherlands 
(342). A total of 347 individuals free of mental disorders enrolled in the NESDA study were 
included in the first two parts of the study and another 1,329 suffering from current and/or 
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past depressive and anxiety disorders episodes were also included in the last part of the 
study. 
  
3.2 Methods 
3.2.1 Clinical Samples 
Serum samples from NESDA were collected from municipalities in the Netherlands. 
Recruitment of 2,981 participants aged 18-65 years took place between 2004-2007 from the 
community (19%), general practice (54%), and secondary mental health care (27%). The 
ethical committees of all participating universities approved the protocols of the study and 
informed written consent was given by all participants. Local ethical approval for use of 
human serum samples was granted by the Cambridgeshire Local Research Ethics 
Committee. 
Control subjects had neither a current nor a lifetime diagnosis of assessed psychiatric 
disorders according to the Composite Interview Diagnostic Instrument (CIDI) and did not 
develop any such disorder by the second year follow-up assessment. In women, use of OCs 
and sex hormones (World Health Organization Anatomical Therapeutic Chemical (WHO-
ATC) classification code G03; yes/no) was assessed by self-report. OCs were combined 
(estrogen and progestogen) or progestogen only with varying doses of estrogen, different 
types of progestogen, and were monophasic or triphasic. Classification of menstrual cycle 
phases in women [follicular (0-13 days) and luteal (14-32 days or more)], postmenopausal 
status (yes/no), hysterectomy (yes/no), and pregnancy or breastfeeding status (yes/no) were 
also self-reported. Women who were pregnant or breastfeeding, using hormones not 
classified as OCs, had ungergone a hysterectomy, or with missing information on hormonal 
status were excluded from further analysis in this study. Other demographic, lifestyle, and 
health information recorded included ancestry (North European/other); education (years); 
systolic and diastolic blood pressure (mm Hg); physical activity (measured in 1000 metabolic 
equivalent (MET)-minutes per week, assessed with the International Physical Activity 
Questionnaire (343)); self-reported presence of treated chronic somatic disease (yes/no, 
further details below); use of lipid modifying agents (ATC code C10; yes/no); use of anti-
inflammatory drugs (ATC codes H02, R03BA, R03AK, D07, M01A, M01B, A07EB or A07EC; 
yes/no); use of antihypertensive medication (ATC codes C02, C03, C07, C08, or C09; 
yes/no); collection area (Amsterdam, Leiden, and Groningen); body mass index (BMI; 
kg/m2); waist circumference (centimetres); age (years); alcohol consumption (drinks/week); 
smoking status (never smoked/former smoker/regular smoker/not a regular smoker); 
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recreational drug use in the past month (yes/no, further details below); partner status 
(with/without partner); sex (male/female); and female hormonal status (see above). Chronic 
diseases considered were cardiovascular disease, diabetes, lung disease, osteoarthritis, 
rheumatic disease, cancer, ulcer, intestinal problem, liver disease, epilepsy, thyroid gland 
disease and others. Presence of cardiovascular disease was assessed by self-report and 
confirmed by use of appropriate medication, while presence of diabetes was assessed by 
use of anti-diabetic medication (ATC code A10) or by fasting plasma glucose level ≥7.0 
mmol l−1. Other chronic diseases were treated and assessed by self-report. Recreational 
drugs considered were cannabis, speed, cocaine, heroin, and LSD. Medication use was 
evaluated by self-reporting and inspection of drug containers used in the past month, from 
which ATC codes were recorded.  
Diagnoses of depressive disorders (MDD and dysthymia) and anxiety disorders (social 
phobia, generalized anxiety disorder, panic disorder, and agoraphobia) were carried out 
during a baseline interview by specially trained research staff using the CIDI in accordance 
with the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria (22). 
Patients with current disorders were classified as having a depressive and/or anxiety 
episode within the past six months. Participants completed a 30-item self-rated Inventory of 
Depressive Symptomatology (IDS) and 21-item self-report Beck Anxiety Inventory (BAI) 
(344, 345). Remitted patients had a lifetime diagnosis of a depressive and/or anxiety 
disorder but were not currently experiencing an episode. Patients and controls were 
excluded who were not fluent in the Dutch language, had a primary clinical diagnosis of 
other psychiatric disorders not studied in NESDA: bipolar disorder, obsessive compulsive 
disorder, severe substance use disorder, or psychotic disorder. Further details of the NESDA 
study design and protocol and descriptions of all participant information recorded have been 
previously described (342). 
Blood samples from NESDA were collected at the baseline assessment at approximately 
0800 hours from all participants.  The Human DiscoveryMAP® multiplex immunoassay 
platform, described in Chapter 2, was used to measure the serum concentrations of 243 
total analytes across 1,840 available NESDA participant samples assigned to 26 plates. 
Remaining samples did not participate in both baseline and two-year follow-up assessments, 
had insufficient volume, or were otherwise unusable. Of these, three samples were removed 
after internal quality control checks.  
3.2.2 Data pre-processing 
Data analysis and pre-processing was carried out as described in Chapter 2. Seventy-two 
assays were removed with more than 30% missing values, leaving 171 for further analysis. 
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A list of these 171 analytes, their UniProtKB accession or PubChem compound identifiers, 
and the percentage of missing values in each assay can be found in the Appendix (Table 
A.1). In addition, one sample with more than 30% missing assays was removed. Remaining 
missing assay values were replaced as described in Chapter 2. To adjust for batch effects 
caused by running samples on different plates, ComBat was used after log2 transforming the 
analyte data, as described in Chapter 2. Multivariate outlier assessment (Chapter 2) 
resulted in the removal of an additional four samples. Missing covariate data (MET: 5.0% 
missing, alcohol consumption: 0.8% missing, and recreational drug use: 0.5% missing) was 
replaced with the mean or most frequent value for continuous and discrete variables, 
respectively.   
3.2.3 Sample exclusion 
After data pre-processing, 1,832 samples remained for analysis. Additional samples were 
excluded for the following reasons: 1) the participants had not fasted when blood was 
withdrawn (N=56); or the participants were females who, 2) were pregnant or breastfeeding 
(N=10), 3) used sex hormones not classified as OCs (N=18), 4) had undergone a 
hysterectomy (N=61), and 5) had missing hormonal status information (N=11). This left 
1,676 samples for further analysis, consisting of 347 control subjects (140 males/207 
females) and 1,329 subjects with a current or remitted diagnosis of depression, anxiety, 
and/or dysthymia, or who were diagnosed with a mental disorder in the second year follow-
up assessment (261 males/1068 females). 
3.2.4 Data analysis 
A linear model was used to detect sex differences in the concentrations of analytes in 
NESDA control subjects. Demographic and other information for males and females is 
summarized in Table 3.1A. The analysis also considered collection area (Amsterdam, 
Leiden, and Groningen in the Netherlands); recruitment method (community/general 
practice); chronic disease (yes/no);  use of lipid modifying agents (yes/no); use of anti-
inflammatory drugs (yes/no); use of antihypertensive medication (yes/no); ancestry (North 
European/other); education (years); physical activity (1000 MET-minutes per week); body 
mass index (BMI; kg/m2); age (years); alcohol consumption (drinks/week); smoking status 
(never smoked/former smoker/regular smoker/not a regular smoker); recreational drug use 
(yes/no); partner status (with/without partner); and IDS score as additional covariates for this 
analysis of analyte data. Covariates were selected using stepwise regression with 
simultaneous forward selection and backward elimination using BIC selection criterion, as 
described in Chapter 2. Robust regression (MM-estimator) was used where regression 
outliers were present (with Bonferroni-corrected p-value < 0.05), calculated using the 
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robustbase package in R (317). The log2 ratios of serum molecular concentrations in males 
compared to females were found from the coefficients of the linear regression. Gene 
ontology (GO) biological process (BP) terms for significant proteins were found using the R 
Bioconductor package Uniprot.ws (335) and these were mapped to all ancestor terms using 
the GOSim package (338). A summary of GO terms for each significant protein was 
prepared, with GO terms selected based on relevance and number of annotated proteins. 
The results were compared to the Ramsey et al (2012) (341) meta-analysis findings. 
Furthermore, the relevance of the findings to schizophrenia and MDD were evaluated. This 
was done by compiling lists of reported peripheral markers (plasma or serum) of 
schizophrenia (130, 209, 212, 278, 346) and MDD (129, 130) and comparing these to 
analytes that varied significantly with sex and hormonal status in the current study.  
In order to investigate the effect of female hormonal status on concentration of serum 
analytes, ANOVA was used to evaluate the effect of adding these (male/follicular 
phase/luteal phase/postmenopausal status/OC use) to the linear model. Where robust 
regression was used, ANOVA used a robust Wald-type test implemented in the robustbase 
package in R (317). Contrasts were used to evaluate the levels of serum analytes in females 
using OCs compared to females with a menstrual cycle (females in the follicular and luteal 
phases of menstruation), postmenopausal compared to females with a menstrual cycle, 
males compared to females with a menstrual cycle, and females in the follicular compared to 
luteal phase of the menstrual cycle. The log2 ratios of serum molecular concentrations 
between hormonal statuses were assessed. Finally, the first two principal components (PCs) 
from a principal component analysis (PCA) of all analyte data were used to visualize 
patterns of variation arising with sex and female hormonal status.  
The FDR analogue of the p-value (q-value) was calculated for these analyses to control the 
expected proportion of false positive findings due to multiple testing, described in Chapter 2. 
Q-values were considered significant at the 5% level. 
 Table 3.1. Demographic, lifestyle, and health characteristics for (A) NESDA controls (training set) and (B) NESDA test set subjects. The set of subjects in (A) was 
used to evaluate variations in serum analyte levels with sex and female hormonal status and to construct random forest classifiers to group subjects as males, oral 
contraceptive (OC) users, postmenopausal females, and females with a menstrual cycle. The set of subjects in (B) was used as a test set for the random forest classifiers built 
using the NESDA control cohort. Values are shown as the mean ± the standard deviation. Differences between groups were assessed using ANOVA (continuous data) or 
Fisher's exact test (categorical data). Variables in bold are significantly different (p < 0.05) between groups. Abbreviations: BMI (body mass index); IDS (Inventory of 
Depressive Symptomatology). 
 
  
(A) Female 
Male 
 
OC user Follicular phase Luteal phase Postmenopausal 
N 79 34 37 57 140 
Age (years) 28±10 36.4±12 35.8±10 55.9±6 39.7±15 
BMI (kg/m
2
) 23.4±4 25.1±6 25.1±5 25.8±5 25.3±4 
Waist circumference (cm) 79.5±12 82.5±13 85.4±14 88.3±12 93.1±13 
North European ancestry % (Yes/No) 96/4 94/6 100/0 98/2 99/1 
Area % (Amsterdam/Groningen/Leiden) 10/68/22 15/38/47 22/41/38 26/23/51 11/51/38 
Frame % (General population/Primary care) 48/52 29/71 27/73 0/100 33/67 
Education (years) 12.6±3 13.1±4 13.7±3 11.9±4 12.7±3 
Partner % (Yes/No) 73/27 79/21 76/24 82/18 74/26 
Smoking % (Current smoker/Former smoker/Never smoker) 19/30/51 32/35/32 30/19/51 23/44/33 31/37/32 
Alcohol (drinks per week) 4.4±5 2.8±5 5.5±7 6.6±8 10.8±11 
Recreational drug use in last month % (Yes/No) 5/95 9/91 3/97 0/100 9/91 
Chronic disease % (Yes/No) 19/81 38/62 22/78 51/49 31/69 
Anti-inflammatory medication % (Yes/No) 3/97 3/97 5/95 4/96 1/99 
Lipid modifying agents % (Yes/No) 1/99 0/100 0/100 7/93 8/92 
Antihypertensive medication % (Yes/No) 9/91 3/97 3/97 23/77 15/85 
Physical activity (MET) 3822.4±2571 4616.2±4093 3079.5±2595 3626.2±2687 4154.5±3551 
Systolic blood pressure (mm Hg) 127.6±15 122.5±12 124.7±14 139.5±28 144.8±18 
Diastolic blood pressure (mm Hg) 77.3±10 74.4±8 76.8±11 80.7±15 81.7±12 
IDS score 8.5±7 8.8±9 7.3±6 9.8±8 5.5±5 
 
 
(B) Female 
Male 
 
OC user 
Follicular 
phase Luteal phase Postmenopausal 
N 263 149 211 261 445 
Age (years) 30.9±10 36.2±9 36.5±9 55±6 43.4±13 
BMI (kg/m
2
) 24.4±5 25.3±5 25.3±6 26.9±5 26.3±5 
Waist circumference (cm) 81.8±12 84.7±13 84.4±14 90.7±13 96.2±14 
North European ancestry % (Yes/No) 95/5 97/3 94/6 94/6 97/3 
Area % (Amsterdam/Groningen/Leiden) 17/44/38 22/38/40 25/42/33 16/38/46 16/42/42 
Frame % (General population/Primary care) 25/39/36 18/48/34 15/44/41 12/72/16 20/42/38 
Education (years) 11.9±3 12.3±3 12.3±3 11.5±3 11.8±3 
Partner % (Yes/No) 69/31 66/34 67/33 70/30 72/28 
Smoking % (Current smoker/Former smoker/Never 
smoker) 37/27/37 36/28/36 46/29/25 29/46/25 43/34/23 
Alcohol (drinks per week) 4±6 4.8±8 5.6±9 6.3±8 11±14 
Recreational drug use in last month % (Yes/No) 10/90 5/95 7/93 2/98 9/91 
Chronic disease % (Yes/No) 35/65 33/67 33/67 60/40 47/53 
Anti-inflammatory medication % (Yes/No) 6/94 7/93 3/97 8/92 6/94 
Lipid modifying agents % (Yes/No) 1/99 2/98 1/99 12/88 11/89 
Antihypertensive medication % (Yes/No) 3/97 6/94 7/93 27/73 18/82 
Physical activity (MET) 3763.3±3264 3703.6±2772 3340.5±2920 3749.2±2908 3728.3±3241 
Systolic blood pressure (mm Hg) 126.8±13 126.7±17 124.9±19 143.1±22 144.1±20 
Diastolic blood pressure (mm Hg) 77.8±9 79.6±11 77.7±13 85.6±11 84.5±12 
IDS score 23.6±12 24.4±13 24.7±13 24±13 24.5±13 
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3.2.5 Simulation of group imbalance of sex and female hormonal status 
In order to assess the effect of ignoring sex and female hormonal status on false discovery 
in biomarker studies, simulations were performed. In the first, an imbalance in the number of 
males and females in two groups was simulated. The sex composition was varied from 
having an even split of males and females in each group to having each group entirely 
composed of samples of one sex. For each simulation, 50 samples were selected with 
replacement from male and female NESDA control subjects to represent each group. A t-test 
was used to test for differences between the two groups in each of the 171 analyte levels 
and the number of false discoveries (p-value < 0.05) was recorded. Ten thousand 
simulations were performed for each male/female group composition and the average 
percentage of false discoveries was calculated. In the second simulation, this procedure was 
repeated to investigate false discoveries in two groups of females with an imbalance in the 
composition of reproductive-age OC users.  
3.2.6 Classification of sex and female hormonal status 
Data from NESDA control subjects were used to build a random forest classifier to 
distinguish between males, postmenopausal females, OC users, and females with a 
menstrual cycle. In addition to the concentrations of the 171 serum analytes, covariates used 
in the linear models were included, apart from recruitment method. Additional covariates 
waist circumference (centimetres), systolic blood pressure and diastolic blood pressure (mm 
Hg) were also used. The out-of-bag (OOB) error in this training sample was assessed and 
the remaining 1,329 NESDA samples were used to test the performance of the classifier. 
These test samples were largely comprised of samples from individuals diagnosed with a 
current, lifetime, or second year follow-up diagnosis of depressive and/or anxiety disorders. 
Demographic and other information for these remaining NESDA samples can be found in 
Table 3.1B. This procedure was repeated to construct a random forest classifier for female 
hormonal status only using age and a subset of 79 assays measured in previous versions of 
the Human DiscoveryMAP® multiplex immunoassay platform (see the Appendix (Table 
A.1) to see analytes measured in NESDA and previous cohorts). For both classifiers, 5000 
trees were constructed using the randomForest packages in R (329). Mean decrease in the 
Gini index, a measure of node purity, was used to assess variable importance. Chapter 2 
provides more details on random forests.  
 
3.3 Results 
In the NESDA controls a number of demographic, lifestyle, and health variables differed 
significantly between males, postmenopausal females, females using OCs, and females in 
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the follicular and luteal phases of the menstrual cycle. These included differences in age, 
BMI, waist circumference, alcohol consumption, presence of chronic disease, use of 
antihypertensive medication, blood pressure, IDS scores, collection area, and recruitment 
method (Table 3.1A). With the exception of IDS scores and collection area, these 
differences were also observed in the remaining NESDA data (Table 3.1B). These variables 
were associated with changes in analyte levels. For example, the levels of 47 of the 171 
analytes differed by recruitment method (whether participants were recruited from the 
community, general practice, or specialised mental health care facility; p<0.05). Age, BMI, 
collection area, recruitment method, use of antihypertensive medication, and weekly alcohol 
consumption were the variables most often selected in the stepwise regression of NESDA 
control data as additional covariates.  
ComBat was effective in normalizing analyte concentrations across plates, as illustrated for 
selected molecules in Figure 3.1. The concentrations of 96 serum analytes differed between 
males and females (q<0.05) in the linear model described in Section 3.2.4. Of these, 43 had 
higher concentrations in females and 53 had higher concentrations in males (Table 3.2; 
Figure 3.2). Findings from the meta-analysis of Ramsey et al (2012) (341) were largely 
consistent with the current study, with 49 of the findings replicated out of 60 assays 
overlapping between the studies (Table 3.2; Figure 3.2).  
Sex differences in 45 of the 96 serum analytes varied significantly (q<0.05) with female 
hormonal status (postmenopausal, OC use, follicular, and luteal phase of the menstrual 
cycle). An additional 21 serum analytes also showed significant (q<0.05) variation in their 
concentrations with female hormonal status (Table 3.3; Figure 3.3). Linear contrasts in the 
model revealed significant differences between females using OCs and those with menstrual 
cycles in the levels of 55 of these 66 serum analytes. Twenty-six of these analytes were 
different between postmenopausal females and females with a menstrual cycle. Table 3.3 
and Figure 3.3 show that most of the significant differences between postmenopausal 
females and females with menstrual cycles opposed the differences in analyte levels 
between females with menstrual cycles and males. Only five of the 66 serum analytes 
differed significantly between females in the luteal and follicular phases of the menstrual 
cycle (Table 3.3). Follicle-stimulating hormone (FSH), neuropilin-1, and insulin-like growth 
factor binding proteins (IGFBP)-2 and -3 were increased in the follicular phase, while 
progesterone was increased in the luteal phase. The PCA plot in Figure 3.4 was constructed 
using analyte data and further illustrates the differences in serum molecular profiles between 
males and females for each hormonal status. In the first principal component, OC users and 
males showed the greatest separation between groups, while females in the follicular and 
luteal phases of the menstrual cycle showed the smallest separation. Analytes that varied 
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significantly with sex and female hormonal status were related to metabolic processes, 
developmental processes, cell communication and signal transduction, transport, growth and 
cell proliferation, chemotaxis, response to stress, cell death, defence, inflammatory, and 
immune response, nervous system development, vasculature development, and others 
(Table 3.2 and Table 3.3). In total, 45 of the 117 analytes that differed between males and 
females or with hormonal status were also reported to be altered in schizophrenia patients 
and 23 were changed in MDD patients.  
   
Figure 3.1. ComBat-normalized 6Ckine and insulin-like growth factor binding protein (IGFBP)-5 analyte 
concentrations. Boxplots across all plates are shown for log2-transformed analyte concentrations before (left) 
and after (right) applying ComBat.  
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Table 3.2. Serum analytes elevated in (A) females and (B) males. Analytes are ordered from top to bottom 
by decreasing significance in the discovery cohort (reported in the columns of q-values). Robust regression 
was used where * follows the analyte name. The log2 ratios of serum molecular concentrations in males 
compared to females shown in the plots were coefficients from the linear regression. Serum analytes that 
varied significantly with female hormonal status are indicated (see Table 3.3). These are coloured in blue 
where analytes were significantly different between oral contraceptive pill users and females with a menstrual 
cycle; orange where they were significantly different between postmenopausal females and females with a 
menstrual cycle; and yellow where there were multiple significant contrasts. Agreement with our previous study 
is shown by a . SCZ and MDD markers are indicated by  (elevated in patients);  (reduced in patients); or 
 (conflicting evidence for elevated and reduced levels in patients). Biological processes were found from 
gene ontology (GO) terms. Abbreviations: NM (not measured in our previous study); SCZ (schizophrenia); 
MDD (major depressive disorder); MP (metabolic process); DP (developmental process); CC & ST (cell 
communication and signal transduction); IR (defense/immune/inflammatory response); CP (cell proliferation); 
NSD (nervous system development); VD (vasculature development). Analyte abbreviations can be found in the 
Appendix (Table A.1). GO terms (left to right): GO:0008152; GO:0032502; GO:0007154 and GO:0007165; 
GO:0006810; GO:0040007 and GO:0008283; GO:0006935; GO:0006950; GO:0008219; GO:0006952 and 
GO:0006955 and GO:0006954; GO:0007399; GO:0001944. 
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Leptin -2.06 4.E-64 

   





FABP, adipocyte* -0.68 1.E-31  NM 
  

   



 
GH -2.38 1.E-29     
     
SHBG -1.09 4.E-29  
  

 

     
Apo A-I* -0.25 3.E-17 

   



Adiponectin -0.60 8.E-15 

   


 
TBG -0.29 6.E-11   




      
IGFBP-1 -1.04 1.E-10  NM 
  





   
FSH* -0.99 1.E-10 






     
CRP -1.16 4.E-10     


 




uPAR* -0.37 1.E-09 

NM 
  



 

   
ErbB3* -0.52 3.E-09  NM 
  




NT proBNP -0.91 5.E-09  
 

    

OPG* -0.23 1.E-08  NM 
  

   

  
AAT* -0.20 1.E-07   


 

 



 
A2Macro -0.21 2.E-07 



 
 



 
PRL* -0.36 7.E-07 
    

     
ENA- 78* -0.41 1.E-06 

  
 





 
BAFF* -0.15 3.E-06 

NM 
   

  

 
Factor VII* -0.17 2.E-05   


 

   
CLU* -0.09 6.E-05 
  




TFF3* -0.17 1.E-04  
       



 
Transferrin -0.11 3.E-04    
  

 

   
IgM -0.27 7.E-04  


          
VEGFR-3* -0.27 8.E-04  NM 
  





 

GRO-A* -0.24 0.001 


 






Fetuin A -0.12 0.002   


 



 
Collagen IV -0.23 0.002  NM 
  





MMP-7 -0.12 0.003 


 

 





 
Galectin-3* -0.11 0.003 

NM 
  

 
MDC -0.38 0.004 
 

  

 



 
Haptoglobin -0.14 0.004 

 


 

 

 
THP* -0.17 0.005 


  

 





 
TSH* -0.23 0.008 
  
 




     
TG* -0.27 0.013 

NM 
  

    


uPA -0.13 0.016  NM 
  





   
Apo A-II* -0.08 0.016  NM  
 

 



 
LOX-1* -0.20 0.018  
 

    

 
M-CSF* -0.15 0.018 
  







 
Vitronectin -0.08 0.029  
 

 



 
Resistin -0.15 0.032 
 



     
IL-12p40* -0.10 0.049 

 




 
C-Peptide* -0.11 0.050 
  



 
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Testosterone* 1.98 3.E-174  
            
MMP- 3 0.99 2.E-46 


 



  

  
FRTN 1.65 4.E-27    
  

  

 
HER- 2* 0.38 1.E-14  NM 
  





Eotaxin-1 0.58 8.E-13 


 







AXL*  0.33 5.E-10  
 

 


VKDPS* 0.19 3.E-09 


 

 

 



 
tPA 0.33 4.E-09  NM 
  



 

   
NrCAM 0.40 4.E-09 
NM  
 



  

Myoglobin* 0.34 1.E-08 


  

   

   
TM* 0.20 1.E-08  
       

   
TTR 0.17 1.E-07   




      
PSAT* 0.43 2.E-07 
NM 
  

         
E-Selectin 0.35 4.E-07  
 



 



 
IL-6rB* 0.11 9.E-07  NM 
  






Osteopontin 0.41 1.E-06  
  

 




CK-MB 0.45 2.E-06 


 

      


IGFBP-6* 0.17 4.E-06 
NM 
  





     
SAP* 0.21 5.E-06     
   



 
Apo D 0.18 6.E-06   






HCC-4* 0.29 1.E-05  
   

 



 
Prostasin* 0.22 2.E-05 
NM 
  

 

      
Angiogenin 0.15 7.E-05  NM 
  



  

ALDR* 0.14 8.E-05 
NM 
  

    

   
Cathepsin D 0.16 1.E-04 
NM 
  

         
HGF 0.26 1.E-04 
   



FAS* 0.22 2.E-04 


 

  

 
Eotaxin-2 0.39 2.E-04 
NM 
  







Apo H* 0.14 2.E-04   






 

PGI* 0.17 4.E-04 
NM 
  

         
MIP-1B 0.26 5.E-04     






 
A1Micro 0.10 5.E-04 


 



 



 
IL-18 0.26 5.E-04 
 









ACE 0.16 6.E-04 
 
 


     
CEA* 0.35 6.E-04 

 
 

    

  
MCP-1* 0.21 7.E-04 

 


LGL* 0.27 8.E-04 
NM 
  

    

  
Gelsolin 0.12 0.001 
NM 
  






CA 15-3 0.26 0.002 
NM 
  



  

  
GSTA 0.44 0.002 
 



        
NSE* 0.21 0.003 
NM 
  

         
IL-6r 0.14 0.005 
 





 
MCP-4 0.18 0.008  
  

 



 
Cystatin-C 0.06 0.018 


 

   



 
CgA* 0.17 0.021 


           
SCF* 0.09 0.022 
 







 
TSP1 0.12 0.023 

 




6Ckine 0.07 0.024 
NM 
  



 
MCP-2* 0.13 0.032 
   







 
IGFBP-2 0.15 0.035   




     
Tetranectin* 0.08 0.038 
NM 
  

        
SOD-1* 0.15 0.039 



 





MIF* 0.18 0.043 
 
  
 
  
Figure 3.2. Serum analytes elevated significantly in (A) females and (B) males. Analytes are ordered from top to bottom by decreasing significance in the discovery cohort 
(reported in the columns of q-values). Robust regression was used where * follows the analyte name. The log2 ratios of serum molecular concentrations in males compared to 
females shown in the plots were coefficients from the linear regression. Analytes in the plots are coloured in red where sex differences varied significantly with female hormonal 
status (whether females were postmenopausal, in the luteal or follicular phase of the menstrual cycle, or taking the oral contraceptive pill). NM was used to indicate that the 
analyte was not measured in our previous study. To the right of the plots, biomarkers of schizophrenia (SCZ) and major depressive disorder (MDD) indicated by  (elevated in 
patients);  (reduced in patients); or  (conflicting evidence for elevated and reduced levels in patients). Analyte abbreviations can be found in the Appendix (Table A.1).
 Table 3.3. Serum analytes varying significantly with female hormonal status. Analytes are ordered from top to bottom by decreasing significance in the discovery 
cohort (reported in the column of ANOVA q-values). Robust regression was used where * follows the analyte name. The log2 ratios of serum molecular concentrations were 
coefficients from the linear regression. SCZ and MDD markers are indicated by  (elevated in patients);  (reduced in patients); or  (conflicting evidence for elevated and 
reduced levels in patients). Biological processes were found from gene ontology (GO) terms. Significant differences in analyte concentrations between groups are 
highlighted. Abbreviations: Q (q-value); R (log2 ratio); SCZ (schizophrenia); MDD (major depressive disorder); MP (metabolic process); DP (developmental process); CC & 
ST (cell communication and signal transduction); IR (defense/immune/inflammatory response); CP (cell proliferation); NSD (nervous system development); VD (vasculature 
development). Analyte abbreviations can be found in the Appendix (Table A.1). GO terms (left to right): GO:0008152; GO:0032502; GO:0007154 and GO:0007165; 
GO:0006810; GO:0040007 and GO:0008283; GO:0006935; GO:0006950; GO:0008219; GO:0006952 and GO:0006955 and GO:0006954; GO:0007399; GO:0001944. 
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Analytes Q R Q R Q R Q R Q 
LH* 3.E-135 0.27 0.17 -0.46 3.E-06 2.03 6.E-39 -0.24 0.024  
 
  
       
FSH* 2.E-78 0.69 7.E-04 -0.93 4.E-09 2.68 2.E-39 -0.50 4.E-05  
 
  


     
TFF3* 2.E-65 0.10 0.32 3.43 2.E-48 0.01 0.97 -0.15 0.008 
       



 
TBG 8.E-24 0.01 0.98 0.48 1.E-18 -0.18 0.008 -0.16 0.001  
 
 


      
AAT* 8.E-20 0.14 0.055 0.43 1.E-16 -0.03 0.78 -0.05 0.31  
 

 

 



 
SHBG 1.E-16 0.21 0.32 0.86 8.E-12 -0.21 0.16 -0.83 1.E-13 
  

 

     
ErbB3* 2.E-15 -0.32 0.12 0.91 1.E-11 0.11 0.54 -0.18 0.15 
  
    

   

Osteopontin 2.E-15 0.14 0.46 -0.61 1.E-07 0.64 7.E-06 0.38 2.E-04 
  

 
  

 

SAP* 1.E-14 -0.03 0.85 0.49 2.E-14 0.18 0.025 0.44 1.E-16    
   



 
Testosterone* 4.E-13 -0.11 0.24 -0.32 2.E-08 0.18 0.012 1.91 2.E-137 
            
Progesterone 6.E-12 -0.72 5.E-08 -0.44 2.E-06 -0.27 0.020 -0.22 0.010  
           
Transferrin 3.E-11 -0.08 0.25 0.27 5.E-11 -0.02 0.81 -0.01 0.85   
  

 

   
IGFBP-2 1.E-10 0.33 0.025 -0.65 8.E-11 -0.11 0.43 -0.12 0.24  
 
  


     
HER-2* 9.E-10 -0.02 0.95 -0.34 2.E-06 0.28 0.002 0.34 4.E-08 
  
  

  

  
CRP 4.E-09 0.22 0.66 1.45 4.E-08 -0.06 0.91 -0.64 0.008    


 


 

Vitronectin 4.E-09 0.06 0.51 0.29 3.E-08 -0.07 0.33 0.00 0.98 
  
   
 



 
Factor VII* 5.E-07 0.02 0.89 0.33 4.E-08 0.16 0.017 0.00 0.99  
 
  
 
 
   
TTR 7.E-07 -0.13 0.056 0.23 1.E-07 0.13 0.006 0.30 2.E-13  
 


 
      
MCP-4 4.E-06 0.03 0.89 -0.39 7.E-05 0.22 0.072 0.10 0.30 
  
 
 
 


 
OPG* 5.E-06 0.14 0.11 0.34 1.E-06 0.09 0.19 -0.09 0.11 
  
 
   

  
CLU* 6.E-06 0.02 0.78 0.18 1.E-06 0.11 0.014 0.00 0.99 
  
    

   

C3 7.E-06 -0.01 0.98 0.24 3.E-07 0.09 0.081 0.10 0.017      
 





Fetuin-A 8.E-06 -0.06 0.51 0.27 2.E-06 0.00 0.99 -0.02 0.81  
 
   
 



 
M-CSF* 1.E-05 -0.13 0.32 0.43 3.E-06 0.04 0.78 0.02 0.85 
  
  






 
uPA 9.E-05 0.11 0.41 -0.34 2.E-05 -0.07 0.47 -0.28 7.E-05 
  




  
   
VEGFR-2* 2.E-04 -0.04 0.67 0.22 1.E-05 0.07 0.30 0.11 0.009 
  
  

 


 

CgA* 2.E-04 -0.09 0.64 -0.42 2.E-04 0.16 0.32 0.07 0.51  
           
 AXL* 2.E-04 0.15 0.30 -0.02 0.87 0.29 0.001 0.41 8.E-08 
  
   
 
   

IGFBP-3* 2.E-04 0.08 0.034 -0.07 0.026 0.06 0.11 -0.03 0.31 
  
  


 

  
VEGFR-3* 2.E-04 -0.12 0.52 0.47 5.E-05 0.01 0.98 -0.10 0.37 
  
  



 
 

Apo A-II* 3.E-04 -0.02 0.91 0.21 4.E-05 0.14 0.008 0.04 0.41  
 
   
 



 
MSP* 3.E-04 0.00 1.00 0.39 1.E-04 0.28 0.004 0.18 0.017 
  

        
IgM 5.E-04 0.27 0.15 0.16 0.24 -0.43 0.003 -0.34 0.002 
 
 
          
Lp(a) 5.E-04 0.80 0.071 -0.87 0.004 0.23 0.54 -0.48 0.082 
 
 
 

      
IGFBP-1 5.E-04 0.35 0.36 0.95 8.E-05 0.29 0.33 -0.59 0.006 
  
  




   
VDBP 5.E-04 -0.23 0.15 0.40 2.E-04 0.04 0.85 0.07 0.51 
  

 

      
MMP-9* 8.E-04 0.05 0.83 0.25 0.008 -0.12 0.28 0.03 0.85      







VCAM-1 9.E-04 0.08 0.37 -0.17 0.002 0.02 0.80 0.00 0.99     

  


 
tPA 0.001 0.00 0.99 -0.28 8.E-04 0.08 0.52 0.26 7.E-04 
  


 
 

   
Fib 1C* 0.002 0.08 0.41 -0.15 0.007 0.04 0.55 0.00 0.99 
  

        
Neuropilin-1 0.002 0.18 0.021 -0.14 0.012 0.01 0.91 0.02 0.83 
  
       

 
Apo D 0.003 -0.11 0.24 -0.20 0.002 -0.16 0.026 0.06 0.32  
 
    



  
TM* 0.003 0.08 0.32 -0.09 0.091 0.15 0.025 0.21 4.E-06 
       

   
Insulin 0.005 0.01 0.99 0.62 4.E-04 0.23 0.27 0.29 0.082       

  
 
Angiogenin 0.005 0.01 0.98 0.20 6.E-04 0.14 0.063 0.27 1.E-07 
  
    


  

IGFBP-4* 0.005 0.00 0.99 0.17 5.E-04 0.10 0.11 0.03 0.61 
  
  






 
HCC-4* 0.008 0.06 0.81 0.34 0.003 0.32 0.008 0.51 3.E-08 
   

 
 


 
ANG-2* 0.009 0.00 1.00 -0.39 0.002 -0.08 0.59 -0.17 0.11  
 
 
 
 
  

NT proBNP 0.010 0.30 0.44 0.00 0.99 -0.87 0.002 -1.16 2.E-08 
  
    
    

Apo C-III 0.010 -0.15 0.25 0.24 0.003 0.19 0.055 0.07 0.40   

 
 



 
IL-1ra 0.011 -0.06 0.66 0.23 0.002 -0.01 0.96 0.06 0.41      
 
  
 
FRTN 0.013 -0.02 0.99 0.06 0.89 0.86 0.002 1.92 1.E-21   
  
 
  

 
Angiotensinogen 0.013 0.22 0.84 1.44 0.002 0.24 0.74 0.25 0.64 
  
    

    
E-Selectin 0.015 -0.17 0.32 -0.28 0.009 0.00 0.99 0.25 0.009 
  


 
 



 
Apo H* 0.016 0.00 0.99 0.07 0.30 0.23 0.002 0.24 1.E-05  
 
 

 

 
 

MIG* 0.016 0.22 0.28 0.33 0.012 0.27 0.11 0.15 0.22 
  
      


 
HGF receptor* 0.020 0.01 0.96 0.17 0.006 0.14 0.025 0.09 0.056 
  
       



IL-6rB* 0.021 0.00 0.99 -0.02 0.62 0.12 0.010 0.14 2.E-05 
  
  



   

C-Peptide* 0.023 0.01 0.98 0.23 0.003 0.14 0.15 0.02 0.89 
  
    

  
 
LOX-1* 0.024 -0.01 0.99 0.17 0.25 -0.25 0.064 -0.21 0.055 
  

    
  
 
ACE 0.031 -0.10 0.41 -0.10 0.20 0.13 0.14 0.16 0.017 
 
  

 
     
GH 0.031 -0.13 0.86 0.68 0.032 -0.24 0.55 -2.19 3.E-16       
     
SDF-1* 0.032 -0.04 0.52 -0.10 0.016 -0.10 0.025 -0.04 0.25 
  
         
MIP-1B 0.034 0.27 0.13 -0.26 0.026 0.04 0.85 0.18 0.10   

 

 


 
FABP, adipocyte* 0.037 0.16 0.19 0.12 0.22 0.24 0.020 -0.57 4.E-16 
  
 
   



 
Collagen IV 0.039 0.32 0.064 -0.15 0.23 -0.27 0.034 -0.37 3.E-04 
  
     



 
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Figure 3.3. Serum analytes varying significantly with female hormonal status. Analytes are ordered from 
top to bottom by decreasing significance in the discovery cohort (reported in the column of q-values). Robust 
regression was used where * follows the analyte name. The log2 ratios of serum molecular concentrations of 
males, postmenopausal females, and females taking the oral contraceptive pill compared to females with a 
menstrual cycle, shown in the plot with their 95% confidence intervals (FDR-adjusted), were coefficients from the 
linear regression. To the right of the plot, biomarkers of schizophrenia (SCZ) and major depressive disorder 
(MDD) are indicated by  (elevated in patients);  (reduced in patients); or  (conflicting evidence for elevated 
and reduced levels in patients). Analyte abbreviations can be found in the Appendix (Table A.1). 
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Figure 3.4. Principal component analysis (PCA) plot of NESDA control samples. The first two principal 
components (PCs) are plotted and coloured according to sex and female hormonal status. PCA was performed 
using all analyte data and percentage of variation accounted for by each principal component is included in 
brackets with the axis labels.  
 
Simulations showed that analyte data with an imbalanced representation of males and 
females yielded a false discovery rate of up to 39.3%, as seen in Table 3.4. Furthermore, 
when the proportion of OC users differed between groups of pre-menopausal females, up to 
41.5% of measured analytes were significantly different. For comparison, balanced groups 
had a false discovery of 4.4% of analytes on average. By constructing a random forest 
classifier from covariate and analyte data, correct classification of samples as male, 
postmenopausal female, OC user, or female with a menstrual cycle could be made for 
94.5% of the control data (OOB samples) and 92.0% of test samples from the remaining 
NESDA cohort (depressive/anxiety disorders) (Table 3.5A). A similar performance was 
achieved (86.5% out-of-bag and 87.6% test accuracy) classifying females with menstrual 
cycles, OC users, and postmenopausal females using a subset of the variables and analyte 
measurements collected in previous experiments (Table 3.5B). Testosterone, FSH, trefoil 
factor 3 (TFF3), luteinizing hormone (LH), matrix metalloproteinase-3 (MMP-3), sex 
hormone-binding globulin (SHBG), leptin, age, ferritin, and thyroxine binding globulin (TBG) 
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were the ten most important variables for classification of sex and female hormonal status 
using the full set of analytes and demographic and other variables (Figure 3.5).                  
Table 3.4. Average percentage of false discoveries in groups with imbalances in sex and female 
hormonal status. Each group contained 50 individuals sampled with replacement. In the first set of trials, the 
effect of imbalances between the number of males and females in each group on the false discovery of 
differences in analyte means between groups (p<0.05) were tested. The first column shows the percentage of 
males in each group and the second column shows the mean percentage of analytes falsely discovered from a 
total of 10,000 simulations. In the second set of trials, the effect of imbalances in groups composed of 
reproductive-age women between the number of females using oral contraceptives (OC) and females with a 
menstrual cycle on the false discovery of differences in analyte means between groups were tested. The first 
column shows the percentage of OC users in each group and the third column shows the mean percentage of 
analytes falsely discovered from a total of 10,000 simulations. Significant differences in analyte means between 
groups were found using Welch’s t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Group 1:Group 2 
Male/OC users 
False discoveries % 
Males vs Females 
False discoveries % 
OC users vs Menstrual cycle 
50:50 4.4 4.4 
60:50 4.9 5.0 
40:50 4.9 4.9 
60:40 6.6 6.7 
70:50 6.7 6.8 
30:50 6.7 6.7 
20:50 9.8 10.2 
80:50 10.1 10.2 
70:30 13.6 14.4 
10:50 13.6 14.7 
90:50 14.3 14.7 
0:50 18.0 19.7 
100:50 19.0 19.8 
80:20 22.6 24.2 
90:10 31.4 33.6 
100:0 39.3 41.5 
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Table 3.5A-B. Test error for random forest classifiers. (A) shows the error in the test set for the classifier 
constructed to predict sex and female hormonal status using the full set of covariates and analyte measurements. 
(B) shows the error in the test set for the classifier constructed to predict oral contraceptive (OC) users, 
postmenopausal females, and females with a menstrual cycle using age and a reduced set of analyte 
measurements. The out-of-bag (OOB) error is shown for the training data (control subjects).  
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Plot of random forest variable importance for classifying sex and female hormonal status. This 
figure shows variable importance, measured as the mean decrease in Gini index, for the top 20 variables for the 
random forest classifier constructed to predict sex and female hormonal status using the full set of covariates and 
serum analyte measurements. Abbreviations: BP (blood pressure). Analyte abbreviations can be found in the 
Appendix (Table A.1). 
 
 
 
A
c
tu
a
l 
c
la
s
s
  Predicted class 
Error 
(%) 
OOB 
error (%) 
 OC Menstrual cycle Postmenopausal   
B OC 220 36 7 16.3 13.9 
Menstrual cycle 37 312 11 13.3 19.7 
 Postmenopausal 2 17 242 7.2 5.3 
 
A
c
tu
a
l 
c
la
s
s
 
 
Predicted class 
Error 
(%) 
OOB 
error (%) 
 OC Menstrual cycle Postmenopausal Male   
A OC 220 32 7 4 16.3 7.6 
Menstrual cycle 20 318 14 8 11.7 12.7 
 Postmenopausal 1 16 241 3 7.7 5.3 
Male 0 1 0 444 0.2 0.7 
Chapter 3 | 
74 
 
3.4 Discussion 
This chapter presents a comprehensive investigation of variations with sex and female 
hormonal status in the serum concentrations of a large panel of proteins and small 
molecules in individuals not affected by mental disorders. A previous meta-analysis by 
Ramsey et al (2012) (341) of serum molecular sex differences did not evaluate the effect of 
female hormonal status or take into account many potentially gendered demographic, 
lifestyle, and health variables. The extensive characterization of the NESDA cohort allowed 
analyses to account for differences in age, BMI, alcohol consumption, IDS scores, and other 
covariates among males, postmenopausal females, OC users, and females in the luteal and 
follicular phases of their menstrual cycles.     
In total, the serum concentrations of 117 molecules were associated with sex and/or female 
hormonal status and these had diverse functions in immune, cardiovascular, metabolic, 
nervous, and endocrine pathways. Almost half of the 96 molecules found to have different 
concentrations between males and females also varied significantly with female hormonal 
status. Future studies should therefore use caution when interpreting sex differences in the 
concentrations of these and in the 21 additional molecules that varied with female hormonal 
status. In particular, extensive differences in serum molecular concentrations of OC users 
were identified compared to females with menstrual cycles. In the Ramsey et al (2012) (341) 
meta-analysis for example, the magnitude and/or significance of sex differences reported in 
the serum concentrations of TFF3, α1-antitrypsin (AAT), CRP, fetuin A, serotransferrin, TBG, 
SHBG, and a number of others were likely due to OC use by females in the study. The 
extensive differences in serum molecular profiles between reproductive-age females with 
menstrual cycles and using OCs was reflected in the high rates of false discovery of 
significantly different analyte concentrations between groups with imbalanced compositions 
of OC users and females with menstrual cycles. These findings may provide insight into 
processes involved in the reduced all-cause mortality (347), lower risk of endometrial and 
ovarian cancer and bacterial pelvic inflammation (348), higher risk of certain cardiovascular 
events (348), higher risk of Crohn’s disease and ulcerative colitis (349), and potential effects 
on symptoms of depression (350) in OC users. Deviations in molecular serum 
concentrations in postmenopausal females were found that tended towards the levels found 
in males. These included TBG that binds thyroid hormone; osteopontin, involved in bone 
remodelling and immune functions; immunoglobulin M (IgM), an antibody made in response 
to first exposure to an antigen; and others. This likely obscured and/or reduced the 
magnitude of the sex differences found in the Ramsey et al (2012) (341) meta-analysis, 
further emphasizing the need to consider hormonal status in analyses of sex differences. 
Serum molecules that differ in postmenopausal females may play a role in the increased 
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prevalence of a number of conditions after menopause, including cardiovascular disease 
(351), osteoporosis (352), metabolic syndrome (353), Alzheimer’s disease and late-onset 
schizophrenia (354), and others. On the other hand, few differences were observed between 
females in the follicular and luteal phases of their menstrual cycles. However, the 
considerable variability in hormonal levels within phases and particularly prior to ovulation, 
timing of phases between individuals, and self-reporting of menstrual cycle status likely 
contributed to the lack of findings.   
Sex hormones and hormones involved in reproductive processes have been implicated in 
schizophrenia, MDD, and other mental disorders. These include estrogen, testosterone, 
progesterone, FSH, and LH (209, 267–269). Imbalances in levels of these hormones may 
affect the function of endocrine, immune, metabolic, cardiovascular, and other pathways in a 
sex-dependent manner. Progesterone, testosterone, and estrogen are known to modulate 
immune response (53). The levels of proteins associated with acute inflammatory response 
like C-reactive protein (CRP), serum amyloid P-component (SAP), AAT, and interleukin-1 
receptor antagonist (IL-1ra) were elevated in OC users compared to females with menstrual 
cycles. However, other inflammatory proteins, such as E-selectin, eotaxins -1 and -2, 
monocyte chemotactic protein (MCP) -1, -2, and -4, and interleukin (IL) -6 receptor and -6 
receptor subunit β were reduced in females compared to males. Ferritin and osteopontin 
levels were lower in females with menstrual cycles and OC users compared to males and 
increased after menopause, further illustrating the relationship between inflammatory 
markers and reproductive hormones. Many of these serum molecules, including CRP, SAP, 
AAT, ferritin, IL-1ra, IL-6 receptor, and MCP-1, were also reported to be elevated in 
schizophrenia and/or MDD patients. Inflammatory processes are hypothesized to play an 
important role in these and other mental disorders (31, 355, 356) and these results raise the 
possibility of a sex-dependent component to these. Levels of serum molecules involved in 
metabolic processes also varied with sex and hormonal status and are reported to be 
disturbed in mental disorders (49, 51, 132, 207, 357, 358). This included serum levels of 
apolipoproteins AI, AII, CIII, D, and H involved in lipid transport, which were also reported to 
be altered in patients with MDD and/or schizophrenia diagnoses. Furthermore, sex and 
female hormonal variations in insulin-like growth factor (IGF)-1 activity may have implications 
for sex-dependent metabolic alterations in mental disorders. Insulin resistance has been 
reported in MDD and schizophrenia (132, 359). IGF-1 deficiency may play a substantial role 
in early stage schizophrenia (359) and IGF-1 has been observed to have antidepressant-like 
effects in rats (360). Although IGF-1 was not measured in this study, serum levels of insulin, 
C-peptide, growth hormone, and insulin-like growth factor-binding protein (IGFBP)-1, -2, -3, -
4, and -6 differed with sex and hormonal status. Evidence was also found for sex and 
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hormonal status influencing serum concentrations of analytes involved in vasculature 
development, including angiogenin and neuropilin-1 and components of the renin-
angiotensin system, angiotensinogen and angiotensin-converting enzyme (ACE). These may 
be relevant to MDD and schizophrenia, as abnormalities in the renin-angiotensin system 
(361), angiogenesis (362, 363), and brain blood flow (115, 197) have been observed in 
these conditions. Interactions between metabolic, inflammatory, and cardiovascular 
processes have the potential to further result in a complex host of sex-dependent 
pathophysiological mechanisms in mental disorders. However, the implications of these 
findings for sex differences in brain function remain to be seen.    
Results from this investigation show that accounting for sex and female hormonal status may 
help to avoid confounding with a variable of interest. Although many biomarker and other 
studies currently match cases and controls for sex, some ignore sex, do not report it, and/or 
do not account for it. For example, a highly-cited study by James et al (2004) (364) of 
metabolic biomarkers found evidence of increased oxidative stress in autism, but reported 
only the proportion of boys in the autistic group (70%) and not in the control group. The 
simulations performed in this study support the practice of matching for sex, with the most 
severe discrepancy in the proportion of males and females between two groups yielding 
almost 40% false positive results. Less severe imbalances also yielded high numbers of 
false positives. For instance, a ratio of 70% males in one group to 30% males in the other 
generated 13.6% false positive results. These discrepancies are more likely in studies of 
diseases and mental disorders with a higher prevalence in one sex, such as MDD or autism 
spectrum disorders. Female hormonal status was also an important variable to consider and 
one for which most biomarker studies do not account, unless they are specifically designed 
to investigate sex effects. Simulations yielded up to 40% false positives where the 
composition of two groups made up of OC users and females with menstrual cycles were 
uneven. Group imbalances in OC use may be more likely when investigating mental 
disorders, as depressed female adults and adolescents have been reported to be more likely 
to have unprotected sex (365) and the consistency of contraceptive use was found to be 
reduced in female veterans with mental illness, particularly among those with comorbid 
substance use disorders (366). Apart from reducing the number of false discoveries in 
biomarker studies, accounting for sex and female hormonal status can also increase the 
power of analyses by accounting for variability in analyte concentrations. In light of these 
considerations, high accuracy classification tools were developed here to assist in labelling 
samples as males, postmenopausal females, OC users, and females with a menstrual cycle 
where this information has not been collected. This classification tool was effective in 
labelling subjects free of mental illness and also those with a current, lifetime, or second year 
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diagnosis of depressive and/or anxiety disorders. It was also effective in classifying 
hormonal status of female subjects when a limited number of serum analytes and other 
variables, measured in previous versions of the multiplex immunoassay platform, were used 
as predictors. This may provide a means of re-evaluating past cohorts accounting for female 
hormonal status. 
In this study estrogen dose, progestogen type, brand, and monophasic or triphasic OC use 
were not recorded. However, Dutch medical guidelines recommend that if a combined OC is 
chosen, preference is for one with levonorgestrel and 30μg of ethynyl estradiol (367). OCs 
with levonorgestrel were used by the largest proportion of subjects (57%) in the control arm 
of a recent study on venous thrombosis in the Netherlands and progestogen-only pills were 
used by the smallest proportion of subjects (0.6%) (368). In addition, active-pill or hormone-
free interval for OC users, duration of OC use, and timing of menopause were also not 
recorded and would need to be taken into account in future studies. Other potentially 
gendered lifestyle variables were not recorded or were unavailable. Pregnant and 
breastfeeding females, females who had undergone a hysterectomy, and individuals 
undergoing treatment with sex hormones other than OCs were not evaluated in this 
investigation. Molecular alterations in these cases should be considered in future and 
included in the classifier. These subjects comprised approximately 5% of the samples in this 
study, but could be important for investigating other populations. Furthermore, the links 
between these sex and hormonal status variations in serum and brain analyte 
concentrations and brain function should be investigated. Future studies should further 
examine sex-specific mechanisms in inflammatory, metabolic, and cardiovascular processes 
in peripheral and central tissues and in control and patient populations. This may shed more 
light on sex-based differences in mental disorders. 
This investigation has established sex differences in serum concentrations of a number of 
proteins and small molecules involved in endocrine, immune, metabolic, and other biological 
functions. These are largely consistent with the Ramsey et al (2012) (341) meta-analysis 
and a number of novel findings in this investigation have provided further contributions to the 
body of literature on sex differences. Many of the investigated analytes were found to vary 
with female hormonal status and have previously been associated with schizophrenia and 
MDD. These results provide insight into the influence of sex and hormonal variation on 
biological processes and their potential impact on sex differences in the mechanisms 
involved in mental disorders. However, the relationships between brain and peripheral 
effects of these analytes have not been established. The extensive differences between 
males and females with menstrual cycles, using OCs, and after menopause also pose a 
challenge of previously undocumented significance to biomarker studies. A high rate of false 
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positive results was observed in groups with simulated imbalances in the proportions of 
males or OC users. Therefore, a classifier was constructed capable of grouping subjects by 
sex and female hormonal status. Future studies should be designed to collect this 
information, but this classifier may be useful to investigators wishing to retrospectively 
evaluate the effects of sex and hormonal status on biomarker studies.
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Chapter 4 Sex differences in serum 
markers of major depressive disorder 
in the Netherlands Study of Depression 
and Anxiety  
 
 
4.1 Introduction 
Major depressive disorder (MDD) is a highly prevalent, disabling, and recurrent condition. A 
higher prevalence of MDD in women (approximately twice that of males) has been 
consistently found in many countries and cultures beginning in late adolescence (150). 
Comorbid anxiety disorders are present in more than half of those suffering from MDD and 
are also more prevalent in women (155). Studies have suggested that sex differences in 
biological processes may contribute to the increased risk of MDD in females. Hypotheses 
implicating hypothalamic-pituitary-adrenal (HPA) (161) and hypothalamic-pituitary-gonadal 
(HPG) axis dysfunction (160, 164), inflammation and immune function, and others involving 
genetic factors, the hypothalamic-pituitary-thyroid (HPT) axis, and neurotransmitter and brain 
function (156, 157) have emerged (see Chapter 1). However, no convincing explanation for 
the higher rate of MDD in females has been found.  
Furthermore, changes in peripheral inflammation, oxidative stress, and metabolic markers, 
growth factors, and endocrine factors have been associated with MDD and these have been 
proposed as potential biomarkers (122, 369). Sex differences in these pathways have been 
demonstrated in Chapter 3 and elsewhere (see Chapter 1). Biomarkers may help to 
diagnose individuals as part of a screening programme (369) or to improve recognition and 
treatment of MDD in primary care settings (91, 370). Recently, differences between MDD 
patients and controls have been found in their blood metabolic, transcriptomic, and 
proteomic profiles (129–131, 371, 372), although further validation of these is required. Sex 
differences in biomarkers of MDD were only reported in the work of Domenici et al (2010) 
(130), who found 11 plasma analytes with significant interactions between sex and 
diagnosis, including growth hormone and proteins involved in immune response. However, 
these were not evaluated as predictive markers and subjects were medicated MDD patients 
with recurrent episodes, who were not extensively characterized for psychiatric 
comorbidities, demographic, lifestyle, or health characteristics, and who were not followed 
up. The importance of sex-dependent markers of MDD requires further investigation, as 
highlighted by a recent finding that elevated morning cortisol was a biomarker for later 
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depression only in adolescent boys with high depressive symptoms (166). An extensive 
investigation of sex differences in a large panel of potential biomarkers of MDD may help to 
elucidate sex differences in the pathophysiology of MDD in addition to their potential use in 
diagnosis.  
4.1.1 Aims and objectives 
The investigations carried out in the present study had the following aims and objectives: 
1.) To identify sex differences in serum biomarkers and potential pathophysiological 
mechanisms in MDD using a Human DiscoveryMAP® multiplex immunoassay panel 
of 243 molecules. These were then also evaluated in patients with comorbid MDD 
and anxiety disorder(s) (CMA) and in remitted individuals previously diagnosed with 
MDD and not currently experiencing an episode.  
2.) To evaluate the performance of a panel of analytes for MDD/control classification 
using logistic regression for males and females separately. The performance of these 
sex-specific models was then tested in CMA and remitted MDD to evaluate specificity 
of these models for MDD. 
3.) To investigate HPG axis function in females by testing how the levels of reproductive 
hormones vary in the follicular and luteal phases of the menstrual cycle, during oral 
contraceptive (OC) use, and after menopause in MDD, CMA, and remitted MDD 
compared to controls. Hormones evaluated were follicle stimulating hormone (FSH), 
luteinizing hormone (LH), testosterone, and progesterone.    
 
Samples from the Netherlands Study of Depression and Anxiety (NESDA) were used to 
carry out these investigations. The same multiplex immunoassay panel was used to evaluate 
overall markers of current and remitted MDD in the NESDA cohort previously (Bot et al 
(2015) (373)) and to investigate variations in serum analyte concentrations with sex and 
female hormonal status in NESDA control subjects in Chapter 3. Bot et al (2015) (373) 
found 28 analytes with significantly different serum concentrations in MDD compared to 
controls involved in cell communication and signal transduction, protein metabolism, and 
immune response. These findings included reduced levels of reproductive hormones FSH 
and LH in MDD compared to controls.   
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4.2 Methods 
4.2.1 Clinical Samples 
Serum samples were from NESDA, a large and ongoing cohort study described in Chapter 
3. Diagnoses of depressive disorders (MDD and dysthymia) and anxiety disorders (social 
phobia, generalized anxiety disorder, panic disorder, and agoraphobia) were carried out 
using the Composite Interview Diagnostic Instrument (CIDI) in accordance with Diagnostic 
and Statistical Manual of Mental Disorders (DSM)-IV criteria (22). Patients with current 
disorders were classified as having a depressive and/or anxiety episode within the past six 
months and remitted patients had a lifetime diagnosis, but were not currently experiencing 
an episode. History of MDD and anxiety disorders, age of onset, and presence of first onset 
or recurrent MDD was determined with the CIDI. Family history of depression or anxiety in 
first degree relatives was assessed (374), as well as antidepressant and benzodiazepine 
use. Control subjects had neither a current nor a lifetime diagnosis of assessed psychiatric 
disorders according to the CIDI and did not develop any such disorder by the second year 
follow-up assessment (N=365). Patients and controls were excluded when not fluent in the 
Dutch language and when they had a primary clinical diagnosis of other psychiatric disorders 
not studied in NESDA: bipolar disorder, obsessive compulsive disorder, severe substance 
use disorder, or psychotic disorder. Further details of the NESDA study design and protocol, 
including other demographic, lifestyle, and health information assessed, can be found in 
Chapter 3 and have also been previously described (342). 
Patients were categorized into three separate groups. These consisted of MDD patients 
(current episode; N=231), comorbid MDD and anxiety disorder(s) patients (CMA; concurrent 
episode of at least one anxiety disorder; N=360), and remitted MDD patients (lifetime 
diagnosis, but no current episode; N=287). Demographic and other information for the three 
patient groups (MDD, CMA, and remitted MDD) and the control group is reported in Table 
4.1A-B.  
Blood samples from NESDA participants were collected at the baseline assessment at 
approximately 0800 hours. As discussed in Chapter 3, the Human DiscoveryMAP® 
multiplex immunoassay platform was used to measure the serum concentrations of 243 total 
analytes across 1,840 available NESDA participant samples assigned to 26 plates. Three 
samples were removed after internal quality control checks.  
 
 
Table 4.1. Female (A) and male (B) demographic, health, and lifestyle characteristics for MDD, CMA, remitted MDD, and controls. Values are shown as mean ± 
the standard deviation.  Differences between controls and individual conditions were assessed using Welch's t-test (continuous data) or Fisher's exact test (discrete 
data). Variables in bold were significantly different (p < 0.05) from controls. Abbreviations: MDD (major depressive disorder); CMA (comorbid MDD and anxiety 
disorder(s)); BMI (body mass index); MET (metabolic equivalent of task); OC (oral contraceptive); TCA (tricyclic antidepressant); SSRI (selective serotonin reuptake 
inhibitor). 
(A) Control (N=225) MDD (N=149) CMA (N=259) Remitted MDD (N=205) 
Collection sites 
    Area % (Amsterdam/Groningen/Leiden) 18/44/37 21/38/42 19/36/46 16/54/30 
Frame % (General population/Primary care/Specialised mental health care) 26/74/0 11/40/50 7/38/55 38/62/0 
Lifestyle and demographic variables 
    Hormone status (Follicular/Luteal phase/OC use/ Postmenopausal/Other) 34/37/79/57/18 21/35/46/36/11 45/64/71/57/22 31/33/50/69/22 
Age (years) 39±14 39.3±13 40.2±12 43.8±13 
BMI (kg/m
2
) 24.6±5 24.9±5 26.3±6 25.8±5 
Waist circumference (cm) 83.3±13 84.3±12 87.5±16 86±12 
North European ancestry (Yes/No) 97/3 95/5 92/8 99/1 
Education (years) 12.8±3 12.4±3 11.1±3 12.5±3 
Partner % (Yes/No) 78/22 62/38 65/35 74/26 
Smoking % (Never/ex-smoker/not regular/regular) 44/34/10/12 32/30/13/25 29/29/13/29 32/36/14/19 
Alcohol % (drinks per week) 5±6 5.2±7 5.1±10 6±7 
Drug use in last month % (Yes/No/NA) 4/96/0 3/97/0 5/93/2 6/94/0 
Physical activity (MET) 3819.4±2893 3436.6±3112 3448.4±3028 4107.2±3137 
Health and medication 
    Systolic blood pressure (mm Hg) 129.4±20 129.2±17 132.8±21 132.8±21 
Diastolic blood pressure (mm Hg) 77.6±11 79.4±9 81.6±13 80.5±11 
Chronic disease % (Yes/No) 31/69 44/56 46/54 39/61 
Anti-inflammatory medication % (Yes/No) 3/97 6/94 6/94 7/93 
Lipid modifying agents % (Yes/No) 3/97 1/99 5/95 6/94 
Antihypertensive medication % (Yes/No) 10/90 8/92 12/88 15/85 
Depression characteristics 
    Symptoms (Inventory of Depressive Symptomatology; IDS) 8.6±7 26.6±11 34.2±12 14.9±9 
Symptoms (Becks Anxiety Inventory; BAI) 4.2±5 11.5±7 20.1±11 5.9±6 
Family history % (Yes/No) 72/28 83/17 86/14 83/17 
MDD type % (first episode/recurrent) 
 
43/57 43/57 54/46 
Anxiety % (Lifetime/No lifetime diagnosis) 
 
34/66 100/0 47/53 
Benzodiazepine use % (Yes/No) 
 
11/89 18/82 1/99 
Antidepressant use % (TCA/SSRI/Other/Mixed/None) 
 
1/28/9/1/61 5/32/7/1/55 1/13/1/85 
  
(B) Control (N=140) MDD (N=82) CMA (N=101) Remitted MDD (N=82) 
Collection sites 
    Area % (Amsterdam/Groningen/Leiden) 11/51/38 13/50/37 17/39/45 15/48/38 
Frame % (General population/Primary care/Specialised mental health care) 33/67/0 7/35/57 6/33/61 57/43/0 
     Lifestyle and demographic variables 
    Age (years) 39.7±15 44.8±12 43.8±11 42.9±14 
BMI (kg/m
2
) 25.3±4 26.1±5 26.5±5 26.3±4 
Waist circumference (cm) 93.1±13 96.1±14 97.4±14 95.8±12 
North European ancestry (Yes/No) 99/1 99/1 97/3 96/4 
Education (years) 12.7±3 12±3 11.3±3 11.8±3 
Partner % (Yes/No) 74/26 76/24 71/29 78/22 
Smoking % (Never/ex-smoker/not regular/regular) 32/37/14/16 21/38/15/27 27/33/10/31 22/28/22/28 
Alcohol (drinks per week) 10.8±11 11±15 11.6±15 10.3±12 
Drug use in last month % (Yes/No/NA) 9/89/2 9/91/0 9/90/1 6/93/1 
Physical activity (MET) 4154.5±3551 3521.2±3118 3291.3±2668 4317.8±3530 
     Health and medication 
    Systolic blood pressure (mm Hg) 144.8±18 142.5±18 143.8±26 143.9±18 
Diastolic blood pressure (mm Hg) 81.7±12 83.9±10 85.2±15 83.8±11 
Chronic disease % (Yes/No) 31/69 45/55 54/46 45/55 
Anti-inflammatory medication % (Yes/No) 1/99 9/91 7/93 5/95 
Lipid modifying agents % (Yes/No) 8/92 20/80 11/89 9/91 
Antihypertensive medication % (Yes/No) 15/85 21/79 15/85 16/84 
     Depression characteristics 
    Symptoms (Inventory of Depressive Symptomatology; IDS) 5.5±5 27.6±11 34.3±13 13.8±9 
Symptoms (Becks Anxiety Inventory; BAI) 2.5±4 11.9±9 20.8±12 4.1±5 
Family history % (Yes/No) 66/34 82/18 80/20 78/22 
MDD type % (first episode/recurrent) 
 
40/60 52/48 52/48 
Anxiety % (Lifetime/No lifetime diagnosis) 
 
22/78 100/0 46/54 
Benzodiazepine use % (Yes/No) 
 
6/94 16/84 2/98 
Antidepressant use % (TCA/SSRI/Other/Mixed/None) 
 
4/16/6/2/72 3/32/16/0/50 1/10/0/89 
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4.2.2 Data pre-processing 
Data analysis and pre-processing was carried out as described in Chapters 2 and 3. 
Seventy-two assays and one sample were removed with more than 30% missing values. 
ComBat was used after log2 transforming the analyte data to adjust for plate effects and 
multivariate outlier assessment (Chapter 2) resulted in the removal of four samples. Missing 
covariate and analyte data were replaced as described in Chapter 2.   
4.2.3 Sample exclusion 
A total of 1,832 samples remained after data pre-processing. Additional samples were 
excluded from analysis in this study for the following reasons, as shown in Figure 4.1: 1) the 
participants had not fasted when blood was withdrawn (N=44); or the participants were 
diagnosed with 2) current or lifetime dysthymia only (N=28), 3) current or lifetime anxiety 
disorder(s) only (N=384), 4) current minor depression only (N=12), 5) bipolar disorder 
(lifetime diagnosis) in the second year follow-up assessment (N=85), or 6) depressive and/or 
anxiety disorder episode within two years of the baseline measurement (N=36). This left 
1,243 samples for further analysis.  
Figure 4.1. Sample exclusion for patient groups and controls after data pre-processing. Numbers are 
indicated in brackets. Red boxes = initial data after pre-processing; blue boxes = excluded data; green boxes = 
data after exclusion. Participants were excluded if they were not fasting or if they had a current/lifetime dysthymia 
or anxiety disorder only, current minor depression only, a depressive and/or anxiety diagnosis within two years of 
the baseline measurement, or a lifetime bipolar disorder diagnosed at the two-year assessment. 
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4.2.4 Data analysis 
A logistic regression model was used with patient/control status as the outcome variable to 
test for sex differences in the associations between log2-transformed analyte concentration 
and log-odds of MDD diagnosis, indicated by a significant interaction between analyte level 
and sex. Logistic regression and interactions are further described in Chapter 2. Sex, 
analyte concentration, and their interaction were included in the model. Additional covariates 
(further described in Chapter 3 and summarized in Table 4.1A-B) were also considered, 
including: ancestry, education, diastolic blood pressure, physical activity, family history of 
anxiety or depression, presence of chronic disease, use of lipid modifying agents, use of 
anti-inflammatory drugs, use of antihypertensive medication, collection area, BMI, age, 
alcohol consumption, smoking status, recreational drug use, partner status, and hormonal 
status (follicular phase of menstrual cycle/luteal phase/use of oral contraceptives 
(OCs)/postmenopausal status/other), as well as interactions between them and sex. These 
additional covariates were selected using stepwise regression with simultaneous forward 
selection and backward elimination using the Bayesian Information Criterion (BIC) selection 
criterion. Analytes with significant sex-analyte interaction terms (p<0.05) were tested 
separately in males and females for each disorder and classified as either male-specific, 
female-specific or qualitative markers. Male-specific markers were significant in males only 
(p<0.05 in males, p>0.20 in females) and female-specific markers were significant in females 
only (p<0.05 in females, p>0.20 in males). Qualitative markers had opposite associations 
with diagnosis between males and females. The false discovery rate (FDR) analogue of the 
p-value (q-value) was calculated for all analyses, described in Chapter 2. Ratios of the 
geometric means of analyte concentrations between patient and control groups were 
calculated after adjustment for batch effects using ComBat. MDD/control sex interaction 
tests using log2-transformed analyte concentrations were compared with analyses using 
untransformed analyte concentrations. Significant analytes from log2-transformed analyses 
were subsequently tested for sex-analyte interactions in CMA and in remitted MDD 
compared to controls. Note that the same control subjects were used as the reference 
population for MDD, CMA, and remitted MDD. Significant differences between the sex-
dependent markers of MDD and CMA were also tested, using CMA/MDD status as the 
outcome variable and checking for significant interactions between log2-transformed analyte 
level and diagnosis. Variation in sex-analyte interactions with female hormonal status 
(follicular phase of the menstrual cycle, luteal phase, OC use, and postmenopausal status, 
other) were evaluated by testing for significant interactions between log2-transformed analyte 
concentration and female hormonal status. Gene ontology (GO) biological process (BP) 
terms for significant proteins were assessed using the UniProt website (www.uniprot.org; 
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accessed March 2015) and European Bioinformatics Institute’s QuickGO online database 
(www.ebi.ac.uk/QuickGO; accessed March 2015).  
4.2.5 Joint analyte effects and classification 
To evaluate the predictive performance of a set of molecular markers in classification of 
male and female MDD, a forward stepwise logistic regression model with BIC was used to 
define the optimal set from all 171 analytes measured and retained after quality control. 
Details on assessment of classification performance can be found in Chapter 2 (Section 
2.3.13). Briefly, a repeated ten-fold cross-validation procedure was used to estimate 
accuracy of the models for males and females separately. In this procedure, ten-fold cross-
validation was repeated 50 times in order to allow for random partitioning of the data in each 
cross-validation step. Average receiver operating characteristic (ROC) curves were then 
plotted and area under the ROC curve (AUC) was calculated. Finally, the specificity of the 
model for MDD was evaluated by testing its ability to correctly classify CMA and remitted 
MDD. 
4.2.6 Female HPG axis function 
Generalized least squares (GLS) regression was used to assess female HPG axis function 
by evaluating the variation in log2-transformed levels of reproductive hormones in controls 
compared to MDD, CMA, and remitted MDD conditions in females in the follicular and luteal 
phases of the menstrual cycle, using OCs, and after menopause. GLS was used to account 
for heteroskedasticity in hormone levels across hormonal status and diagnosis and was 
implemented using the nlme package (320) in R. Main effects for diagnosis and interactions 
between hormonal status and diagnosis were evaluated for testosterone, progesterone, 
follicle stimulating hormone (FSH) and luteinizing hormone (LH). Where testosterone 
showed a significant main effect or interaction, sex hormone-binding globulin (SHBG) was 
also evaluated to determine how levels of free testosterone may be affected. Additional 
covariates (further described in Chapter 3 and summarized in Table 4.1A-B) were again 
selected using stepwise regression with simultaneous forward selection and backward 
elimination using the BIC selection criterion. P-values less than 0.05 were considered 
statistically significant.  
 
4.3 Results 
In the NESDA cohort, females were overrepresented in the MDD (65%), CMA (72%), 
remitted MDD (71%), and control (62%) classifications (Table 4.1A-B). MDD, CMA, and 
remitted patients had significantly higher diastolic blood pressure and were more likely than 
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controls to suffer from a chronic disease, use anti-inflammatory medication, smoke, and 
have a family history of depression or anxiety. CMA and remitted patients were older and 
had a higher BMI, while CMA and MDD patients were less likely to have a partner. CMA 
patients also had higher a waist circumference, fewer years of education, were less 
physically active, and were less likely to have North European ancestry. There were no 
significant sex differences in MDD type (first episode or recurrent), benzodiazepine or 
antidepressant use, IDS or BAI scores, or presence of lifetime anxiety disorder diagnosis in 
MDD, CMA, or remitted MDD.  
Twenty-eight analytes had a significant interaction between log2-transformed serum 
concentration and sex in the logistic regression analysis of MDD patients and controls 
(Table 4.2; Figure 4.2). Presence of family history of depression or anxiety, use of anti-
inflammatory medication, partner status, age, sex-age interaction, and chronic disease were 
selected as additional covariates to sex, analyte level, and their interaction in the stepwise 
logistic regression analyses. Insulin-like growth factor binding protein (IGFBP)-5, 
macrophage inflammatory protein (MIP)-3β, and interleukin (IL)-2 receptor α were the only 
female-specific markers, with lower serum levels associated with increased odds of MDD in 
females. Of the remaining 25 analytes, 12 were male-specific and 13 had a qualitative 
interaction (males and females had opposite associations between MDD diagnosis and 
serum concentration). With the exception of hepatocyte growth factor (HGF) receptor and 
eotaxin-1, higher levels of male-specific analytes and analytes with qualitative interactions 
were associated with increased odds of MDD relative to females. Eight of the analytes [trefoil 
factor 3 (TFF3), C-reactive protein (CRP), CD5 antigen-like (CD5L), IGFBP-4, β2-
microglobulin (B2M), osteoprotegerin (OPG), tumor necrosis factor receptor 2 (TNFR2), and 
fetuin-A] were also significant at q<0.10. Many of the significant analytes were involved in 
defence, inflammatory, and/or immune response. Others, including IGFBP-4 and -5, HGF 
receptor, von Willebrand factor (vWF), urokinase-type plasminogen activator receptor 
(uPAR), thyroxine binding globulin (TBG), pancreatic polypeptide (PPP), tenascin-C (TN-C), 
OPG, factor VII, and myoglobin, participated in a variety of biological processes. Among 
these were blood coagulation, apoptosis, signal transduction, cell adhesion, oxygen 
transport, regulation of cell growth, glucose metabolism, skeletal system development, and 
regulation of appetite.   
Most results remained significant using untransformed serum concentrations compared to 
log2-transformed concentrations (Table 4.2; Figure 4.2). However, interactions between sex 
and IGFBP-5, FASLG receptor (FAS), TN-C, PPP, and uPAR were no longer significant 
using untransformed concentrations. Most significant sex-dependent markers of MDD were 
also not altered with female hormonal status, with only one analyte showing a significant 
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interaction between female hormonal status and concentration. Reduced levels of uPAR 
were associated with increased odds of MDD in females in the follicular phase of the 
menstrual cycle and not in females in the luteal phase, OC users, postmenopausal females, 
or in other aggregated hormonal statuses (data not shown).  
Table 4.2. Analytes with significant interactions between log2-transformed serum concentration and sex 
in MDD compared to controls. Interaction p-values are also shown for untransformed (raw) serum 
concentrations. Odds ratios (OR) represent the ratio of odds of MDD associated with a two-fold increase in the 
serum concentration of that analyte from the logistic model. Ratio (R) represents the ratio between the geometric 
means of patient and control analyte concentrations. Orange boxes = male-specific analytes; white boxes = 
analytes with a qualitative interaction; blue boxes = female-specific analytes. Presence of significant differences 
in sex-dependent markers between MDD and CMA are marked with [×]. Abbreviations: R (ratio, patient/control); 
OR (odds ratio); P (p-value); Q (q-value); CMA (comorbid MDD and anxiety disorder(s)). Analyte abbreviations 
can be found in the Appendix (Table A.1). 
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 Analytes P Q OR P Q R OR P Q R 
TFF3 3.E-07 5.E-05 9E-07  0.95 0.46 0.52 0.90 7.36 5.E-06 3.E-04 1.21 × 
IGFBP-4 8.E-04 0.029 0.001  0.72 0.38 0.48 0.98 5.74 8.E-04 0.008 1.12  
B2M 8.E-04 0.029 0.001  0.70 0.27 0.38 0.98 3.74 8.E-04 0.008 1.14 × 
Fetuin-A 0.004 0.080 0.002  0.91 0.77 0.80 0.99 4.50 9.E-04 0.008 1.10  
uPAR 0.007 0.12 0.14  0.83 0.28 0.38 1.00 1.80 0.012 0.058 1.20  
Cystatin-C 0.010 0.13 0.013  1.50 0.41 0.49 1.02 12.91 2.E-04 0.006 1.09 × 
FABP, adipocyte 0.012 0.15 0.006  1.00 0.98 0.98 1.03 1.87 0.002 0.014 1.26  
TBG 0.018 0.19 0.014  0.74 0.31 0.41 0.97 2.94 0.033 0.085 1.06 × 
HGF receptor 0.025 0.23 0.014  1.13 0.68 0.72 1.00 0.37 0.018 0.063 0.90 × 
vWF 0.028 0.24 0.020  0.92 0.65 0.69 1.00 1.72 0.019 0.063 1.15 × 
PPP 0.038 0.29 0.24  1.02 0.88 0.90 1.05 1.51 0.010 0.058 1.30  
TN-C 0.049 0.30 0.078  0.86 0.55 0.62 0.99 1.83 0.042 0.10 1.07 × 
CRP 7.E-05 0.005 9E-07  0.87 0.019 0.063 0.73 1.29 0.002 0.014 1.76 × 
CD5L 9.E-05 0.005 7E-05  0.47 8.E-04 0.008 0.89 1.97 0.024 0.069 1.13 × 
OPG 0.001 0.032 0.002  0.55 0.030 0.080 0.95 2.72 0.020 0.063 1.09 × 
TNFR2 0.001 0.032 7E-04  0.45 0.012 0.058 0.95 2.27 0.043 0.10 1.09 × 
VCAM-1 0.007 0.12 0.006  0.40 0.013 0.058 0.96 1.97 0.15 0.23 1.05 × 
Factor VII 0.008 0.13 0.015  0.59 0.050 0.10 0.95 1.96 0.078 0.14 1.07  
Myoglobin 0.010 0.13 0.023  0.72 0.084 0.15 0.94 1.59 0.059 0.12 1.09  
FAS 0.015 0.17 0.39  0.78 0.18 0.26 0.97 1.54 0.050 0.10 1.19  
Eotaxin-1 0.019 0.19 0.004  1.35 0.044 0.10 1.13 0.74 0.15 0.23 0.97 × 
C-Peptide 0.023 0.22 0.023  0.76 0.13 0.21 0.95 1.53 0.091 0.15 1.11  
MDC 0.035 0.29 0.011  0.71 0.18 0.26 0.97 1.74 0.11 0.18 1.04  
PARC 0.043 0.30 0.035  0.87 0.33 0.43 0.95 1.48 0.082 0.15 1.13  
MMP-7 0.043 0.30 0.022  0.79 0.40 0.49 0.98 1.94 0.067 0.13 1.10  
MIP-3β 0.039 0.29 0.050  0.61 0.019 0.063 0.92 1.32 0.37 0.47 1.03 × 
IGFBP-5 0.046 0.30 0.066  0.29 0.013 0.058 0.96 1.42 0.58 0.63 1.00  
IL-2 receptor α 0.049 0.30 0.035  0.55 0.029 0.080 0.94 1.30 0.45 0.52 1.03 × 
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Figure 4.2. Analytes with significant interactions between log2-transformed serum concentration and sex 
in MDD compared to controls. Interaction p-values are also shown for untransformed (raw) serum 
concentrations. The natural logarithm of the odds ratio (OR; the ratio of the odds of MDD diagnosis associated 
with a two-fold increase in the serum concentration of that analyte from the logistic model) is shown for males 
and females with 95% confidence intervals. Abbreviations: OR (odds ratio); P (p-value); Q (q-value). Analyte 
abbreviations can be found in the Appendix (Table A.1). 
Five analytes with significant interactions between sex and log2-transformed analyte 
concentration in the CMA/control and four in the remitted MDD/control comparisons 
overlapped with the 28 in the MDD/control comparisons (Table 4.3; Figure 4.3). Two 
analytes, TFF3 and factor VII, had significant sex differences in associations with all three 
conditions. However, most sex-dependent markers of MDD did not overlap with CMA and 
fifteen had significantly different sex-dependent associations with CMA (Table 4.2), including 
many of the most significant sex-dependent markers of MDD, such as CRP, TFF3, CD5L, 
TNFR2, osteoprotegerin, and β2-microglobulin.     
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Table 4.3. Analytes with overlapping significant sex-log2 concentration interactions between MDD and 
CMA (A) and between MDD and remitted MDD (B) compared to controls. Odds ratios (OR) represent the 
ratio of odds of the condition associated with a two-fold increase in the serum concentration of that analyte from 
the logistic model. Ratio (R) represents the ratio between the geometric means of condition and control analyte 
concentrations. Abbreviations: R (ratio, patient/control); OR (odds ratio); P (p-value); Q (q-value); MDD (major 
depressive disorder); CMA (comorbid MDD and anxiety disorder(s)). Analyte abbreviations can be found in the 
Appendix (Table A.1). 
(A) CMA 
 
Interaction Females Males 
Analytes P Q OR P Q R OR P Q R 
IGFBP-4 0.002 0.057 0.90 0.74 0.74 1.01 6.01 0.001 0.010 1.09 
Myoglobin 0.009 0.11 0.69 0.03 0.095 0.97 1.44 0.12 0.19 1.10 
FAS 0.012 0.11 0.80 0.19 0.23 1.01 1.70 0.034 0.095 1.15 
TFF3 0.024 0.14 0.92 0.17 0.23 0.80 2.26 0.047 0.095 1.10 
Factor VII 0.025 0.14 0.80 0.39 0.43 1.00 2.18 0.041 0.095 1.10 
(B) Remitted MDD 
Factor VII 0.006 0.10 0.74 0.25 0.40 0.97 2.67 0.016 0.043 1.12 
TFF3 0.007 0.10 0.95 0.40 0.53 0.78 3.38 0.011 0.043 1.11 
MIP-3β 0.039 0.23 0.97 0.87 0.87 1.01 1.97 0.024 0.047 1.11 
B2M 0.049 0.23 1.08 0.80 0.87 1.03 2.89 0.013 0.043 1.11 
 
 
 
Figure 4.3. Analytes with overlapping significant sex-log2 concentration interactions between MDD, CMA, 
and remitted MDD compared to controls. The natural logarithm of the odds ratio (OR; ratio of the odds of 
diagnosis associated with a two-fold increase in the serum concentration of that analyte from the logistic model) 
is shown for males and females with 95% confidence intervals. P- and q-values are shown for the interaction 
tests. Abbreviations: OR (odds ratio); P (p-value); Q (q-value); MDD (major depressive disorder); CMA 
(comorbid MDD and anxiety disorder(s)). Analyte abbreviations can be found in the Appendix (Table A.1). 
Next, the classification performance of the forward stepwise logistic regression using the 171 
measured analytes was evaluated in males and females with MDD separately. Based on 
repeated ten-fold cross-validation, a AUC of 0.63 was found for males and a AUC of 0.50 
was found for females. The ROC curves for males and females and the analytes selected 
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using forward stepwise logistic regression are shown in Figure 4.4. Two analytes were 
selected for female classification (CD5L and IGFBP5), and five were selected for male 
classification (TFF3, angiogenin, transthyretin, HGF receptor, and epidermal growth factor 
(EGF) receptor). Performance of the classifier in males with CMA and remitted MDD 
compared to controls was also tested. Using the fitted logistic regression model found for 
males in MDD, AUCs of 0.69 and 0.62, were obtained for male remitted MDD and CMA, 
respectively.  
Serum levels of FSH and testosterone varied with diagnosis in females (Figure 4.5) in the 
linear model. Reduced FSH was found in MDD (regression coefficient        ,        
impact of diagnosis on analyte level) and remitted MDD (              ), and 
increased testosterone was found in CMA (            ). Variations in serum 
testosterone across hormonal status also differed between female MDD and controls, with 
increased levels in OC users with MDD compared to control OC users (            ). 
SHBG levels were not significantly different in CMA (p=0.99) and did not show a significant 
interaction between diagnosis and hormonal status in MDD (p=0.91), suggesting that 
differences in total testosterone reflected differences in free testosterone.       
Figure 4.4. ROC curve illustrating classification of MDD for males and females using repeated ten-fold 
cross validation of BIC forward stepwise logistic regression. The logistic regression model for male MDD 
was also used to classify male CMA and remitted MDD. The legend shows AUCs in brackets. Markers selected 
in BIC forward stepwise logistic regression of all data for classification of female and male MDD are shown in the 
right panel. Abbreviations: AUC (area under the curve); MDD (major depressive disorder); CMA (comorbid 
major depressive and anxiety disorder(s)). Analyte abbreviations can be found in the Appendix (Table A.1). 
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Figure 4.5. Serum concentrations of testosterone and FSH in controls and current and remitted female 
MDD. Mean log2-transformed concentrations are plotted for each analyte across follicular and luteal phases of 
the menstrual cycle, during OC use, and after menopause for female controls, MDD, CMA, and remitted MDD 
conditions. Where a significant main effect of diagnosis or interaction with hormonal status was found, a star is 
marked and the p-value is written below the plot with the q-value in brackets. Abbreviations: MDD (major 
depressive disorder); CMA (comorbid MDD and anxiety disorder(s)); REM (remitted MDD); FSH (follicle 
stimulating hormone); FP (follicular phase); LP (luteal phase); OC (oral contraceptive use); PM 
(postmenopausal); int (interaction); P (p-value); Q (q-value).    
 
4.4 Discussion 
This chapter identified sex-dependent serum markers of MDD in a large, well-characterized 
cohort. Previous studies have measured only a few molecules testing specific hypotheses, 
assessed limited information about participants, and/or studied specific patient populations. 
NESDA provides extensive information on a large number of serum analytes and sample 
characteristics and importantly, includes comorbid disorders and follow-up diagnoses in a 
large cross-section of the patient population from the community, primary care, and 
specialized health care settings.  
The present study found evidence to support a link between MDD and elevated levels of 
certain molecules involved in inflammation, immune, and defence response specifically in 
males, including CRP, TFF3, cystatin-C, fetuin-A, β2-microglobulin, CD5L, and TNFR2. The 
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association between elevated CRP and male MDD had been found in a previous NESDA 
and other large cohort studies (167–171, 375). Bot et al (2015) (373) also found elevated 
levels of inflammatory molecules α1-antitrypsin, α1-antichymotrypsin, and MIF in MDD 
patients compared to controls in the combined sample of male and female NESDA subjects. 
Previous studies suggested changing hormonal levels may be responsible for the absence 
of association between elevated CRP and female depression (168). However, there was no 
evidence indicating that female hormonal status interacted with CRP or other significant 
immune markers in determining odds of MDD. Alternatively, stress pathways may influence 
inflammatory processes differently in males and females, as suggested by Toker et al (2005) 
(169). This could occur by three-way interactions between the HPA and HPG axes and the 
immune system (29, 355, 376, 377). Chronic stress may impair glucocorticoid regulation of 
the immune system in males and result in higher levels of inflammatory markers in 
depression (144, 377, 378). However, it has also been proposed that inflammation itself 
causes the behavioural, neuroendocrine, and neurochemical changes in MDD (142, 143). 
The results of this study indicate that this causal mechanism could be sex-dependent. This 
would be consistent with extensive sex differences in immune function, including a higher 
male susceptibility to infection and proneness to autoimmune diseases characterized by a 
proinflammatory Th1 immune response (379, 380). However, complex bidirectional 
relationships between depression and inflammation have been observed and further work 
will be required to elucidate the mechanisms involved. Other mental disorders are also 
characterized by male-specific elevations in the serum concentrations of inflammatory 
molecules, including first-onset antipsychotic naive schizophrenia (see Chapter 5) and 
Asperger syndrome (10, 381).  
Few female-specific markers were found in this study. There were also no significant sex-
dependent or overall associations between total serum cortisol levels and MDD that would 
provide an indication of HPA axis dysfunction. However, a previous study of NESDA 
participants found that individuals with a current or remitted diagnosis of MDD had a higher 
cortisol awakening response compared to controls, as measured using a series of seven 
salivary samples over the course of one hour (137). Additionally, there were no sex 
differences in associations between MDD and thyroid stimulating hormone that would have 
indicated a greater prevalence of subclinical hypothyroidism in female MDD (156). Most of 
the sex-dependent markers of MDD in this work did not overlap with analytes found to have 
significant sex-diagnosis interactions in Domenici et al (2010) (130). The exceptions to this 
were MDC and eotaxin, although the specific eotaxin family member was not recorded. This 
small overlap may be due to differences in the patients included in these studies, who were 
largely chronic/recurrent and medicated.    
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Few sex-dependent markers of MDD overlapped with CMA, and several were also 
significantly different in CMA. This suggests that different sex-dependent pathophysiological 
mechanisms could be involved in MDD and CMA and that the conditions should be 
investigated separately for sex differences. Heterogeneity of anxiety disorders may 
contribute to these differences and should be further investigated in future. Furthermore, 
most sex differences in MDD markers were only present during an episode and not in 
remitted MDD. However, elevated TFF3 was significantly associated with male CMA and 
remitted MDD and was important in classifying male MDD. 
The performance of male and female MDD classification based on serum molecular 
concentrations in this study was poor. The measured markers classified female MDD 
patients from controls with an accuracy no greater than chance (AUC = 0.50) and classified 
male MDD patients from controls with an accuracy slightly higher than chance (AUC=0.63). 
The male MDD model was able to classify male CMA and remitted MDD with similar 
accuracies, despite having few overlapping markers with MDD. These classifiers would not 
be adequate to use as diagnostic tools for depression, but male markers could potentially be 
used together with clinical data to aid in diagnosis.  
There was evidence for a disturbance in levels of reproductive hormones in female MDD, 
CMA, and remitted MDD, providing further evidence for HPG axis dysfunction in female 
MDD (164). Reproductive hormones and their fluctuations across the female life cycle have 
previously been hypothesized to play a role in female depression as they are known to 
interact with the HPA axis, autonomic nervous system response to psychosocial stress, and 
serotonergic processes (156, 160, 382). Elevated testosterone was found in CMA and 
specifically in female OC users with MDD compared to controls. Consistent with this finding, 
higher rates of depression have been found in polycystic ovary syndrome (PCOS) 
characterized by high levels of androgens in females (383, 384), elevated negative mood-
scale scores have been associated with upper normal free testosterone levels slightly in 
females (384), and increased testosterone has been correlated with depression in pubertal 
females (385). FSH was also reduced in MDD and remitted MDD patients compared to 
controls. This finding was largely consistent with Bot et al (2015) (373), but contrasted with 
previous studies showing normal FSH and LH levels in females with menstrual cycles (386) 
and higher levels in females aged 36-45 years with MDD (387). Sources of discrepancy may 
be the small sample size analysed in Young et al (2000) (386) and the specific focus on 
perimenopause in Harlow et al (2003) (387). Future studies should investigate larger 
samples of females with more precise reporting of hormonal status and record more 
measures of reproductive function, including estrogen levels.  
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Certain limitations and future work should be considered. First, future studies are needed to 
validate these results and investigate a broader range of biological pathways than is 
presently covered in the multiplex immunoassay panel. In particular, this may reveal female-
specific biomarkers of MDD, largely absent in this study. Second, although the present study 
analyzed current comorbid MDD and anxiety disorder(s) separately, the number of different 
anxiety disorders included in the study and the high comorbidity between them prevented 
further investigation of sex differences in markers of specific anxiety disorders comorbid with 
MDD. Future studies should further investigate the influence of other psychiatric 
comorbidities and features of MDD not considered here, such as prior anxiety, chronicity of 
MDD and dysthymia, atypical and melancholic features, and postpartum depression on 
markers of depression. Third, integration of this molecular data with brain imaging,  
psychosocial, genetic, and other relevant biological data would enable investigators to 
consider a greater number of factors thought to influence the higher prevalence of female 
MDD and potentially elucidate the role of male-specific associations with elevated immune 
and inflammation markers. Finally, further work is required to understand the role of female 
hormonal processes in MDD. In particular, hormonal status information is self-reported and 
the considerable variability in hormonal levels associated with ovulation, perimenopause, 
and other reproductive events could not be considered here.  
This study presents a significant step forward in understanding molecular sex differences in 
MDD and has important implications for future studies. Distinct differences between males 
and females were found in molecular markers of MDD, including male-specific associations 
between MDD and elevated levels of immune and inflammatory molecules. Some of these 
were shared in CMA and persisted in remitted MDD, but most were not consistent across 
conditions. Studies should therefore consider the presence of comorbid anxiety disorder(s) 
in future studies of sex differences in MDD. Sex differences in markers of MDD had 
implications for the classification of subjects with MDD. Only male MDD could be classified 
with an accuracy higher than chance, although this was still low. Furthermore, disturbed 
serum levels of testosterone and FSH in females with current and remitted MDD conditions 
offer support for the involvement of HPG axis dysfunction in MDD.    
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Chapter 5 Sex-dependent serum 
molecular differences in first onset, 
antipsychotic naive schizophrenia 
 
5.1 Introduction 
Schizophrenia is characterized by a higher male incidence (12, 236) and older female age of 
onset (12, 236, 239) with better social course and short to medium term prognosis (12, 236, 243, 
244). Other sex and gender differences in schizophrenia include fewer affective and more 
negative symptoms in males (238) and better response to treatment with antipsychotic 
medication in premenopausal females (243, 245, 246). Hypotheses for the differences between 
males and females in schizophrenia include a differential predisposition to subtypes of 
schizophrenia (273–276), favourable effects of estrogen (260), sex differences in genetic risk 
(272), and neurodevelopment theories (238, 277) (see Chapter 1). However, evidence for each 
of these hypotheses is inconclusive and the causes of sex and gender differences in 
schizophrenia remain elusive.  
 
Previous studies have largely focused on female-specific disturbances of estrogen and other sex 
hormones in schizophrenia (261–263, 267) without considering other biological pathways that 
may be important in the disorder. Disturbed inflammatory and immune (227, 388), metabolic and 
oxidative stress (51, 207, 208), endocrine (209), and growth factor (210, 389) pathways have 
been reported in peripheral and brain tissue in schizophrenia (see Chapter 1). Many of these are 
altered by sex and female hormonal status in serum, as demonstrated in Chapter 3. Previous 
studies were also limited by small sample sizes, investigated only patients with a chronic course 
taking antipsychotic medication, and did not use control subjects. Further investigation of a large 
panel of relevant proteins and small molecules in serum of antipsychotic naive, first onset 
schizophrenia patients and controls may provide insights into potential sex differences in the 
aetiology and pathophysiology of schizophrenia.   
5.1.1 Aims and objectives  
The investigations carried out in the present study had the following aims and objectives: 
 
1.) To assess potential pathophysiological mechanisms in schizophrenia by investigating 
overall and sex-dependent differences in the serum concentrations of a panel of 190 
analytes between antipsychotic naive, first onset schizophrenia patients and control 
Chapter 5 | 
97 
 
subjects. Analytes with sex-dependent differences were further tested for 
confounding with age at first episode. 
2.) To investigate the relationship between serum molecular concentrations and Positive 
and Negative Syndrome Scale (PANSS) scores of schizophrenia for sex-dependent 
findings in males and females. 
3.) To further examine the potential role of these analytes in schizophrenia by assessing 
the effects of six weeks of antipsychotic treatment on serum molecular 
concentrations for sex-dependent findings.  
These investigations were carried out using Human DiscoveryMAP® multiplex immunoassay 
data from serum of four independent German cohorts of 133 first onset, antipsychotic naive 
patients (79 males; 54 females) and 133 control subjects. Patients and controls were 
matched based on sex, age, body mass index (BMI), waist circumference, and tobacco and 
cannabis consumption where this information available. These cohorts have individually 
been used previously to derive highly sensitive and specific biomarker tests for 
schizophrenia (212, 278) and to find subgroups of schizophrenia patients with alterations in 
either immune or growth factor/hormone function in schizophrenia (389).  
 
5.2 Materials and Methods 
5.2.1 Clinical samples 
All patients were suffering from their first episode of illness and were antipsychotic naive at 
the time of sample collection. Diagnoses were carried out using the Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-IV and clinical tests were performed by 
psychiatrists under Good Clinical Practice-compliance to minimize variability. Only patients 
diagnosed with the paranoid subtype of schizophrenia (295.30) were included in the study in 
order to reduce variability caused by possible heterogeneity of the disorder. Symptom 
severity was assessed using the PANSS rating system. Clinicians had access to all detailed 
clinical files including medical histories by proxy and referral letters from their general 
practitioners. This information, together with that provided by family members, was used to 
confirm first episode and antipsychotic naive status. Controls were recruited in the same 
time period from the community by advertising or were chosen from a clinical database of 
volunteers. Patients and controls with severe substance abuse and other medical conditions 
such as type 2 diabetes mellitus, hypertension, endocrine abnormalities, or cardiovascular or 
autoimmune diseases were excluded from the study. Controls with a family history of mental 
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illness were also excluded from the study. All patients and controls were white European. 
Collection of samples occurred over a period of approximately ten years from 2000 to 2010. 
Patient and control characteristics for each of the four cohorts are shown in Table 5.1. 
Cohort 1 was from the University of Cologne, Department of Psychiatry, Germany; Cohort 2 
was from the University of Muenster, Germany; and Cohorts 3 and 4 were from the 
University of Magdeburg, Germany. For each cohort, male and female patients were 
matched to controls according to age, BMI, waist circumference, and tobacco and cannabis 
consumption where this information was available. Thirty-three patients from Cohort 3 were 
also assessed before and after a six-week inpatient treatment period (Table 5.2). Patients 
were treated with olanzapine, quetiapine, risperidone, and other atypical and typical 
antipsychotics. Cumulative chlorpromazine units over the course of treatment were 
calculated. 
The ethical committees of the participating hospitals at the Universities of Cologne, Muenster 
and Magdeburg each approved the protocols of the study, informed written consent was 
given by all participants, and studies were conducted according to the Declaration of 
Helsinki. In cases where participants had a compromised capacity to give consent, next of 
kin, care takers, or guardians consented on their behalf. Medication was not withheld and 
was given when possible after diagnosis was completed. 
Samples were collected between 0800 and 1000 hours from all participants, with no 
systematic differences between patients and controls. The Human DiscoveryMAP® 
multiplex immunoassay platform was used to measure the serum concentrations of 190 total 
analytes across all samples in the separate cohorts.  
5.2.2 Data pre-processing 
Data analysis and pre-processing was carried out as described in Chapter 2. Forty-seven 
assays not measured in all cohorts were removed and a further 48 were removed with 30% 
or more missing values in at least one cohort. A list of the 95 remaining assays and the 
percentage of missing values contained in each assay can be found in the Appendix (Table 
A.1). Remaining missing values were replaced as described in Chapter 2 and values were 
log2-transformed. Outlying samples were assessed in each cohort based on a robust 
measure of the Mahalanobis distance (Chapter 2).  
 
 
 
  
 
Table 5.1. Patient and control characteristics by cohort. Values are shown as mean ± sd. Tobacco and cannabis use is displayed as (yes/no/NA) and age is in years. 
Female hormonal status was predicted (see Chapter 3) and is displayed as (oral contraceptive user/menstrual cycle/postmenopausal). The final two columns show that there 
were no significant (p<0.05) differences in age, BMI, smoking, cannabis use, or predicted hormonal status between schizophrenia patients and controls for males or females in 
the final combined cohort. Welch’s t-test was used to test for differences in continuous data and Fisher’s exact test was used for categorical data. Abbreviations: M (male); F 
(female); N (number); BMI (body mass index (kg/m
2
)); PANSS (Positive and Negative Syndrome Scale); P (positive); N (negative); G (general). 
 Cohort 1 Cohort 2 Cohort 3 Cohort 4 P-values 
Centre Cologne Muenster Magdeburg Magdeburg  
Collection period 2000-2009 2000-2007 2008-2010 2010  
 M F M F M F M F M F 
Patients N 23 25 34 11 14 10 8 8 - - 
Controls N 23 25 34 11 14 10 8 8 - - 
Patients age 26.4±6 30.4±9 27.6±9 23.5±7 28.5±9 36.2±14 33.3±11 37.0±12 
0.81 0.75 
Controls age 27.1±6 30.2±7 27.6±8 23.6±7 29.6±9 35.6±14 32.0±10 34.3±10 
Patients BMI 22.8±2 23.1±5 22.7±2 20.9±2 23.7±4 25.3±5 22.2±2 21.2±3 
0.55 0.67 
Controls BMI 22.7±2 22.3±4   24.5±5 24.9±4 23.2±1 22.0±4 
Patients tobacco  13/7/3 8/8/9 15/15/4 1/10/0 9/5/0 7/3/0 4/4/0 2/5/1 
0.13 0.17 
Controls tobacco 11/12/0 11/14/0   6/8/0 2/8/0 3/5/0 2/6/0 
Patients cannabis  12/9/2 13/6/6 14/16/4 1/10/0 0/14/0 0/10/0 0/8/0 0/7/1 
1.0 0.63 
Controls cannabis 13/8/2 12/12/1   0/14/0 0/10/0 0/8/0 0/8/0 
Patients hormonal status (predicted)  7/15/3  6/4/1  3/4/3  1/5/2  
0.24 
Controls hormonal status (predicted)  11/12/2  7/3/1  3/5/2  4/4/0  
PANSS P1-P7  23.4±5 23.3±5 17.2±6 18.0±10 22.4±7 18.8±6 14.4±5 23.9±9 - - 
PANSS N1-N7 24.5±9 22.7±6 17.7±7 17.4±9 20.1±9 18.3±8 14.9±2 16.4±5 - - 
PANSS G1-G16 49.0±9 50.0±10 37.6±10 36.6±13 44.3±14 40.1±9 33.4±6 40.8±15   
Total PANSS 96.9±19 96.0±19 72.5±20 72.0±30 86.9±27 77.2±15 62.6±11 81.0±25 - - 
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Table 5.2. Treated schizophrenia cohort characteristics. First episode patients were from Cohort 3 and were 
initially antipsychotic naïve.  Values are shown as mean ± sd. Tobacco and cannabis use is displayed as (yes/no/NA) 
and age is in years. Abbreviations: M (male); F (female); N (number); BMI (body mass index (kg/m
2
)); PANSS 
(Positive and Negative Syndrome Scale); P (positive); N (negative); G (general); T0 (initial time point); T6 (after six 
weeks of antipsychotic treatment). 
 
 
 
 
 
 
 
 
 
5.2.3 Hormonal status 
Hormonal status was not recorded for female subjects in the study. Therefore, the random 
forest classifier developed in Chapter 3 was used to classify females as oral contraceptive (OC) 
users, as having menstrual cycles, or as postmenopausal. Prior to prediction, overlapping 
analyte data consisting of 79 assays from NESDA and from the current study were combined 
using ComBat, implemented in the sva package (303, 304) in R.   
5.2.4 Data analysis 
The data for the combined cohorts were initially analysed to identify analytes present at 
significantly different levels in schizophrenia compared to control subjects. A stepwise 
regression was performed with simultaneous forward selection and backward elimination using 
Bayesian Information Criterion (BIC) to select additional covariates from age, sex, cohort, and 
interactions between cohort and these variables. Regression diagnostic plots were inspected for 
analytes with regression outliers, identified with the Bonferoni outlier test for Studentized 
residuals (p<0.05) implemented in the car package (316) in R. Robust regression (MM-
estimator) was then used, implemented in the robustbase package (317) in R. The percentage 
impact of schizophrenia diagnosis on analyte level was calculated from the regression 
coefficient. A p-value cut-off of 0.05 was used to determine statistical significance.  
Next, sex-diagnosis interactions were calculated for each log2-transformed analyte using 
stepwise regression with the same additional covariates, implementing robust regression when 
regression outliers were identified. Analytes found to have significant sex-diagnosis interactions 
(p<0.05) were re-analysed separately in males and females. Analytes were then classified as 
 Antipsychotic follow-up 
Patients N 33 
Patients sex (M/F) 22/11 
Patients age 31.0±10 
Patients BMI 24±4 
Patients tobacco  24/9/0 
Patients cannabis  9/24/0 
 T0 T6 
PANSS P1-P7 21.3±6 11.6±4 
PANSS N1-N7 18.7±9 14.3±6 
PANSS G1-G16 42.6±12 28.1±8 
Total PANSS 82.6±22 54.0±17 
Antipsychotic type (olanzapine/ 
quetiapine/ risperidone/other) 
0 8/7/9/9 
Cumulative chlorpromazine units (mg) 0 16 650±14 000 
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male-specific, female-specific, or as having a qualitative or quantitative interaction. Male-
specific analytes were significant in males only (p<0.05 in males, p>0.20 in females) and 
female-specific analytes were significantly different in females only (p<0.05 in females, p>0.20 
in males). Analytes with qualitative interactions showed opposing differences between males 
and females, while quantitative interactions showed differences in the same direction, but these 
differences were greater in one sex. Interaction tests for log2-transformed analyte 
concentrations were compared with analyses using untransformed analyte concentrations. Free 
testosterone levels were also assessed, approximated using the free androgen index (FAI) as 
the ratio of total testosterone divided by sex hormone binding globulin (SHBG) (390). The 
analysis was then repeated to find log2-transformed analytes with significant age-diagnosis 
interactions and potential confounding with sex-diagnosis interaction was assessed by 
examining the overlap between significant analytes. Sex-diagnosis interactions were re-
analysed for overlapping analytes using age-diagnosis interaction as an additional covariate. 
Interactions between sex and positive, negative, and general PANSS scores for log2-
transformed analyte levels in schizophrenia patients were also investigated using the same 
method as above. Average Pearson correlation coefficients between log2-transformed analyte 
levels and scores across cohorts were found using Fisher’s z transformation (391). The FDR 
analogue of the p-value (q-value) was calculated for these analyses, described in Chapter 2. In 
all analyses, heterogeneity in regression coefficients across the cohorts was evaluated by 
assessing the impact of adding an interaction between cohort and the variable of interest to the 
linear regression. Evidence of heterogeneity was deemed to be present when p<0.05. Finally, 
the effect of six weeks of treatment with antipsychotic medication on serum analyte levels for 33 
patients in Cohort 3 was evaluated using a paired t-test. See Chapter 2 for more details on the 
analyses used. Gene ontology (GO) biological process (BP) terms for significant proteins were 
found using the UniProt website (www.uniprot.org; accessed March 2015) and European 
Bioinformatics Institute’s QuickGO online database (www.ebi.ac.uk/QuickGO; accessed March 
2015).  
5.2.5 Classification of schizophrenia patients and controls 
Serum molecular data from the four cohorts of schizophrenia patients and control subjects was 
combined using ComBat (303) in the sva package (304). They were then used to build random 
forest classifiers to distinguish between patients and controls in males and females separately. 
For both classifiers, 5000 trees were constructed using the randomForest package in R (329). 
The out-of-bag (OOB) error of these classifications was assessed and the mean decrease in the 
Gini index, a measure of node purity, was used to assess variable importance. Chapter 2 
provides more details on random forests. The male classifier was then used to classify female 
patients and the female classifier was used to classify male patients in order to assess the 
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generalizability of the classifiers to patients and controls of the opposite sex. Receiver operating 
characteristic (ROC) curves were plotted and area under the ROC curve (AUC) was calculated. 
 
5.3 Results 
There were no significant differences in age, BMI, tobacco, or cannabis use between patients 
and controls in cohorts where this information was present (Table 5.1). Female hormonal status 
(OC use/menstrual cycle/postmenopausal), as predicted from the classifier in Chapter 3, also 
did not differ between patients and controls. Females were older than males, but did not differ in 
BMI, tobacco or cannabis consumption, or in general, positive, negative, or total PANSS scores. 
Patients treated with antipsychotic medication experienced a significant improvement in all 
PANSS scores (Table 5.2). 
Multiplex immunoassay measurement of serum samples resulted in identification of 45 analytes 
with significantly different concentrations in schizophrenia patients compared to controls after 
accounting for selected covariates in the linear model (Figure 5.1). Q-values<0.10 were found 
for all significant analytes. However, 14 of these had significant heterogeneity in coefficients 
across cohorts. Thirty-three of the 44 analytes were previously identified as altered in 
schizophrenia compared to control patients in analyses of individual cohorts included in this 
study and in independent studies (130, 209, 212, 268, 346). Most analytes were present at 
higher levels in schizophrenia patients compared to controls. Seven of the 45 analytes identified 
showed significant interactions with sex.  
In total, 16 log2-transformed analytes had significant sex-diagnosis interactions in the linear 
model, with three [testosterone, interleukin (IL)-15, and ferritin] having q<0.10 (Table 5.3; 
Figure 5.2). After using untransformed (raw) analyte concentrations, six of these were no longer 
significant, including testosterone. Eight analytes showed significant heterogeneity in regression 
coefficients across cohorts. All seven male-specific analytes [IL-15, α1-antitrypsin (AAT), IL-8, 
macrophage derived chemokine (MDC), thyroxine binding globulin (TBG), intercellular adhesion 
molecule-1 (ICAM-1), and macrophage inflammatory protein-1α (MIP-1α)] and one quantitative 
male analyte [ferritin] were present at higher levels in male schizophrenia patients. With the 
exception of TBG, all were related to immune/inflammatory response. Female-specific analytes 
[vascular endothelial growth factor (VEGF), angiotensin-converting enzyme (ACE), stem cell 
factor (SCF), von Willebrand factor (vWF), prolactin, and SHBG] and testosterone (quantitative 
female analyte) were involved in various biological processes. These include reproduction, 
circulatory system and immune processes, blood coagulation, and neuron development and 
function. VEGF, ACE, SCF, and SHBG were reduced in female schizophrenia patients, while 
vWF, prolactin, and testosterone were increased. FAI also showed a female-specific increase in 
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schizophrenia patients. Plasminogen activator inhibitor 1 (PAI-1), which plays a role in 
regulating blood coagulation, also had a qualitative interaction and was increased in male 
schizophrenia patients relative to females. Interactions between age and diagnosis were also 
assessed for these analytes to account for potential confounding with the sex-diagnosis 
interaction due to the older age of female subjects. Only vWF had a significant age-diagnosis 
interaction (p = 0.001). The sex-diagnosis interaction for this analyte was no longer significant (p 
= 0.10) after including age-diagnosis interaction as an additional covariate.  
Four analytes with significant sex-diagnosis interactions [testosterone, MDC, prolactin, and 
AAT] also showed significantly different associations with positive and/or general PANSS 
scores between male and female schizophrenia patients (Table 5.4) in the linear model. 
Despite higher levels being found in male schizophrenia patients only, serum levels of AAT and 
MDC were negatively associated with female positive and general PANSS scores and with 
female general PANSS scores, respectively. In addition, prolactin and testosterone levels, 
elevated in female schizophrenia patients, were negatively associated with positive and general 
symptoms in males.  
Finally, after six weeks of various antipsychotic treatments the levels of five analytes with 
significant sex-diagnosis interactions [prolactin, MDC, ICAM-1, ACE, and SHBG] were changed 
(Table 5.3). The largest change in concentration was seen for prolactin (154% increase from 
baseline). MDC and ICAM-1 were increased after antipsychotic treatment and were also 
increased specifically in male schizophrenia patients. SHBG levels, reduced in female 
schizophrenia patients only, were also reduced after antipsychotic treatment.  In contrast, serum 
ACE concentration was decreased specifically in female schizophrenia patients, but increased 
after treatment.  
Good classification accuracy of patients and controls was achieved for both male (AUC = 0.90) 
and female (AUC = 0.92) random forest classifiers (Figure 5.3). In addition, the performance of 
the classifier built on male data was comparable when used to classify female subjects (AUC = 
0.84) and vice versa (AUC = 0.89 for classification of male subjects using a classifier built using 
female molecular data). Seven of the twenty most important serum analytes for male and 
female classifiers were shared, including IL-10, sortilin, cortisol, α2-macroglobulin, luteinizing 
hormone (LH), carcinoembryonic antigen (CEA), and macrophage migration inhibitory factor 
(MIF).  
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Figure 5.1. Analytes with significantly different log2-transformed serum concentration between schizophrenia 
patients and controls. The log2 ratios of serum molecular concentrations of schizophrenia patients compared to 
controls, shown in the plot with their 95% confidence intervals, were coefficients from the linear regression. Robust 
regression was used where * follows the analyte name. Analytes with significant sex-diagnosis interactions are 
marked (see Table 5.3/Figure 5.2). Analytes identified as having significantly different serum concentrations in 
schizophrenia in previous studies of individual cohorts included in the study or in independent cohorts are marked. 
Presence of cohort heterogeneity is marked. Abbreviations: P (p-value); Q (q-value); R (log2 ratio (patient/control)). 
Analyte abbreviations can be found in the Appendix (Table A.1).
 Table 5.3. Log2-transformed analytes with significant interactions between schizophrenia diagnosis and sex. Interaction p-values are also shown for the untransformed 
(raw) analyte concentrations. The log2 ratios of serum molecular concentrations (R; patient/control) were coefficients from the linear regression. The percentage impact (%) of 
antipsychotic treatment on serum molecular concentrations was calculated from the regression coefficient in the linear model. Use of robust regression and presence of cohort 
heterogeneity for log2 transformed analyses is marked. Orange boxes = male-specific analytes; white boxes = analytes with a qualitative interaction; blue boxes = female-specific 
analytes. Free androgen index (FAI) was the ratio of testosterone to SHBG. Darker colours represent a quantitative interaction for which the difference in analyte concentration 
between patients and controls is greater in males (dark orange) or females (dark blue).  Analyte abbreviations can be found in the Appendix (Table A.1). 
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 Treatment Main Effect 
P-value Q-value R P-value  Q-value R P-value  Q-value 
 
% P-value 
Ferritin 0.002 0.052 1E-04 0.58 0.019 0.043 1.59 1.E-13 3.E-12    -13.9 0.082 
IL-15 0.001 0.052 0.001 -0.06 0.40 0.55 0.25 2.E-05 3.E-04    -8.6 0.59 
AAT 0.019 0.24 0.075 0.01 0.85 0.97 0.18 1.E-04 8.E-04    -3.5 0.26 
MDC 0.025 0.24 0.017 0.00 1.00 1.00 0.23 5.E-04 0.002    18.5 2E-06 
IL-8 0.025 0.24 0.090 0.04 0.77 0.91 0.43 1.E-04 8.E-04    -13.2 0.36 
MIP-1α 0.026 0.24 0.062 -0.07 0.40 0.55 0.15 0.010 0.031    -3.0 0.28 
ICAM-1 0.028 0.24 0.030 -0.04 0.50 0.67 0.14 0.013 0.034    13.8 0.006 
TBG 0.035 0.26 0.11 0.00 0.97 1.00 0.17 9.E-04 0.004    4.4 0.40 
PAI-1 0.045 0.28 0.045 -0.08 0.27 0.41 0.10 0.071 0.13    3.3 0.35 
Testosterone 1E-04 0.013 0.75 0.65 4E-08 6.E-07 0.12 0.12 0.21    2.1 0.79 
FAI 1E-04 
 
0.24 1.04 5E-06  0.05 0.80       
SHBG 0.005 0.11 0.009 -0.44 0.007 0.024 0.15 0.24 0.39    -19.2 0.008 
ACE 0.010 0.19 2E-04 -0.43 0.001 0.005 0.02 0.89 0.97    21.5 6E-05 
SCF 0.015 0.24 0.014 -0.18 0.035 0.071 0.09 0.20 0.34    6.2 0.10 
VEGF 0.031 0.25 0.034 -0.22 0.014 0.035 0.03 0.68 0.84    -0.3 0.93 
vWF 0.042 0.28 0.024 0.36 0.011 0.033 -0.01 0.91 0.97    -4.4 0.63 
Prolactin 0.046 0.28 0.11 0.47 0.033 0.070 -0.10 0.59 0.75    153.6 6E-6 
 
 
 
 
Figure 5.2. Log2-transformed analytes with significant interactions between schizophrenia diagnosis and sex. Interaction p-values are also shown for the untransformed 
(raw) analyte concentrations. The log2 ratios of serum molecular concentrations of schizophrenia patients compared to controls, shown in the plot with their 95% confidence 
intervals for males and females separately, were coefficients from the linear regression. Robust regression was used where * follows the analyte name. Analyte abbreviations 
can be found in the Appendix (Table A.1). 
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Figure 5.3. ROC curve illustrating classification of schizophrenia for (A) males and (B) females using 
random forests. The classifier for male schizophrenia was used to classify female schizophrenia (illustrated in 
A) and vice versa (illustrated in B). The legends show AUCs in brackets. The twenty most important variables for 
(A) male and (B) female classification are shown in the right panel. Analyte abbreviations can be found in the 
Appendix (Table A.1). 
 
 
 
 
  
 
Table 5.4. Sex differences in associations of serum molecular concentrations with positive, negative, and general PANSS score ratings. Only analytes with significant 
interactions between schizophrenia diagnosis and sex were investigated (see Table 5.3/Figure 5.2). Sex-specific associations with symptoms (p<0.05 in one sex and p>0.20 
in the other) are recorded for the sex with the significant association, while qualitative interactions are recorded for both sexes. Analytes without a significant interaction 
between symptom severity and sex are not included. The coefficient from the linear model represents the percent change in analyte concentration for a small change in 
symptom severity in the linear model and significant coefficients (p<0.05) are highlighted. Presence of cohort heterogeneity is included, with PHET < 0.05 indicating significant 
cohort heterogeneity. Pearson correlation coefficients were averaged across cohorts using Fisher’s z transformation. Robust regressions were used for MDC. Abbreviations: 
P (p-value); Q (q-value); HET (cohort heterogeneity); r (averaged Pearson correlation coefficient). Analyte abbreviations can be found in the Appendix (Table A.1). 
 
 
Testosterone MDC Prolactin AAT 
Positive 
symptoms 
P = 0.003, Q = 0.052,  PHET = 0.74 
 
P = 0.016, Q = 0.088,  PHET = 0.060 P = 0.010, Q = 0.077,  PHET = 0.37 
Male -1.75 (P = 0.017, Q = 0.034, r = -0.38) 
 
-4.22 (P = 0.007, Q = 0.020, r = -0.41) 
 
Female 1.34 (P = 0.070, Q = 0.10, r = 0.21) 
  
-1.18 (P = 0.002,Q = 0.015,  r = -0.35) 
Negative 
symptoms     
Male 
    
Female 
    
General 
symptoms 
P = 0.010, Q = 0.11, PHET = 0.73 P = 0.014, Q = 0.11, PHET = 0.039 P = 0.036, Q = 0.16,  PHET = 0.038 P = 0.039, Q = 0.16,  PHET = 0.12 
Male -0.95 (P = 0.022, Q = 0.10 r = -0.38) 
 
-1.83 (P = 0.041,Q = 0.11,  r = -0.35) 0.17 (P = 0.42, Q = 0.42, r = 0.095) 
Female 0.67 (P = 0.15, Q = 0.24, r = 0.19) -0.74 (P = 0.025, Q = 0.10, r = -0.32) 
 
-0.46 (P = 0.055, Q = 0.11, r = -0.17) 
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5.4 Discussion 
This chapter investigated overall and sex-dependent differences in serum molecular 
concentrations in first onset, antipsychotic naive schizophrenia patients compared to 
controls. A number of differences were found between paranoid subtype schizophrenia 
patients and controls in the concentrations of hormones, growth factors, and analytes 
involved in immune/inflammatory and other pathways. The majority of these analytes have 
been identified in previous analyses of individual cohorts included in this study or in 
independent investigations (130, 209, 212, 268, 346).  However, the finding of increased 
levels of progesterone, LH, and FSH in first onset schizophrenia contradicts Bergemann et al 
(2005) (267), who found low levels of progesterone and LH in chronic female schizophrenia 
patients. This may be due in part to the chronic course of illness and hyperprolactinemia 
caused by treatment with typical antipsychotic medication in most patients in the study. 
Together with increased levels of cortisol in first episode schizophrenia these findings 
suggest abnormalities in the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-
pituitary-gonadal (HPG) axes.  
To this end, the most novel outcome of the study was the finding that 16 log2-transformed 
molecules showed significant sex-diagnosis interactions. Among the most significant were 
findings that testosterone levels were increased and SHBG levels were decreased in first 
onset female schizophrenia patients. Together this meant that FAI, measuring the 
approximate amount of biologically available, unbound testosterone in serum, was also 
significantly increased specifically in females with schizophrenia. For males, higher 
testosterone levels were associated with lower positive and general symptom scores. 
Polycystic ovary syndrome (PCOS), diagnosed in females with infrequent ovulation and 
hyperandrogenemia, is often characterized by insulin resistance, and similar to the current 
study elevated LH and increased HPA axis activity (392–395). Studies in female sheep and 
Rhesus monkeys have found that fetal androgen exposure can cause adult ovarian 
hyperandrogenism, increased LH secretion with abnormal pulsatility, and metabolic 
disturbances (396). A genetic predisposition to excess androgen production may influence 
fetal, infant, and adolescent development and play an important part in PCOS’s aetiology 
(397). This aetiology would be consistent with the disrupted sexual dimorphisms reported in 
cortical brain volumes in schizophrenia (249), reversed normal sexual dimorphisms in 
cerebral activation during processing of aversive stimuli (251) and during mental rotation 
(252), and other evidence of a reversed or disturbed cerebral sexual dimorphism (250, 277). 
Together with increased prolactin levels, the current study points to more endocrine 
abnormalities in female schizophrenia. Prolactin secretion is inhibited by dopamine, which 
has been implicated in schizophrenia and in the action of antipsychotic medication. 
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Furthermore, there was an association in males only between lower positive PANSS scores 
and higher prolactin levels. This may suggest sex differences in dopamine involvement and 
regulation in schizophrenia. These endocrine abnormalities appear to be further influenced 
by six weeks of antipsychotic treatment, after which levels of prolactin were increased and 
levels of SHBG were decreased. Elevated prolactin levels caused by first-generation 
antipsychotics and certain second-generation antipsychotics are thought to contribute to 
menstrual disturbance and sexual dysfunction in schizophrenia patients (265, 398).  
Other female-specific differences included lower serum levels of ACE and VEGF. Decreased 
serum VEGF has previously been found in patients with childhood trauma in first episode 
psychosis (399) and both decreased and increased VEGF mRNA expression has been 
reported in different studies of the prefrontal cortex in schizophrenia patients (291, 400). 
VEGF mediates angiogenesis and neurogenesis and has been shown to protect 
dopaminergic neurons from death in a rat model of Parkinson’s disease (401). However, the 
cause of reduced serum VEGF in female schizophrenia patients in this study is unclear, as a 
study of brain tumors found tumor extract and serum VEGF concentrations to be 
independent (402) and a study of a genetic rat model of depression found reduced brain, but 
not serum VEGF levels (403). However, others have found a correlation between VEGF 
serum and cerebrospinal fluid (CSF) concentrations in neurotuberculosis patients (404) and 
have found that peripheral VEGF is required for exercise-induced adult hippocampal 
neurogenesis in mice (405). Serum ACE was also decreased in female schizophrenia 
patients in this study. Peripheral administration of ACE inhibitors has been shown to have 
effects on dopaminergic neurotransmission, as it can cross the blood-brain barrier and result 
in increased levels of striatal dopamine dialysate in rats (406), inhibition of apomorphine-
induced oral stereotypy in rats similar to haloperidol (407), reduced effects of apomorphine 
on prepulse inhibition in mice (408), and improved dyskinesia and motor fluctuations in 
Parkinson’s disease (409). The current study also showed that serum ACE levels were 
significantly increased following six weeks of antipsychotic treatment. However, positive 
correlations have been found between patient ACE levels in CSF, but not serum, and length 
of schizophrenic psychosis, duration of current psychotic episode, and duration of current 
hospitalization (410). Future studies should investigate how peripheral and central VEGF 
and ACE are correlated in schizophrenia and whether they are involved in sex-specific 
dopaminergic regulation in schizophrenia.  
Finally, male-specific analytes were increased in schizophrenia and largely related to 
immune response and inflammation. This raises the possibility that some aspects of the 
widely-reported immunological abnormalities in schizophrenia may be specific for males. In 
addition to abnormalities in cytokine levels in schizophrenia (211), previous studies have 
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shown that immune-related genes, maternal infection, a higher prevalence of autoimmune 
disease, activated microglial cells, and increased blood-brain-barrier permeability are 
associated with schizophrenia (411). IL-15, one of the most significant findings and 
increased specifically in male schizophrenia patients, is expressed by macrophages and 
other cells, recruits and promotes the proliferation and survival of activated T lymphocytes 
(412), and induces expression of chemokines and their receptors in T lymphocytes, including 
MIP-1α and IL-8 (413) that were also increased in males with schizophrenia. This is in line 
with the macrophage-T-lymphocyte theory of schizophrenia proposed by Smith and Maes 
(1995) (224), which postulates that chronically activated macrophages and T-lymphocytes 
are key mediators of schizophrenia. In fact, males are more prone to autoimmune diseases 
characterized by acute inflammation and proinflammatory immune response involving 
macrophages, neutrophils, and T cells (380). MDC was also increased specifically in male 
schizophrenia patients, and is associated with chronic inflammation and produced by 
microglia and CNS-infiltrating leukocytes in mice with experimental autoimmune 
encephalomyelitis (414). MDC and ICAM-1 were increased after six weeks of antipsychotic 
treatment. Both pro- and anti-inflammatory effects have been observed for antipsychotic 
medication (415) and are thought to be associated with metabolic side effects and an 
increased risk of cardiovascular disease (416, 417) and improvement of psychotic symptoms 
(418, 419), respectively. Sex-specific associations between PANSS scores and levels of 
MDC and AAT were found, with higher levels associated with lower scores only in females. 
Increases in levels of AAT in females may protect against damage from inflammation and 
ameliorate symptoms, but further work is needed to elucidate the role of these analytes in 
male and female schizophrenia.  
The limitations of this study should be taken into account when assessing these findings. A 
number of findings were inconsistent between cohorts and further work is needed to 
establish the causes of this heterogeneity. Fewer female patient samples were available, 
reducing the power to detect molecular differences in this group. In addition, potential 
confounding factors BMI, tobacco, and cannabis consumption were not recorded in cohort 2. 
Information on other prescription drug use and other demographic, lifestyle, and health 
variables, such as socioeconomic status, fasting status, blood pressure, and family history 
were unavailable. Menopausal status, OC use, menstrual cycle phase, and other variables 
were not recorded. Different types of medication were assessed together in the investigation 
of effects of antipsychotic treatment. Larger cohorts with better characterized samples will be 
needed for replication of these results, to assess effects of hormonal status in females, and 
to investigate the broader diagnosis of schizophrenia, as schizophrenia subtypes have been 
eliminated from the DSM-5 (1). Follow-up studies would account for possible misdiagnosis 
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and change in diagnosis over time, thought to occur more frequently in females (238). In 
addition, future studies should include greater numbers of late onset patients to facilitate 
studies of the effects of age on sex-dependent molecular signatures of schizophrenia as 
levels of estrogen in females decline. Larger follow-up studies of antipsychotic treatment 
would allow sex-dependent molecular changes to be assessed in different types of 
medication and in pre- and postmenopausal hormonal states.  
The findings from this study indicate differences in the underlying molecular phenotypes of 
male and female paranoid subtype schizophrenia patients. They include elevated levels of 
certain inflammatory markers specifically in male schizophrenia and endocrine abnormalities 
in female schizophrenia patients. With the exception of vWF, these were not due to 
differences in age at first episode between males and females. This would have been 
predicted by the hypothesis that males are more prone to a neurodevelopmental, early onset 
schizophrenia, while females are more prone to a late onset schizophrenia similar to 
affective psychosis (273–276). Some of these analytes also showed sex differences in their 
associations with symptomatology and were modified by antipsychotic treatment. However, 
consistent with the high degree of overlap in presentation of male and female schizophrenia, 
the majority of analyte concentrations different in schizophrenia were not significantly 
modified by sex. Future studies will be needed to validate these results and further research 
should be conducted on male- and female-specific aetiologies, pathophysiologies, and 
adaptive mechanisms in schizophrenia in order to elucidate the role of these analytes. 
Furthermore, sex-specific treatment options, in line with these findings, should potentially be 
considered. A recent meta-analysis showed estrogen has a beneficial effect in female 
schizophrenia (9). Metformin is a treatment for PCOS and has been found to restore 
menstruation and reduce levels of prolactin, LH, and testosterone in women with 
antipsychotic-induced amenorrhea during first-episode schizophrenia (420). Further studies 
should assess how metformin treatment may affect symptoms of schizophrenia. Non-
steroidal anti-inflammatory drug (NSAID) (421) and glucocorticoid use (422) has been 
associated with a lower risk of psychosis in males only. A meta-analysis of anti-inflammatory 
efficacy in schizophrenia showed significant improvement in symptoms with aspirin and N-
acetylcysteine, but these were not stratified by sex (423). 
 
  Chapter 6 | 
 
113 
 
Chapter 6 A meta-analysis of gene 
expression profiling of the prefrontal 
cortex: schizophrenia, sex, and sex-
schizophrenia diagnosis interaction 
effects 
 
6.1 Introduction 
Post-mortem microarray studies in schizophrenia have focused on the prefrontal cortex 
(PFC), temporal cortex, cingulate cortex, hippocampus, thalamus, and cerebellum as brain 
regions that may be involved in its pathophysiology. The PFC in particular has been the 
subject of a number of microarray studies that have revealed disturbed processes in 
schizophrenia related to synaptic function, neuronal development, mitochondrial function, 
immune and inflammatory functions, oligodendrocyte and astrocyte function, growth factor 
signalling, myelination, metal ion binding, signal transduction, sphingolipid metabolism, and 
others (51, 198, 199, 203, 204, 214, 291, 292, 424–428). Two meta-analyses of Affymetrix 
HG-U133A/HG-U133 Plus 2.0 microarray studies of Brodmann area (BA) 9, 10, and 46 of 
the PFC in schizophrenia have been conducted by Pérez-Santiago et al (2012) (429) (six 
studies) and Mistry, Gillis, and Pavlidis (2012) (430) (seven studies, six overlapping with by 
Pérez-Santiago et al (2012) (429)). These have revealed a number of differentially 
expressed genes in schizophrenia with q<0.1 involved in processes including neuronal cell-
cell signalling, mesenchymal induction, and mitogen-activated protein kinase (MAPK) 
signalling [Pérez-Santiago et al (2012) (429)] and neuronal communication, processes 
affected by synaptic functioning, metabolic processes, ubiquitination, and immune function 
[Mistry, Gillis, and Pavlidis (2012) (430)]. However, due to the use of different datasets, data 
pre-processing, outlier removal, analysis, and/or false discovery rate (FDR) procedures 
between the meta-analyses, only 19 of the findings overlapped between the 160 significant 
probe sets in Pérez-Santiago et al (2012) (429) and 125 significant probe sets in Mistry, 
Gillis, and Pavlidis (2012) (430). These meta-analyses did not make use of robust regression 
in the presence of regression outliers, array weights to deal with arrays of variable quality, or 
moderated t-statistics to potentially further increase power and stability of the meta-analysis. 
In addition, these and other microarray studies have failed to examine potential sex and sex-
diagnosis interaction effects on gene expression. 
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Sex differences in the neuroanatomy and function of the PFC are profound. Cognitive 
processes such as verbal fluency and certain types of visuospatial skills also differ between 
males and females (431). Neurotransmitter systems differ between males and females and 
are further discussed in Chapter 1. Normal adult PFC volumes are sexually dimorphic, in 
line with areas having high levels of estrogen and androgen receptors during brain 
development in animal studies (432). Functional magnetic resonance imaging (fMRI) studies 
have also shown more bilateral and right hemisphere activation in male subjects and left 
hemisphere activation in female subjects (433), and greater intensity changes in females in 
the middle, inferior, and orbital PFC during working memory tasks (434). Furthermore, 
estrogen-dependent stress-induced PFC dysfunction occurs in rats, as measured by a 
working memory task (435). Previous microarray studies of sex-biased gene expression in 
the PFC have revealed sex differences in expression of genes located on the sex 
chromosomes (436–438) and in expression of autosomal genes involved in transcription, 
intracellular signalling, and heat shock proteins (437). 
As described in Chapter 1, schizophrenia is characterized by marked sex and gender 
differences in clinical presentation including a higher male incidence of schizophrenia, older 
female age of onset, differences in symptomatology, better response to antipsychotic 
medication in premenopausal females, and better course of illness in women compared to 
men (238). Chapter 5 showed that some serum molecular concentrations varied differently 
with schizophrenia diagnosis in male and female antipsychotic naive, first onset patients of 
the paranoid subtype. In female patients, total and free serum testosterone, prolactin, and 
von Willebrand factor were elevated, while ACE and VEGF were reduced. On the other 
hand, a number of serum analytes involved in immune and inflammatory response were 
elevated only in male patients. Evidence for sex-specific and sex-dependent genetic risks 
has emerged (271), including genes involved in dopaminergic metabolism (272). Sex 
differences in neuroanatomical and functional brain abnormalities in the PFC have been 
reported in schizophrenia (see Chapter 1), including smaller dorsomedial grey matter (255) 
and frontomedial cortex volumes (249) in male schizophrenia compared to male controls and 
smaller female orbital cortex (255) and dorsolateral prefrontal cortex grey matter (256) 
volume in schizophrenia relative to opposite sex comparisons. Other findings include 
disturbed sex dimorphisms in brain activations during mental rotation and processing of 
aversive stimuli in areas of the PFC (251, 252) and sex differences in the relationship 
between frontal lobe volume and disorganization and suspicion-hostility symptoms in 
schizophrenia (257). Cognitive performances of male and female schizophrenia patients 
may also differ, but there is conflicting evidence for this (439, 440). Taken together, these 
findings suggest sex-specific pathophysiological mechanisms may occur in the PFC in 
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schizophrenia. However, to date no microarray study has investigated this possibility, 
potentially due to the small number of female subjects in individual cohorts. 
6.1.1 Aims and objectives 
The investigations presented in this chapter had the following aims and objectives: 
1.) To assess potential pathophysiological mechanisms in schizophrenia by evaluating 
overall and sex-dependent differences in gene expression in the PFC in 
schizophrenia patients compared to controls. Robust regression, array weights, and 
moderated t-statistics were used in order to improve upon previous analyses. 
2.) To examine the effects of possible confounding factors on gene expression, including 
lifetime antipsychotic medication use, suicide status, alcohol consumption, and drug 
use. 
3.) To investigate potential sex differences in the function of the PFC and their 
implications in mental disorders by assessing sex-biased gene expression in control 
subjects. 
4.) To assess overrepresented gene ontology (GO) biological process (BP) terms in 
PFC findings in order to gain insight into affected processes in each analysis of 
differential gene expression. 
5.) Finally, to compare PFC findings to serum results obtained in Chapters 3 and 5 in 
order to examine the link between the periphery and brain. 
A meta-analysis of five microarray studies containing 238 subjects in post-mortem PFC 
tissue (BA 9, 10, 46) was performed in order to achieve these aims. By combining several 
microarray studies, it was hoped that sufficient power could be obtained to detect significant 
sex-dependent differences in gene expression in schizophrenia. This was particularly 
important given the small number of females included in these microarray studies.  
 
6.2 Materials and Methods 
6.2.1 Clinical samples 
Five microarray datasets of schizophrenia and control prefrontal cortex (PFC; BA 9, 10, 46) 
were downloaded from the Stanley Medical Research Institute (SMRI; two datasets 
(www.stanleygenomics.org, accessed December 2014), Harvard Brain Tissue Resource 
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Centre (HBTRC – Mclean66 collection, national_databank.mclean.harvard.edu, accessed 
December 2014), and Gene Expression Omnibus (GEO) at the National Center for 
Biotechnology (two datasets; www.ncbi.nlm.nih.gov/geo, accessed December 2014). Table 
6.1 contains detailed demographic and additional information for each of these datasets and 
Figure 6.1 shows a lateral view of these regions in the PFC. Demographic and other 
information was obtained from the data repository or from articles published on the individual 
datasets (198, 214, 291–293).  
Datasets were identified from previous meta-analyses by Mistry, Gillis, and Pavlidis (2012) 
(430) (seven studies) and Pérez-Santiago et al (2012) (429) (six studies, overlapping with 
the studies used in Mistry, Gillis, and Pavlidis (2012) (430)). However, raw data for two of the 
studies used in the Mistry, Gillis, and Pavlidis (2012) (430) meta-analysis (named Mirnics 
and Haroutunian in the article) could not be obtained from the authors. Multiple microarray 
SMRI datasets were available, but represented repeated measurements of subjects, so here 
Kato and Altar C datasets were selected for the two independent SMRI brain collections 
(Array and Consortium collections, respectively). In contrast to the current study, Mistry, 
Gillis, and Pavlidis (2012) (430) chose the Bahn dataset and Pérez-Santiago et al (2012) 
(429) did not state which dataset was used to represent the SMRI Array collection. Manual 
searches were also conducted in GEO, ArrayExpress at the European Bioinformatics 
Institute (http://www.ebi.ac.uk/arrayexpress/), and the Stanford Microarray Database 
(http://smd.princeton.edu/), but these did not yield any new datasets. Only data collected 
using Affymetrix (Santa Clara, CA, USA) HG-U133A or HG-U133 Plus 2.0 chips were 
included.  
  
 
 
Table 6.1. Patient and control characteristics by cohort. Values are shown as mean ± sd. (A) presents a summary of data available in all cohorts. P-values in the last 
column are from a Welch’s t-test of differences between male/female patients and controls (p<0.05 considered significant). (B) presents a partial summary of data available in 
only some of the cohorts. Age is reported in years as (21-40 : 41-60 : > 61-80) in the Harvard cohort; smoking at time of death is reported as (yes : no : unknown); lifetime 
alcohol use is reported as (present (heavy/moderate use) : past (heavy/moderate use) : social : none); lifetime drug use is reported as (present (heavy/moderate use) : past 
(heavy/moderate use) : social : little or none : unknown); ethnicity is reported as (white : non-white : unknown); and suicide status is reported as (yes : no : unknown). 
Abbreviations: PMI (post-mortem interval); M (male); F (female); BA (Brodmann area); SMRI (Stanley Medical Research Institute); HBTRC (Harvard Brain Tissue Resource 
Centre); P (p-value). 
 
*Batches consisting of single samples were removed in order to combine data using ComBat. Altar C, Kato, and Harvard cohorts also consisted of bipolar disorder, depression, and other samples, 
which were removed prior to analysis. Duplicate arrays were present in Altar C, which were also removed prior to analysis.  
 
 
 
 
 
(A) Altar C (SMRI 
Consortium 
collection) 
Kato (SMRI Array 
collection) GSE17612 GSE21138 Harvard Overall P 
Controls N (M/F)  11 (7/4) 33 (24/9) 23 (12/11) 29 (24/5) 25 (17/8) 121 (84/37) 
 
Patients N (M/F)  10 (7/3) 35 (26/9) 28 (19/9) 29 (24/5) 15 (12/3) 117 (88/29) 
Controls age (M/F) 49.0±7 / 35.8±6 46.0±8 / 40.0±5 63.0±25 / 75.6±16 43.6±15 / 50.2±22 7:5:5 / 0:1:7  0.48 / 
0.69 Patients age (M/F) 39.1±13 / 50.0±17 41.3±8 / 46.3±9 72.9±13 / 74.2±20 43.3±15/45.8±26 3:5:4 / 0:0:3  
Controls brain pH (M/F) 6.3±0.2 / 6.2±0.3 6.7±0.2 / 6.5±0.3 6.5±0.3 / 6.5±0.3 6.3±0.2 / 6.3±0.1 6.5±0.3 / 6.3±0.3 6.5±0.3 / 6.4±0.3 5E-05 / 
0.18 Patients brain pH (M/F) 6.1±0.3 / 6.1±0.2 6.4±0.3 / 6.6±0.2 6.2±0.2 / 6.0±0.2 6.2±0.2 / 6.3±0.1 6.5±0.2 / 6.2±0.4 6.3±0.3 / 6.3±0.3 
Controls PMI (M/F) 18.9±9 / 32.5±10 28.3±12 / 33.9±15 11.7±4 / 8.0±4 39.1±15 / 46.8±8 22.1±4 / 18.0±7 27.0±14 / 24.3±16 0.89 / 
0.64 Patients PMI (M/F) 34.1±16 / 37.3±20 30.8±17 / 33.2±11 9.4±7 / 7.2±6 39.0±12 / 43.4±12 20.8±5 / 23.0±1 27.3±17 / 26.3±17 
Batches (batches used)* 8 (7) 13 (12) 3 6 (5) 8 38 (35)  
Brain region(s) Frontal BA46/10 Frontal BA46 
Anterior prefrontal 
cortex (BA10) 
Frontal BA46 Prefrontal cortex (BA9)   
Microarray platform HG-U133A HG-U133A HG-U133 Plus 2.0 HG-U133 Plus 2.0 HG-U133A   
References 
Torrey et al (2000) 
(293) 
SMRI Database 
Iwamoto, Bundo, 
and Kato (2005) 
(292) 
SMRI Database 
Maycox et al (2009) 
(291) 
 
Narayan et al (2008) 
(198) 
Glatt et al (2005) (214) 
Maycox et al (2009) (291) 
HBTRC 
  
  
 
 
 
 
 
 
(B) Altar C (SMRI) Kato (SMRI) GSE17612 GSE21138 Harvard 
Antipsychotics (M/F) 
4000-100,000 
(37,400±40,000) / 6000-
50,000 (30,300±22,000) 
(p=0.73) [Lifetime 
antipsychotic use in 
fluphenazine mg 
equivalents] 
50-350,000 (90,200±92,000) 
/ 600-400,000 
(70,100±130,000) (p=0.67) 
[Lifetime antipsychotic use in 
fluphenazine mg equivalents] 
Doses relatively low; only four 
patients took doses >750mg/day 
chlorpromazine equivalents.  
 
Patients were elderly and most were 
treated long term after first 
admission; controls were from 
community/ hospital/ nursing home 
50-750 (330±200) / 
100-750 (390±300) 
(p=0.73) 
[chlorpromazine 
equivalents; 
incorporate lifetime 
exposure] 
Not 
available. 
Controls Smoking (M/F) 2:2:3 / 1:0:3 6:7:11 / 2:2:5 Not reported; data 
divided into short, 
intermediate, and long-
term illness. Suicide 
reported to be higher in 
short- and intermediate 
duration illness 
compared to long-
duration illness and 
controls. 
Patients Smoking (M/F) 3:2:2 / 1:2:0 17:4:5 / 6:0:3 
Controls Alcohol (M/F) 2:1:3:1 / 0:0:2:2 0:2:12:10 / 2:1:0:6 
Patients Alcohol (M/F) 2:1:2:2 / 0:2:1:0 11:4:5:6 / 1:2:2:4 
Controls Drugs (M/F) 0:1:0:6:0 / 0:0:0:4:0 1:0:3:20:0 / 0:0:1:8:0 
Patients Drugs (M/F) 1:0:0:6:0 / 0:1:0:2:0 9:4:4:8:1 / 0:2:0:6:1 
Controls Ethnicity (M/F) 6:1:0 / 4:0:0 24:0:0 / 9:0:0 12:0:0 / 11:0:0 5:0:12 / 3:0:5 
Patients Ethnicity (M/F) 6:1:0 / 2:1:0 25:1:0 / 9:0:0 19:0:0 / 9:0:0 10:0:2 / 3:0:0 
Controls Suicide (M/F) 0:7:0 / 0:4:0 0:24:0 / 0:9:0 Causes of death similar in patients 
and controls (broncho-pneumonia, 
carcinoma, cardiovascular causes 
most common)  
Not 
available. 
Patients Suicide (M/F) 2:5:0 / 1:1:1 4:22:0 / 3:6:0 
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Figure 6.1. Lateral surface of the human PFC. Regions are numbered and coloured according to Brodmann 
area. Image courtesy of Petrides and Pandya (2009) (441); reprinted with permission.  
 
6.2.2 Data pre-processing  
Data pre-processing and analysis was carried out using Bioconductor (v3.0) (294) with the 
statistical programming software R (v3.1.2) (285). Array quality was assessed in each 
dataset with the R Bioconductor arrayQualityMetrics package (295), using Relative Log 
Expression (RLE) plots, Normalized Unscaled Standard Error (NUSE) plots, and spatial 
distribution of feature intensities. The affy (296) and simpleaffy (297) packages were used to 
further examine array quality measures of ribonucleic acid (RNA) degradation, average, 
minimum, and maximum background levels, percentage of genes present, scale factors, 
3’/5’ ratios for beta-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and 
spike-in hybridization controls. A number of poor quality arrays were found, and therefore 
array quality weights were calculated (302) after pre-processing using the limma package 
(300, 301) (described in Chapter 2), and used in subsequent analyses. Raw data were log2 
transformed, background corrected, normalized, and summarized using frozen robust 
multiarray analysis (fRMA) as described in Chapter 2 using the frma package (298). Batch 
information was found from the scan date in the CEL files and arrays scanned on different 
days were regarded as different batches. Considerable variability in expression was found 
between batches and between different datasets, which was removed using ComBat (303) 
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in the sva package (304). For this final step, only probe sets common to the HG-U133A and 
HG-U133 Plus 2.0 chips were used. Where duplicate arrays were processed, the highest 
quality array was chosen from the calculated array quality weights. Bipolar disorder, 
depression, and other samples were removed from the SMRI and Harvard datasets to leave 
only schizophrenia and control subjects. In total, expression values for 22,277 probe sets in 
238 subjects were analyzed. Gene symbols, gene names, and chromosome/band were 
mapped from Affymetrix HG-U133A probe set identifiers using the R Bioconductor package 
biomaRt (336, 337). Gene names and symbols for any remaining unidentified probe sets 
were found by manual search using the Affymetrix NetAffxTM Analysis Centre (442) 
(www.affymetrix.com/analysis/netaffx, accessed February 2015). 
6.2.3 Data analysis 
The limma package was used to identify significant main effects of schizophrenia diagnosis 
and sex and their interaction in probe set intensities (301, 443). Control subjects only were 
used to identify significant sex-biased gene expression. Brain pH, post-mortem interval (PMI) 
measured in hours, sex, and decade of age at death were used as additional covariates. 
Robust regression (MM-estimator) was used where regression outliers were present (with 
Bonferroni-corrected p-value < 0.05), calculated using the robustbase package in R (317). P-
values were calculated from moderated t-statistics (further details in Chapter 2) and q-
values were found as described in Chapter 2. The criterion for significance used was q-
value < 0.10. Analytes with significant sex-diagnosis interaction terms were tested 
separately in males and females for each disorder and classified as either male-specific, 
female-specific or qualitative markers. Male-specific markers were significant in males only 
(p<0.05 in males; p>0.20 in females) and female-specific markers were significant in females 
only (p<0.05 in females; p>0.20 in males). Qualitative markers had opposite associations 
with diagnosis between males and females. In all analyses, heterogeneity in regression 
coefficients across studies was evaluated by assessing the impact of adding an interaction 
between cohort and the variable of interest to the linear regression. Evidence of 
heterogeneity was deemed to be present when p<0.05.  
The overlap between probe sets with a significant main effect of schizophrenia diagnosis in 
the present study and those reported in the individual cohorts and in the Mistry, Gillis, and 
Pavlidis (2012) (430) and Pérez-Santiago et al (2012) (429) meta-analyses was evaluated. 
Lists of significant probe sets from each cohort were found in the publications by Maycox et 
al (2009) (291) for the Harvard and GSE17612 cohorts; Glatt et al (2005) (214) for the 
Harvard cohort; Narayan et al (2008) (198) for the GSE21138 cohort; and from the lists of 
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‘regulated genes’ on the SMRI website (www.stanleygenomics.org, accessed December 
2014).    
6.2.4 Potential confounders 
Potential confounding variables, including lifetime use of antipsychotic medication, suicide 
status, lifetime alcohol consumption, and lifetime drug use, were not reported consistently 
across cohorts. Therefore, the limma package (301, 443) was used to identify effects of 
these variables on gene expression using the SMRI datasets (Altar C and Kato), where this 
information could be obtained. Lifetime antipsychotic use was measured in fluphenazine 
milligram equivalents and its effect on gene expression was evaluated in schizophrenia and 
bipolar patients (N=88). Suicide status was assessed as ‘yes’ or ‘no’, and lifetime 
alcohol/drug use was assessed as ‘moderate or severe’ (past/present) or ‘little or none’ and 
their effects on gene expression were measured in schizophrenia, depression, bipolar 
disorder, and control subjects (N=143). Potential confounding was considered when p<0.05.  
6.2.5 Comparison with serum results 
In Chapter 5, main effects of schizophrenia diagnosis and sex-diagnosis interactions were 
evaluated for serum concentrations of analytes in first onset, antipsychotic naive 
schizophrenia patients compared to controls. Variations in serum analyte concentrations with 
sex and female hormonal status were determined in Chapter 3. The overlap between these 
analytes and the present microarray findings were assessed. For this, serum analyte overlap 
was considered for those proteins without a significant effect of female hormonal status or 
where the direction of effect of hormonal status was consistent compared to males. Where 
multiple probe sets representing a gene were present, the most significant finding was 
reported together with its Affymetrix identifier.  
6.2.6 GO terms 
GO terms for significant genes were found using the R Bioconductor package biomaRt (336, 
337) and these were mapped to all ancestor terms using the GOSim package (338). A 
summary of GO terms for each significant gene was prepared, with GO terms selected 
based on relevance and number of annotated genes. Overrepresented GO BP terms for lists 
of probe sets with significant effects of sex, diagnosis, and sex-diagnosis interactions were 
assessed using the GOstats R Bioconductor package (339). A hypergeometric test that 
conditions on significant child terms was used, requiring at least ten annotated genes for the 
term and p<0.001.  
Further information on microarray technology and analysis can be found in Chapter 2. 
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6.3 Results 
The majority of patient and control samples were male (75% of patients, 69% of controls, 
Table 6.1), varying among cohorts from 61% male (GSE17612) to 83% male (GSE21138) 
samples. There were no significant differences in sex, age, or PMI between schizophrenia 
patients and controls. Male brain pH was lower in schizophrenia patients compared to 
controls. Most subjects across cohorts were white (66%), with the remainder being non-
white (2%) or unknown/unrecorded (32%). Other variables were not reported consistently 
across cohorts, but in the SMRI Altar C and Kato cohorts, lifetime antipsychotic use, 
smoking at time of death, lifetime alcohol and drug use, and suicide status were available. 
Smoking at time of death was unknown for a substantial proportion of subjects (36%), but 
was more prevalent among patients when it was recorded (77% and 50% of recorded 
patients and controls, respectively). Lifetime alcohol and drug use was known for all but two 
SMRI subjects. Present or past moderate/severe alcohol and drug use was more prevalent 
in patients (51% alcohol users and 40% drug users) compared to controls (18% alcohol 
users and 5% drug users). Lifetime antipsychotic use was not different between male and 
female patients in the cohorts where this was reported.  
A total of 38 batches were identified (from scan dates in CEL files) within the microarray 
datasets. In order to combine the batches within each of the five cohorts using ComBat, 
three batches consisting of only one sample were removed. A summary of array quality 
weights calculated and used in subsequent analyses is shown for all cohorts in Figure 6.2. 
Manual verification confirmed that low quality arrays identified from the procedure carried out 
in Section 6.2.2 received low weights. Approximately 4-5% of probes were investigated 
using robust regression.  
 
Figure 6.2. Array quality weights used for data analysis. Array quality weights were calculated using the 
limma Bioconductor package in R.  
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6.3.1 Differential PFC gene expression in schizophrenia 
A total of 209 unique genes [229 probe sets (86 upregulated; 143 downregulated)] were 
significantly differentially expressed in schizophrenia compared to control PFC (q<0.1) in the 
linear model described in Section 6.2.3, as shown in Table 6.2 and Figure 6.3. Repeating 
the analysis without using array weights and robust regression identified only 17 of these 
significant probe sets, as shown in Table 6.3. P-values found without using array weights 
are also shown in Table 6.2. Evidence for heterogeneity between studies was found in 32 
(14%) of these findings. 
Thirty-seven of the significant probe sets from Mistry, Gillis, and Pavlidis (2012) (430) and 44 
probe sets from Pérez-Santiago et al (2012) (429) overlapped with findings in this study (p-
values of overlap were less than 2E-16). In total, 68 (30%) of the current findings overlapped 
with significant probe sets from at least one of the meta-analyses and 13 (12 genes) agreed 
across all studies. The genes common to all studies were TNFSF10, FBXO9, EGR1, CA4, 
LPL, P4HA1, ABCA1, CYP26B1, TMEM176A, TMEM176B, ETV5, and MPPED2. Possible 
causes for discrepancies between the meta-analyses are further discussed in Section 6.4.1. 
Furthermore, 103 (45%) of the significant probe sets overlapped with the findings listed in 
one or more of the individual cohort publications or on the SMRI website (Table 6.2). Most 
consistent with the current meta-analysis was the GSE17612 cohort (46 overlapping probes) 
and least consistent was the GSE21138 cohort (2 overlapping probes). This lack of 
consistency was likely because only the top 50 differentially expressed genes were available 
from Narayan et al (2008) (198) and because findings were divided by short, intermediate, 
and long duration of illness.   
Significant genes were associated with over 3000 unique GO BP terms, including metabolic 
processes (GO:0008152); developmental processes (GO:0032502); cell communication and 
signal transduction (GO:0007154 and GO:0007165); transport (GO:0006810); growth and 
cell proliferation (GO:0040007 and GO:0008283); response to stress (GO:0006950); cell 
death (GO:0008219); defence, immune, and inflammatory response (GO:0006952, 
GO:0006955, and GO:0006954); nervous system development (GO:0007399); synaptic 
transmission (GO:0007268); and others (Table 6.2). A GO BP term analysis revealed 12 
enriched terms (Table 6.4). These included terms related to steroid hormone, estradiol, 
metal ion, lipid, alcohol, and cyclic adenosine monophosphate (cAMP) response, regulation of 
neuronal apoptosis, and mitochondrial function. Genes involved in these enriched functions 
comprised 35% of the differentially expressed genes. 
  
 
 
Table 6.2. Probe sets with significantly different intensity between schizophrenia patients and controls in the PFC. In (A) probe set intensity is higher in schizophrenia, and in (B) probe 
set intensity is lower. The percentage impact of schizophrenia on serum molecular concentrations (%) from the linear regression is reported and use of robust regression is marked for each probe 
set. P-values are also reported for analyses without array weights. The direction of effect of potential confounders is marked with arrows. GO terms were used to assess participation of a gene in 
each biological process. The overlap of these findings with those of previous meta-analyses and individual cohorts is highlighted in blue. Cohorts are numbered (Altar C = 1; Kato = 2; GSE17612 
= 3; GSE21138 = 4; Harvard = 5). Abbreviations: P (p-value); Q (q-value); A (lifetime alcohol use); AP (lifetime antipsychotic use); D (lifetime drug use); S (suicide); MP (metabolic process); DP 
(developmental process); CC & ST (cell communication and signal transduction); IR (defence/immune/inflammatory response); CP (cell proliferation); NSD (nervous system development). GO 
terms (left to right): GO:0008152; GO:0032502; GO:0007154 and GO:0007165; GO:0006810; GO:0040007 and GO:0008283; GO:0006950; GO:0008219; GO:0006952 and GO:0006955 and 
GO:0006954; GO:0007399; GO:0007268.  
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202917_s_at S100A8 S100 calcium binding protein A8 1.E-07 7.E-04 92.2 6.E-07  
S 
AP
  1,3 


 
217911_s_at BAG3 BCL2-associated athanogene 3 2.E-06 0.007 32.2 2.E-05   S   3 
  




204326_x_at MT1X metallothionein 1X 3.E-06 0.007 33.4 2.E-05      2 
 



   
202975_s_at RHOBTB3 Rho-related BTB domain containing 3 3.E-06 0.007 22.6 7.E-05      2 


     
200907_s_at PALLD palladin, cytoskeletal associated protein 3.E-06 0.007 18.8 2.E-05   S   2,5 
         
212332_at RBL2 retinoblastoma-like 2 4.E-06 0.007 9.2 4.E-05      5 
        
208451_s_at C4B complement component 4B 1.E-05 0.013 24.6 9.E-04   AP   2 
 





 
216048_s_at RHOBTB3 Rho-related BTB domain containing 3 1.E-05 0.015 18.9 5.E-04      2 


     
59625_at NOL3 
nucleolar protein 3 (apoptosis repressor with CARD 
domain) 
1.E-05 0.015 8.6 1.E-04   AP    
   

  
205967_at HIST1H4A histone cluster 1, H4a 3.E-05 0.025 12.2 5.E-04       
       
204060_s_at PRKX/PRKY Protein kinase, X/Y-linked 5.E-05 0.035 10.1 8.E-04       
 

    
217546_at MT1M metallothionein 1M 5.E-05 0.035 36.0 8.E-04   S    
   

    
221567_at NOL3 
nucleolar protein 3 (apoptosis repressor with CARD 
domain) 
8.E-05 0.040 6.5 0.004       
   

  
208581_x_at MT1X metallothionein 1X 9.E-05 0.041 22.7 2.E-04      2 
 



   
202481_at DHRS3 dehydrogenase/reductase (SDR family) member 3 9.E-05 0.041 8.8 3.E-04   S    
      
214428_x_at C4B complement component 4B 9.E-05 0.041 17.3 0.003   AP    
 





 
212188_at KCTD12 potassium channel tetramerization domain containing 12 9.E-05 0.041 13.2 6.E-04      3 
 

      
201841_s_at HSPB1 heat shock 27kDa protein 1 1.E-04 0.041 22.6 4.E-04   S   3 
 

  
212859_x_at MT1E metallothionein 1E 1.E-04 0.041 16.9 2.E-04   S   2 
   

    
210800_at TIMM8A translocase of inner mitochondrial membrane 8 homolog 1.E-04 0.041 4.6 4.E-04       
         
  
 
 
A (yeast) 
200897_s_at PALLD palladin, cytoskeletal associated protein 1.E-04 0.041 15.9 1.E-04   S   2 
         
214250_at NUMA1 nuclear mitotic apparatus protein 1 1.E-04 0.046 6.8 4.E-04       
         
216195_at ANK2 ankyrin 2, neuronal 1.E-04 0.046 11.2 6.E-05      2 
         
216336_x_at MT1P3 metallothionein 1 pseudogene 3 1.E-04 0.046 15.1 4.E-04   S   2 
         
203318_s_at ZNF148 zinc finger protein 148 1.E-04 0.050 9.3 2.E-04       
  




210519_s_at NQO1 NAD(P)H dehydrogenase, quinone 1 1.E-04 0.050 14.4 0.007   S    
 

 

203549_s_at LPL lipoprotein lipase 2.E-04 0.051 16.9 8.E-04      5 
 

   
212185_x_at MT2A metallothionein 2A 2.E-04 0.051 18.4 6.E-04      2 
 





 
221590_s_at ALDH6A1 aldehyde dehydrogenase 6 family, member A1 2.E-04 0.055 15.8 7.E-04       
       
202122_s_at PLIN3 perilipin 3 2.E-04 0.055 10.3 0.001   S    
  

     
215338_s_at NKTR natural killer cell triggering receptor 2.E-04 0.055 10.3 2.E-04      5 
        
219550_at ROBO3 
roundabout, axon guidance receptor, homolog 3 
(Drosophila) 
2.E-04 0.057 7.3 0.001   S   5 


     


207543_s_at P4HA1 prolyl 4-hydroxylase, alpha polypeptide I 2.E-04 0.057 10.7 2.E-04      3,5 
        
210057_at SMG1 SMG1 phosphatidylinositol 3-kinase-related kinase 2.E-04 0.057 6.5 4.E-04      3 
 



   
214212_x_at FERMT2 fermitin family member 2 2.E-04 0.057 11.0 5.E-04      5 


      
203535_at S100A9 S100 calcium binding protein A9 2.E-04 0.057 18.2 0.003      3 


 
221527_s_at PARD3 par-3 family cell polarity regulator 3.E-04 0.062 10.7 0.001      5 


 


212732_at MEG3 maternally expressed 3 (non-protein coding) 3.E-04 0.063 21.6 7.E-04       
         
204846_at CP ceruloplasmin (ferroxidase) 3.E-04 0.065 15.4 0.003       
 

     
207547_s_at FAM107A family with sequence similarity 107, member A 3.E-04 0.067 16.2 0.004   S   2 
   

    
220856_x_at NA NA 3.E-04 0.068 6.8 0.006       
         
206870_at PPARA peroxisome proliferator-activated receptor alpha 4.E-04 0.068 6.4 0.005       


  
203504_s_at ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 4.E-04 0.077 10.7 4.E-04      2,3,5 


   
209030_s_at CADM1 cell adhesion molecule 1 5.E-04 0.077 10.0 0.005       





213571_s_at EIF4E2 
eukaryotic translation initiation factor 4E family member 
2 
5.E-04 0.077 6.6 5.E-04       
      
212209_at MED13L mediator complex subunit 13-like 5.E-04 0.077 7.3 4.E-04      2,3 
        
203548_s_at LPL lipoprotein lipase 5.E-04 0.077 16.4 0.003      5 
 

   
204347_at AK4 adenylate kinase 4 5.E-04 0.077 7.0 7.E-04       
     


213900_at FAM189A2 family with sequence similarity 189, member A2 5.E-04 0.077 11.8 0.001      2 
         
212109_at HN1L hematological and neurological expressed 1-like 5.E-04 0.077 5.3 0.005       
         
218618_s_at FNDC3B fibronectin type III domain containing 3B 5.E-04 0.077 8.8 0.001       
         
204560_at FKBP5 FK506 binding protein 5 5.E-04 0.077 12.1 0.029      4 
        
201856_s_at ZFR zinc finger RNA binding protein 5.E-04 0.078 8.8 0.002   A    


       
215628_x_at NA NA 5.E-04 0.079 9.0 0.008   D    
         
206788_s_at CBFB core-binding factor, beta subunit 6.E-04 0.079 7.4 0.050       
       
212469_at NIPBL Nipped-B homolog (Drosophila) 6.E-04 0.079 5.9 0.002       
 

 


210400_at GRIN2C glutamate receptor, ionotropic, N-methyl D-aspartate 2C 6.E-04 0.079 11.3 0.002   S    




  

210068_s_at AQP4 aquaporin 4 6.E-04 0.080 25.9 0.003      2 
  





 
206825_at OXTR oxytocin receptor 6.E-04 0.080 10.8 0.001       


 

201999_s_at DYNLT1 dynein, light chain, Tctex-type 1 6.E-04 0.080 10.2 5.E-04      5 
   


201468_s_at NQO1 NAD(P)H dehydrogenase, quinone 1 7.E-04 0.086 10.1 0.014   S    
 

 

206395_at DGKG diacylglycerol kinase, gamma 90kDa 7.E-04 0.089 6.9 0.003       
 

 


213946_s_at OBSL1 obscurin-like 1 7.E-04 0.090 7.4 0.004      3 


     


217730_at TMBIM1 transmembrane BAX inhibitor motif containing 1 7.E-04 0.091 11.2 0.004       
  

  
201666_at TIMP1 TIMP metallopeptidase inhibitor 1 8.E-04 0.092 17.8 0.002   S    
  
200971_s_at SERP1 stress-associated endoplasmic reticulum protein 1 8.E-04 0.092 7.8 0.009       
   
  
 
 
 
205498_at GHR growth hormone receptor 8.E-04 0.092 6.7 0.001   D    


  
211464_x_at CASP6 
caspase 6, apoptosis-related cysteine peptidase 
8.E-04 0.093 6.9 5.E-04  
A 
D 
   
   

  
206204_at GRB14 growth factor receptor-bound protein 14 8.E-04 0.093 8.9 0.009      3 
 

 

   
215296_at CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 8.E-04 0.093 7.1 8.E-04       
         
216814_at NA NA 8.E-04 0.093 2.9 0.004       
         
212208_at MED13L mediator complex subunit 13-like 8.E-04 0.094 6.5 0.004       
        
208990_s_at HNRNPH3 
heterogeneous nuclear ribonucleoprotein H3 (2H9) 
9.E-04 0.094 7.1 5.E-04  
D 
AP 
  5 
       
210588_x_at HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 9.E-04 0.094 6.3 0.006      5 
       
201201_at CSTB cystatin B (stefin B) 9.E-04 0.096 6.0 0.008   AP   5 
    

  
211456_x_at MT1HL1 metallothionein 1H-like 1 9.E-04 0.096 13.4 0.004      2 
   

    
202581_at HSPA1A heat shock 70kDa protein 1A 9.E-04 0.096 27.2 0.008      3 


  
209355_s_at PPAP2B phosphatidic acid phosphatase type 2B 9.E-04 0.096 24.1 0.007      2 
    


218345_at TMEM176A transmembrane protein 176A 9.E-04 0.096 9.4 0.005       
         
217166_at PTMAP1 prothymosin, alpha pseudogene 1 (gene sequence 26) 9.E-04 0.096 4.9 0.002       
         
215592_at NA NA 9.E-04 0.096 7.9 0.006   D    
         
220532_s_at TMEM176B transmembrane protein 176B 9.E-04 0.098 13.7 0.008      3 


       
221496_s_at TOB2 transducer of ERBB2, 2 0.001 0.098 11.5 0.003       
 

    
222094_at LOC101060714 sulfotransferase 1A3/1A4-like 0.001 0.098 5.4 0.008       
         
201996_s_at SPEN spen family transcriptional repressor 0.001 0.098 11.9 5.E-04       
    


209047_at AQP1 aquaporin 1 (Colton blood group) 0.001 0.099 23.9 0.006      2 



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203180_at ALDH1A3 aldehyde dehydrogenase 1 family, member A3 6.E-08 5.E-04 -12.6 4.E-06      3  
   




202688_at TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 7.E-08 5.E-04 -23.0 3.E-05      2  
  

 
209735_at ABCG2 
ATP-binding cassette, sub-family G (WHITE), member 2 
(Junior blood group) 
7.E-08 5.E-04 -26.3 1.E-05      2 
 

     
217191_x_at COX6CP1 cytochrome c oxidase subunit VIc pseudogene 1 5.E-07 0.002 -5.6 2.E-06       
         
201865_x_at NR3C1 
nuclear receptor subfamily 3, group C, member 1 
(glucocorticoid receptor) 
2.E-06 0.007 -11.5 1.E-05      5  
  

  
212987_at FBXO9 F-box protein 9 4.E-06 0.007 -12.5 8.E-05      1,3  
 



 
205336_at PVALB parvalbumin 7.E-06 0.011 -21.3 1.E-05       
         
206414_s_at ASAP2 
ArfGAP with SH3 domain, ankyrin repeat and PH 
domain 2 
8.E-06 0.012 -10.4 0.002       
        
201310_s_at NREP neuronal regeneration related protein 9.E-06 0.013 -10.1 5.E-05      3 


 

 


203686_at MPG N-methylpurine-DNA glycosylase 1.E-05 0.015 -5.8 9.E-06       
   

   
203162_s_at KATNB1 katanin p80 (WD repeat containing) subunit B 1 1.E-05 0.015 -7.2 7.E-05        


 




220045_at NEUROD6 neuronal differentiation 6 1.E-05 0.016 -12.6 5.E-05        
     


202135_s_at ACTR1B 
ARP1 actin-related protein 1 homolog B, centractin beta 
(yeast) 
2.E-05 0.023 -7.9 2.E-04      3 
         
203586_s_at ARL4D ADP-ribosylation factor-like 4D 3.E-05 0.027 -6.8 9.E-05      3,5 


     
220741_s_at PPA2 pyrophosphatase (inorganic) 2 3.E-05 0.029 -7.0 8.E-04      1,3 
        
217772_s_at MTCH2 mitochondrial carrier 2 3.E-05 0.029 -8.3 3.E-04       
  

 

  
204218_at ANAPC15 anaphase promoting complex subunit 15 4.E-05 0.031 -6.0 7.E-04      1 
         
37005_at MINOS1-NBL1 MINOS1-NBL1 readthrough 4.E-05 0.031 -7.2 1.E-05       


    


209019_s_at PINK1 PTEN induced putative kinase 1 4.E-05 0.034 -7.4 2.E-04      5 




 

208836_at ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide 5.E-05 0.035 -7.5 3.E-04       
 



   
212611_at DTX4 deltex 4, E3 ubiquitin ligase 5.E-05 0.035 -8.6 4.E-04      3 


 



 
205019_s_at VIPR1 vasoactive intestinal peptide receptor 1 5.E-05 0.035 -7.7 2.E-04      3,5 
 



 



205508_at SCN1B sodium channel, voltage-gated, type I, beta subunit 6.E-05 0.036 -10.8 5.E-05      5  




207191_s_at ISLR 
immunoglobulin superfamily containing leucine-rich 
repeat 
6.E-05 0.037 -9.7 0.004  
A 
D 
   
         
221494_x_at EIF3K eukaryotic translation initiation factor 3, subunit K 6.E-05 0.037 -6.2 0.002   S    
        
210638_s_at FBXO9 F-box protein 9 6.E-05 0.037 -10.8 6.E-04      1,3,5  
 



 
217032_at FOXD4 forkhead box D4 6.E-05 0.037 -6.9 8.E-05       
        
217934_x_at STUB1 STIP1 homology and U-box containing protein 1, E3 7.E-05 0.038 -6.0 0.002      5 


 

   
   
 
 
 
ubiquitin protein ligase 
205223_at DEPDC5 DEP domain containing 5 7.E-05 0.038 -5.8 6.E-04   S    


      
221011_s_at LBH limb bud and heart development 7.E-05 0.038 -12.1 5.E-04        
  

   
206382_s_at BDNF brain-derived neurotrophic factor 8.E-05 0.040 -12.0 9.E-05      1,3  
219689_at SEMA3G 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3G 
8.E-05 0.040 -11.3 2.E-04      3 


       
212716_s_at EIF3K eukaryotic translation initiation factor 3, subunit K 8.E-05 0.040 -7.9 0.006      1 
        
200021_at CFL1 cofilin 1 (non-muscle) 1.E-04 0.041 -3.0 7.E-04      5  



203273_s_at TUSC2 tumor suppressor candidate 2 1.E-04 0.041 -5.3 1.E-04   D     


 
203698_s_at FRZB frizzled-related protein 1.E-04 0.041 -11.2 0.002   A   3 









208478_s_at BAX BCL2-associated X protein 1.E-04 0.041 -6.8 8.E-04      5  



219869_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 1.E-04 0.041 -7.7 4.E-04       
  

     
213897_s_at MRPL23 mitochondrial ribosomal protein L23 1.E-04 0.041 -7.7 7.E-04      1 
        
218105_s_at MRPL4 mitochondrial ribosomal protein L4 1.E-04 0.044 -5.9 5.E-05      3 
        
204621_s_at NR4A2 nuclear receptor subfamily 4, group A, member 2 1.E-04 0.050 -12.3 7.E-04   AP   2  
 




201900_s_at AKR1A1 
aldo-keto reductase family 1, member A1 (aldehyde 
reductase) 
2.E-04 0.051 -6.3 0.001   AP    
        
201694_s_at EGR1 early growth response 1 2.E-04 0.051 -15.7 0.002      3  


206209_s_at CA4 carbonic anhydrase IV 2.E-04 0.051 -10.4 5.E-04  
A 
AP 
  3  


     
203286_at RNF44 ring finger protein 44 2.E-04 0.051 -6.0 3.E-04       
         
205061_s_at EXOSC9 exosome component 9 2.E-04 0.051 -5.0 3.E-04      3 
  

 

 
205139_s_at UST uronyl-2-sulfotransferase 2.E-04 0.052 -10.0 0.009      4 
        
201740_at NDUFS3 
NADH dehydrogenase (ubiquinone) Fe-S protein 3, 
30kDa (NADH-coenzyme Q reductase) 
2.E-04 0.055 -5.9 0.001   D   3  







218760_at COQ6 coenzyme Q6 monooxygenase 2.E-04 0.055 -4.8 0.002   D    
        
208827_at PSMB6 proteasome (prosome, macropain) subunit, beta type, 6 2.E-04 0.055 -7.2 6.E-04   S   1 


 

  
202596_at ENSA endosulfine alpha 2.E-04 0.055 -9.4 0.001       


     
219310_at SYNDIG1 synapse differentiation inducing 1 2.E-04 0.055 -8.5 0.003      1 


   

207767_s_at EGR4 early growth response 4 2.E-04 0.055 -12.1 0.001       
  



  
32502_at GDPD5 
glycerophosphodiester phosphodiesterase domain 
containing 5 
2.E-04 0.057 -5.2 9.E-04        
    


212646_at RFTN1 raftlin, lipid raft linker 1 2.E-04 0.057 -8.5 2.E-04   S    
 



 
200657_at SLC25A5 
solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 5 
2.E-04 0.057 -7.2 0.002      1,3 




  
209803_s_at PHLDA2 pleckstrin homology-like domain, family A, member 2 2.E-04 0.057 -11.3 8.E-04        
   

  
212471_at AVL9 AVL9 homolog (S. cerevisiase) 2.E-04 0.057 -5.4 2.E-04       
         
215518_at STXBP5L syntaxin binding protein 5-like 2.E-04 0.058 -9.3 0.003       
 

     
213125_at OLFML2B olfactomedin-like 2B 2.E-04 0.058 -7.8 0.012   AP    
         
214674_at USP19 ubiquitin specific peptidase 19 3.E-04 0.059 -5.6 0.002  
A 
D 
  3  
  

   
204789_at FMNL1 formin-like 1 3.E-04 0.062 -6.8 0.004       


       
202687_s_at TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 3.E-04 0.062 -9.8 0.005        
  

 
215639_at SH2D3C SH2 domain containing 3C 3.E-04 0.062 -5.5 0.002       
         
205249_at EGR2 early growth response 2 3.E-04 0.062 -11.6 3.E-04  
S 
A 
D 
AP 
  2,3 
         
203720_s_at ERCC1 excision repair cross-complementation group 1 3.E-04 0.062 -5.2 0.001        
 



 
  
 
 
203769_s_at STS steroid sulfatase (microsomal), isozyme S 3.E-04 0.065 -8.3 6.E-04        
       
219032_x_at OPN3 opsin 3 3.E-04 0.065 -10.8 0.007   S   5 


      
209192_x_at KAT5 K(lysine) acetyltransferase 5 3.E-04 0.065 -4.9 6.E-04       




   
205483_s_at ISG15 ISG15 ubiquitin-like modifier 3.E-04 0.067 -10.3 3.E-04        
 



 
210910_s_at POMZP3 POM121 and ZP3 fusion 3.E-04 0.068 -15.0 0.007        


 
202698_x_at COX4I1 cytochrome c oxidase subunit IV isoform 1 3.E-04 0.068 -4.2 9.E-04       
 

     
210501_x_at EIF3K eukaryotic translation initiation factor 3, subunit K 4.E-04 0.068 -5.3 0.006      1 
        
209993_at ABCB1 
ATP-binding cassette, sub-family B (MDR/TAP), member 
1 
4.E-04 0.068 -11.1 0.006       
 

    
203719_at ERCC1 excision repair cross-complementation group 1 4.E-04 0.068 -4.8 0.003       
   

   
203697_at FRZB frizzled-related protein 4.E-04 0.069 -13.8 0.014      3 









216248_s_at NR4A2 nuclear receptor subfamily 4, group A, member 2 4.E-04 0.069 -14.3 0.011        
 




208855_s_at STK24 serine/threonine kinase 24 4.E-04 0.069 -5.4 0.006        
 




202746_at ITM2A integral membrane protein 2A 4.E-04 0.070 -13.0 0.011       
         
213316_at KIAA1462 KIAA1462 4.E-04 0.071 -9.1 0.010      1 
         
201002_s_at 
TMEM189-
UBE2V1 
TMEM189-UBE2V1 readthrough 4.E-04 0.072 -6.2 0.008      3  
 



 
217757_at A2M alpha-2-macroglobulin 4.E-04 0.074 -13.5 0.007        




 
204304_s_at PROM1 prominin 1 4.E-04 0.077 -8.8 0.038       


     


213791_at PENK proenkephalin 5.E-04 0.077 -10.7 0.002      2 
 

 



 
207988_s_at ARPC2 actin related protein 2/3 complex, subunit 2, 34kDa 5.E-04 0.077 -6.6 0.002       






 
204622_x_at NR4A2 nuclear receptor subfamily 4, group A, member 2 5.E-04 0.077 -12.5 1.E-03      2  
 




221483_s_at ARPP19 cAMP-regulated phosphoprotein, 19kDa 5.E-04 0.077 -5.3 0.003      3 
 

     
207515_s_at POLR1C polymerase (RNA) I polypeptide C, 30kDa 5.E-04 0.077 -5.1 0.003       
   



 
213385_at CHN2 chimerin 2 5.E-04 0.077 -10.7 0.001       


      
205114_s_at CCL3 chemokine (C-C motif) ligand 3 5.E-04 0.077 -10.9 2.E-04      3  

210605_s_at MFGE8 milk fat globule-EGF factor 8 protein 5.E-04 0.077 -6.2 0.002       




     
204286_s_at PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 5.E-04 0.077 -7.7 0.001       


 
201044_x_at DUSP1 dual specificity phosphatase 1 5.E-04 0.078 -8.8 6.E-04        
 

  
203272_s_at TUSC2 tumor suppressor candidate 2 5.E-04 0.078 -7.2 4.E-04      3  


 
219123_at ZNF232 zinc finger protein 232 5.E-04 0.078 -5.8 0.015       
        
211671_s_at NR3C1 
nuclear receptor subfamily 3, group C, member 1 
(glucocorticoid receptor) 
5.E-04 0.079 -10.1 0.002        
  

  
214112_s_at CXorf40A chromosome X open reading frame 40A 5.E-04 0.079 -5.9 0.003       
         
218651_s_at LARP6 La ribonucleoprotein domain family, member 6 5.E-04 0.079 -7.8 0.002       
        
203851_at IGFBP6 insulin-like growth factor binding protein 6 5.E-04 0.079 -7.1 6.E-04       




    
203367_at DUSP14 dual specificity phosphatase 14 6.E-04 0.079 -7.3 0.006      5 


      
201851_at SH3GL1 SH3-domain GRB2-like 1 6.E-04 0.079 -4.6 0.001       


   


210720_s_at NECAB3 N-terminal EF-hand calcium binding protein 3 6.E-04 0.079 -6.4 5.E-04       
 

     
213366_x_at ATP5C1 
ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1 
6.E-04 0.079 -5.7 0.007   S   3 
 

     
44065_at RITA1 RBPJ interacting and tubulin associated 1 6.E-04 0.080 -6.1 0.008      1  
   


204794_at DUSP2 dual specificity phosphatase 2 6.E-04 0.081 -6.7 0.002        
      
201199_s_at PSMD1 
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 1 
6.E-04 0.083 -5.9 0.010       


 

  
210033_s_at SPAG6 sperm associated antigen 6 6.E-04 0.083 -6.8 0.001       


       
205381_at LRRC17 leucine rich repeat containing 17 6.E-04 0.084 -7.3 0.010      3 


       
203258_at DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) 6.E-04 0.085 -5.3 0.003       
        
200925_at COX6A1 cytochrome c oxidase subunit VIa polypeptide 1 7.E-04 0.085 -4.3 0.010       
 

     
  
 
 
209267_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 7.E-04 0.085 -8.4 0.011       
  

     
205984_at CRHBP corticotropin releasing hormone binding protein 7.E-04 0.086 -10.8 0.002  
S 
AP 
  1,2 








200948_at MLF2 myeloid leukemia factor 2 7.E-04 0.087 -5.9 0.002      5 
    



 
49077_at PPME1 protein phosphatase methylesterase 1 7.E-04 0.087 -5.3 0.004       
        
201677_at HMCES 5-hydroxymethylcytosine (hmC) binding, ES cell-specific 7.E-04 0.090 -7.1 0.014       
        
40472_at LPCAT4 lysophosphatidylcholine acyltransferase 4 7.E-04 0.090 -7.7 0.004      5 
        
214365_at TPM3 tropomyosin 3 7.E-04 0.091 -8.1 0.003       
         
206850_at RASL10A RAS-like, family 10, member A 7.E-04 0.091 -8.5 0.011   A    


     
203872_at ACTA1 actin, alpha 1, skeletal muscle 8.E-04 0.092 -5.6 0.002   A    


 

    
209840_s_at LRRN3 leucine rich repeat neuronal 3 8.E-04 0.092 -9.4 0.004       
         
217405_x_at GPLD1 glycosylphosphatidylinositol specific phospholipase D1 8.E-04 0.093 -5.0 0.001        


 
208165_s_at PRSS16 protease, serine, 16 (thymus) 8.E-04 0.093 -5.4 5.E-04       
        
219825_at CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 8.E-04 0.093 -13.9 0.001   D   3  
  

  
220482_s_at SERGEF secretion regulating guanine nucleotide exchange factor 8.E-04 0.093 -6.2 0.005       


     
217992_s_at EFHD2 EF-hand domain family, member D2 8.E-04 0.093 -8.4 0.002      5 
         
213851_at TMEM110 transmembrane protein 110 8.E-04 0.093 -5.4 0.001       
         
213041_s_at ATP5D 
ATP synthase, H+ transporting, mitochondrial F1 
complex, delta subunit 
8.E-04 0.093 -6.7 0.004      3 
 

     
215716_s_at ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 8.E-04 0.094 -11.5 0.009      1,5 
 



   
203694_s_at DHX16 DEAH (Asp-Glu-Ala-His) box polypeptide 16 9.E-04 0.096 -5.2 0.001       
        
209270_at LAMB3 laminin, beta 3 9.E-04 0.096 -7.8 6.E-04  
S 
AP
   


       
213750_at RSL1D1 ribosomal L1 domain containing 1 9.E-04 0.096 -7.4 0.025       


  

  
211725_s_at BID BH3 interacting domain death agonist 9.E-04 0.096 -7.4 0.001        



203831_at R3HDM2 R3H domain containing 2 9.E-04 0.098 -6.2 0.014   S   3,5 
         
218262_at RMND5B 
required for meiotic nuclear division 5 homolog B (S. 
cerevisiae) 
9.E-04 0.098 -4.6 0.014      3 
         
206258_at ST8SIA5 
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 5 
0.001 0.098 -6.7 0.002       
        
212252_at CAMKK2 
calcium/calmodulin-dependent protein kinase kinase 2, 
beta 
0.001 0.098 -8.2 7.E-05      5 


      
203541_s_at KLF9 Kruppel-like factor 9 0.001 0.098 -5.5 0.003        
      
209699_x_at AKR1C2 aldo-keto reductase family 1, member C2 0.001 0.098 -7.2 8.E-04        
    
218097_s_at CUEDC2 CUE domain containing 2 0.001 0.098 -5.0 0.003       
         
206375_s_at HSPB3 heat shock 27kDa protein 3 0.001 0.098 -8.8 0.001       
    

  
201328_at ETS2 
v-ets avian erythroblastosis virus E26 oncogene 
homolog 2 
0.001 0.099 -8.5 0.005        
       
203349_s_at ETV5 ets variant 5 0.001 0.099 -10.2 0.013   A   1,2,3  


 

205413_at MPPED2 metallophosphoesterase domain containing 2 0.001 0.100 -10.0 0.010      3  
     


 
 
  
  
 
 
 
Figure 6.3. Probe sets with significantly different intensity between schizophrenia patients and controls in the PFC. Probes are listed in the same order as in Table 
6.2.  Probe set intensities in blue were higher in schizophrenia and probe set intensities in pink were lower. The log2 ratios of PFC gene expression in schizophrenia patients 
compared to controls were coefficients from the linear regression. Abbreviation: SCZ (schizophrenia). 
   
 
 
Table 6.3. Results of analysis with and without the use of array weights and robust regression in the presence of regression outlier(s).  
Case 
Analysis using limma Number of 
significant probe 
sets (q<0.1) 
Overlap with 
Case 1 Array weights Robust regression 
1   229  
2   207 205 
3   27 26 
4   17 17 
 
Table 6.4.  Enriched GO BP terms for differentially expressed genes in schizophrenia. Criteria for enrichment are listed in Section 6.2.6. Genes in red have increased 
expression in schizophrenia and genes in green have reduced expression in schizophrenia.  
GO BP ID Term 
Expected 
significant 
genes 
Number of 
significant 
genes 
Annotated 
genes 
P-value Significant genes 
GO:1990267 
response to transition metal 
nanoparticle 
1.2 9 74 3.E-06 ANK2, AQP1, MT1E, MT1M, MT1X, MT2A, ATP5D, S100A8, S100A9 
GO:0010038 response to metal ion 3.8 13 232 1.E-04 
CRHBP, DUSP1, GPLD1, AQP1, MT1E, MT1M, MT1X, MT2A, ATP5D, 
ACTA1, S100A8, S100A9, ABCG2 
GO:0071383 
cellular response to steroid 
hormone stimulus 
1.7 8 107 3.E-04 KAT5, CRHBP, EGR1, NR3C1, AQP1, AQP4, NR4A2, PPARA 
GO:0033993 response to lipid 10.0 22 613 4.E-04 
KAT5, CRHBP, AKR1C2, NQO1, DUSP1, ABCA1, EGR1, GHR, GPLD1, 
NR3C1, AQP1, AQP4, NR4A2, OXTR, PPARA, CYP26B1, ACTA1, 
BDNF, S100A8, S100A9, CA4, ABCG2 
GO:0090200 
positive regulation of release of 
cytochrome c from mitochondria 
0.4 4 22 4.E-04 PMAIP1, BAX, PINK1, TNFSF10 
GO:0051239 
regulation of multicellular 
organismal process 
29.1 47 1790 4.E-04 
LRRC17, KATNB1, KAT5, TOB2, USP19, TUSC2, CRHBP, EGR1, 
EGR2, ETV5, SPEN, DTX4, OBSL1, CADM1, FRZB, NIPBL, GHR, 
SERP1, GPLD1, ANK2, TMEM176B, HSPB1, AQP1, NR4A2, OXTR, 
TMEM176A, PARD3, CYP26B1, BAX, BDNF, SCN1B, TMBIM1, 
FNDC3B, DYNLT1, TIMP1, PHLDA2, SYNDIG1, GDPD5, LBH, STK24, 
PPAP2B, PROM1, NOL3, DHRS3, NREP, POLR1C, ISG15 
GO:0043525 
positive regulation of neuron 
apoptotic process 
0.7 5 40 4.E-04 NQO1, EGR1, NR3C1, PMAIP1, BAX 
GO:0071320 cellular response to cAMP 0.7 5 40 4.E-04 CRHBP, EGR1, EGR2, EGR4, AQP1 
GO:0032355 response to estradiol 1.4 7 89 6.E-04 KAT5, CRHBP, NQO1, DUSP1, GHR, AQP4, OXTR 
GO:0014070 
response to organic cyclic 
compound 
10.4 22 640 7.E-04 
KAT5, CRHBP, NQO1, DUSP1, ABCA1, EGR1, EGR2, EGR4, RFTN1, 
GHR, GPLD1, NR3C1, AQP1, AQP4, NR4A2, OXTR, PMAIP1, PPARA, 
ACTA1, BDNF, CA4, ABCG2 
GO:0022904 respiratory electron transport chain 1.5 7 92 7.E-04 COX4I1, COX6A1, NDUFS3, ATP5C1, ATP5D, BDNF, PINK1 
GO:0097306 cellular response to alcohol 1.1 6 67 7.E-04 KAT5, CRHBP, ABCA1, GPLD1, AQP1, AQP4 
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Fifty of the differentially expressed genes in schizophrenia were associated with suicide or 
lifetime drug, alcohol, or antipsychotic use in the SMRI cohorts (p<0.05). Expression for 29 
of these genes was associated with potential confounders in the same direction as 
schizophrenia diagnosis. Increased expression of C4B, NOL3, HNRNPH3, S100A8, and 
CSTB and decreased expression of CRHBP, LAMB3, EGR2, OLFML2B, CA4, AKR1A1, and 
NR4A2 occurred with increased lifetime antipsychotic use and was consistent with 
expression in schizophrenia patients. Both schizophrenia diagnosis and moderate/severe 
lifetime alcohol or drug use were also related to decreased expression of ETV5, RASL10A, 
EGR2, USP19, CA4, ISLR, TUSC2, CYP26B1, and NDUFS3 and increased expression of 
ZFR, GHR, CASP6, and two other probe sets (Affymetrix IDs 215628_x_at and 215592_at). 
Suicide as cause of death was related to increased expression of PLIN3 and decreased 
expression of RFTN1 and OPN3, also consistent with expression in schizophrenia.  
A comparison of microarray and serum findings (Chapter 5) revealed that both PFC gene 
expression and serum protein concentration of tissue inhibitor of metalloproteinases 1 
(TIMP-1) was increased in schizophrenia. Conversely, α2-macroglobulin protein 
concentration was increased in serum, but gene expression was decreased in the PFC. No 
other overlap was found with differentially expressed PFC genes using q<0.1. However, 
relaxing the q-value cut-off criteria, an additional six genes overlapped with serum results 
(p<0.05) and were in the same direction. Both PFC gene expression and serum protein 
concentration of ferritin, carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA 19-9), 
EN-RAGE, hepatocyte growth factor (HGF), and α1-antitrypsin were increased in 
schizophrenia (Table 6.5). On the other hand, AXL receptor tyrosine kinase was decreased 
in schizophrenia patient serum, but gene expression was increased in the PFC. 
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Table 6.5. Comparison of PFC gene expression findings with serum findings for first onset, antipsychotic 
naive schizophrenia patients compared to controls in Chapter 5.   
Serum (Chapter 5)  PFC 
Analytes 
UniProt/ 
PubChem 
identifier Q-value % 
Microarray 
probe set P-value Q-value % 
Ferritin 
P02792, 
P02794 
1.E-10 125.9 
213187_x_at / 
214211_at 
0.002 / 
0.020 
0.14 / 
0.30 
8.1 / 6.0 
MIF P14174 8.E-10 99.6 217871_s_at 0.52 0.86 -1.5 
Haptoglobin P00738 2.E-06 59.6 206697_s_at 0.90 0.98 0.2 
CEA P06731 2.E-06 57.7 217291_at 0.042 0.39 2.8 
PP P01298 0.026 42.0 210670_at 0.64 0.90 -0.61 
Cortisol 5754 5.E-08 37.7 Not measured 
FSH 
P01225,  
P01215 
0.004 37.4 
214489_at /  
204637_at 
0.43 / 
0.036 
0.83 / 
0.38 
-1.4 / 4.1 
LH 
P01229,  
P01215 
0.006 31.8 
214471_x_at /  
204637_at 
0.57 / 
0.036 
0.88 / 
0.38 
-1.2 / 4.1 
CA 19-9 Q9BXJ9 0.043 30.4 219158_s_at 0.032 0.36 5.3 
EN-RAGE P80511 0.043 26.5 205863_at 0.009 0.22 9.0 
Testosterone 6013 4.E-05 24.4 Not measured 
CgA P10645 0.027 22.7 204697_s_at 0.086 0.51 -4.1 
IL-8 P10145 0.011 20.6 202859_x_at 0.21 0.68 -4.3 
G-CSF P09919 0.027 20.3 210228_at 0.81 0.96 -0.3 
Progesterone 5994 0.010 19.5 Not measured 
HGF P14210 0.037 17.3 209960_at 0.002 0.13 7.8 
RANTES P13501 0.030 16.8 204655_at 0.36 0.79 -2.0 
Eotaxin-1 P51671 0.038 16.7 210133_at 0.83 0.96 -0.4 
A2Macro P01023 8.E-07 16.2 217757_at 4E-04 0.074 -13.5 
IGFBP-2 P18065 0.038 14.7 202718_at 0.23 0.70 -3.4 
TN-C P24821 0.037 14.1 216005_at 0.66 0.91 -0.75 
PDGF P01127 0.030 13.5 216055_at 0.20 0.67 1.9 
IL-10 P22301 4.E-05 12.6 207433_at 0.61 0.89 -0.6 
IL-18 Q14116 0.038 11.0 206295_at 0.44 0.83 -1.1 
HCC-4 O15467 0.060 10.8 207354_at 0.65 0.91 0.8 
MDC O00626 0.027 9.9 207861_at 0.88 0.97 -0.2 
SAP P02743 0.038 9.4 206350_at 0.35 0.78 -1.2 
IL-15 P40933 0.030 9.2 205992_s_at 0.34 0.78 1.4 
AAT P01009 0.012 8.2 202833_s_at 0.005 0.18 12.0 
TNFR2 P20333 0.038 7.6 203508_at 0.76 0.94 0.6 
TBG P05543 0.032 7.5 206386_at 0.85 0.97 0.3 
TIMP-1 P01033 0.013 7.0 201666_at 8E-04 0.092 17.8 
C3 P01024 0.010 7.0 217767_at 0.76 0.94 2.0 
Apo H P02749 0.018 6.8 205216_s_at 0.75 0.94 0.5 
AXL P30530 0.098 -6.9 202685_s_at 0.027 0.34 3.5 
PAP P15309 0.060 -8.8 204393_s_at 0.62 0.90 0.6 
Resistin Q9HD89 0.074 -9.9 220570_at 0.68 0.92 0.6 
Apo A-I P02647 0.026 -10.6 217073_x_at 0.42 0.82 -1.5 
Apo-CIII P02656 0.013 -11.6 205820_s_at 0.65 0.91 -0.6 
TSH 
P01222,  
P01215 
0.071 -12.6 
214529_at /  
204637_at 
0.56 / 
0.036 
0.88 / 
0.38 
-0.8 / 4.1 
Sortilin Q99523 3.E-04 -15.1 212797_at 0.75 0.94 -1.1 
RAGE Q15109 0.027 -15.2 217046_s_at 0.51 0.86 -1.2 
CK-MB 
P12277, 
P06732 
0.007 -24.3 
200884_at / 
204810_s_at 
0.66 / 
0.29 
0.91 / 
0.75 
-0.7 / -
1.8 
CD40L P29965 0.030 -24.6 207892_at 0.30 0.75 -1.6 
Leptin P41159 0.042 -25.6 207092_at 0.71 0.92 0.6 
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6.3.2 Sex-biased gene expression 
Thirty-three genes [46 probe sets] were differentially expressed in control male compared to 
control female PFC (Table 6.6 and Figure 6.4) in the linear model. Fourteen of the probe 
sets had higher intensity in females compared to males, while the remaining 32 were higher 
in males. Eighteen (39%) of these probe sets showed evidence of heterogeneity between 
cohorts. The majority of sex-biased genes were located on the X- or Y- chromosomes. Sex 
biased genes were associated with over 1000 GO BP terms and enriched for four of these, 
including histone demethylation and translation initiation (Table 6.7). Genes involved in 
these enriched functions comprised 21% of the sex-biased genes. Sex differences in serum 
protein concentration found in Chapter 3 were compared to sex differences in PFC gene 
expression, but this revealed limited overlap. Adiponectin (207175_at) PFC gene expression 
and serum concentration were both higher in females (p=0.046, q=0.72). Cancer antigen 15-
3 (207847_s_at; p=0.027, q=0.68), neuronal cell adhesion molecule (204105_s_at; p=0.037, 
q=0.70), and monocyte chemotactic protein 2 (214038_at; p=0.003, q=0.45) were also 
consistent with serum results and were higher in males. 
6.3.3 Sex-schizophrenia diagnosis interactions in PFC gene expression 
No probe set intensities showed significant sex-diagnosis interactions in the linear model 
with q<0.1. Probe sets having sex-diagnosis interactions with p<0.01 were examined (Table 
6.8 and Figure 6.5), all of which had q=1.0 with the exception of HSPA6 (q=0.43). There 
were 105 genes [107 probe sets] meeting this criteria, 5 of which showed male-specific 
differences in probe set intensity in schizophrenia, 41 of which showed female-specific 
differences, and the remaining 61 of which showed qualitative interactions. Eleven of these 
(10%) showed evidence of heterogeneity between cohorts. These 105 genes were 
associated with over 2000 GO BP terms, but were not significantly enriched for any of these. 
There was no overlap between them and the serum proteins found in Chapter 5 to have a 
significant sex-diagnosis interaction in concentration (or with genes with p<0.05). None of 
the probe sets showing different intensity in schizophrenia patients in Table 6.2 (q<0.1) had 
a sex-diagnosis interaction with p<0.01. 
  
 
 
Table 6.6. Probe sets with significantly different intensity between male and female control PFC. In (A) probe set intensity is higher in males, while in (B) 
probe set intensity is higher in females.  The percentage impact on serum molecular concentrations of male (A) and female (B) sex (%) from the linear regression 
is reported and use of robust regression is marked for each probe set. GO terms were used to assess participation of a gene in each biological process. 
Abbreviations:  P (p-value); Q (q-value); A (lifetime alcohol use); AP (lifetime antipsychotic use); D (lifetime drug use); S (suicide); MP (metabolic process); DP 
(developmental process); CC & ST (cell communication and signal transduction); IR (defense/immune/inflammatory response); CP (cell proliferation); NSD 
(nervous system development). GO terms (left to right):  GO:0008152; GO:0032502; GO:0007154 and GO:0007165; GO:0006810;  GO:0040007 and 
GO:0008283; GO:0006950; GO:0008219; GO:0006952 and GO:0006955 and GO:0006954; GO:0007399; GO:0007268.    
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201909_at RPS4Y1 ribosomal protein S4, Y-linked 1 924.6 2.E-73 4.E-69 Y p11.2   

     
205000_at DDX3Y 
DEAD (Asp-Glu-Ala-Asp) box helicase 3, 
Y-linked 
707.1 1.E-67 1.E-63 Y q11.221   
        
206700_s_at KDM5D lysine (K)-specific demethylase 5D 444.0 9.E-57 4.E-53 Y q11.223   
        
214983_at TTTY15 
testis-specific transcript, Y-linked 15 
(non-protein coding) 
113.4 7.E-56 2.E-52 Y q11.221  
         
206624_at USP9Y ubiquitin specific peptidase 9, Y-linked 288.4 8.E-46 2.E-42 Y q11.221   


      
207703_at NLGN4Y neuroligin 4, Y-linked 142.1 8.E-42 2.E-38 Y q11.221   
     


204409_s_at EIF1AY 
eukaryotic translation initiation factor 1A, 
Y-linked 
172.4 3.E-37 8.E-34 Y q11.223   
        
205001_s_at DDX3Y 
DEAD (Asp-Glu-Ala-Asp) box helicase 3, 
Y-linked 
103.9 1.E-35 2.E-32 Y q11.221   
        
207063_at TTTY14 
testis-specific transcript, Y-linked 14 
(non-protein coding) 
78.3 2.E-34 5.E-31 Y q11.222  
         
211149_at UTY 
ubiquitously transcribed tetratricopeptide 
repeat containing, Y-linked 
31.2 5.E-26 1.E-22 Y q11.221   
        
204410_at EIF1AY 
eukaryotic translation initiation factor 1A, 
Y-linked 
84.8 6.E-24 1.E-20 Y q11.223   
        
36554_at ASMTL acetylserotonin O-methyltransferase-like 42.2 5.E-15 8.E-12 X/Y 
p22.33/ 
p11.3 
  
        
209394_at ASMTL acetylserotonin O-methyltransferase-like 30.0 5.E-13 8.E-10 X/Y 
p22.33/ 
p11.3 
  
        
  
 
 
 
 
 
 
218951_s_at PLCXD1 
phosphatidylinositol-specific 
phospholipase C, X domain containing 1 
40.6 7.E-13 1.E-09 X/Y 
p22.33/ 
p11.32 
  
        
36553_at ASMTL acetylserotonin O-methyltransferase-like 35.8 7.E-13 1.E-09 X/Y 
p22.33/ 
p11.3 
  
        
210292_s_at 
PCDH11X 
PCDH11Y 
protocadherin 11 X/Y-linked 59.8 1.E-12 1.E-09 X/Y 
q21.31/ 
p11.2 
  
        
214131_at TXLNGY taxilin gamma pseudogene, Y-linked 40.9 9.E-12 1.E-08 Y q11.222  
         
203043_at ZBED1 zinc finger, BED-type containing 1 19.0 5.E-10 5.E-07 X/Y 
p22.33/ 
p11 
  
        
201029_s_at CD99 CD99 molecule 45.7 6.E-10 6.E-07 X/Y 
p22.33/ 
p11.3 
 
         
203314_at GTPBP6 GTP binding protein 6 (putative) 18.2 4.E-09 4.E-06 X/Y 
p22.33/ 
p11.32 
 
         
201028_s_at CD99 CD99 molecule 43.7 1.E-08 1.E-05 X/Y 
p22.33/ 
p11.3 
 
         
210322_x_at UTY 
ubiquitously transcribed tetratricopeptide 
repeat containing, Y-linked 
13.8 6.E-08 5.E-05 Y q11.221   
        
266_s_at CD24 CD24 molecule 26.5 9.E-08 7.E-05 6 q21   
207246_at ZFY zinc finger protein, Y-linked 10.6 1.E-07 9.E-05 Y p11.2   
        
216379_x_at CD24 CD24 molecule 36.5 2.E-07 2.E-04 6 q21   
209771_x_at CD24 CD24 molecule 33.5 1.E-06 0.001 6 q21   
211227_s_at 
PCDH11X 
PCDH11Y 
protocadherin 11 X/Y-linked 10.5 2.E-06 0.001 X/Y 
q21.31/ 
p11.2 
 
         
208748_s_at FLOT1 flotillin 1 15.9 4.E-05 0.023 6 p21.33  


    


208651_x_at CD24 CD24 molecule 16.3 5.E-05 0.026 6 q21   
205378_s_at ACHE acetylcholinesterase (Yt blood group) 15.9 9.E-05 0.045 7 q22.1   
 

203290_at HLA-DQA1 
major histocompatibility complex, class II, 
DQ alpha 1 
10.9 9.E-05 0.046 
  
 
        
218784_s_at SAYSD1 SAYSVFN motif domain containing 1 9.2 1.E-04 0.067 6 p21.2  
         
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221728_x_at XIST 
X inactive specific transcript 
(non-protein coding) 
2278.2 1.E-64 9.E-61 X q13.2  
         
214218_s_at XIST 
X inactive specific transcript 
(non-protein coding) 
1480.4 2.E-60 1.E-56 X q13.2  
         
203974_at HDHD1 
haloacid dehalogenase-like 
hydrolase domain containing 
1 
17.9 1.E-08 1.E-05 X p22.31 



        
201210_at DDX3X 
DEAD (Asp-Glu-Ala-Asp) box 
helicase 3, X-linked 
21.9 1.E-08 1.E-05 X p11.4 

 




 
203992_s_at KDM6A 
lysine (K)-specific 
demethylase 6A 
26.0 3.E-08 3.E-05 X p11.3 

 


  


200933_x_at RPS4X 
ribosomal protein S4, X-
linked 
10.8 7.E-07 5.E-04 X q13.1 

 


    
213347_x_at RPS4X 
ribosomal protein S4, X-
linked 
11.7 2.E-06 0.001 X q13.1 

 


    
212515_s_at DDX3X 
DEAD (Asp-Glu-Ala-Asp) box 
helicase 3, X-linked 
25.9 3.E-06 0.002 X/8 p11.4/p21.2 

 




 
209740_s_at PNPLA4 
patatin-like phospholipase 
domain containing 4 
16.0 3.E-06 0.002 X p22.31 

 
        
201100_s_at USP9X 
ubiquitin specific peptidase 9, 
X-linked 
9.8 4.E-05 0.022 X p11.4 

 


  


204121_at GADD45G 
growth arrest and DNA-
damage-inducible, gamma 
14.7 4.E-05 0.025 9 q22.2 

 
 

  
201147_s_at TIMP3 
TIMP metallopeptidase 
inhibitor 3 
21.5 7.E-05 0.038 22 q12.3 

 
        
218711_s_at SDPR serum deprivation response 18.4 1.E-04 0.056 2 q32.3 


         
204939_s_at PLN phospholamban 21.9 2.E-04 0.087 6 q22.31        
  
 
 
 
 
Figure 6.4. Probe sets with significantly different intensity between male and female control PFC. Probes are listed in the same order as in Table 6.6.  Probe set 
intensities in blue were higher in males and probe set intensities in pink were higher in females. The log2 ratios of PFC gene expression in males compared to females were 
coefficients from the linear regression. 
  
 
 
Table 6.7. Enriched GO BP terms for genes with sex-biased expression. Criteria for enrichment are listed in Section 6.2.6. Genes in orange have increased expression in males 
and genes in blue have increased expression in females.  
GO BP ID Term 
Expected 
significant 
genes 
Number of 
significant 
genes 
Annotated 
genes 
P-value Significant genes 
GO:0016577 histone demethylation 0.04 3 19 9.E-06 KDM6A, UTY, KDM5D 
GO:0008214 protein dealkylation 0.05 3 21 1.E-05 KDM6A, UTY, KDM5D 
GO:0070988 demethylation 0.09 3 39 9.E-05 KDM6A, UTY, KDM5D 
GO:0006413 translational initiation 0.30 4 135 2.E-04 DDX3X, RPS4X, RPS4Y1, EIF1AY 
 
Table 6.8. Probe sets with sex-schizophrenia diagnosis interactions with p<0.01. Probe sets in orange represent male-specific differences, blue are female-specific, and white are 
qualitative interactions. The percentage impact on serum molecular concentrations of schizophrenia for males and females (%) from the linear regression is reported and use of robust 
regression is marked for each probe set. The direction of effect of potential confounders is marked with arrows. GO terms were used to assess participation of a gene in each biological 
process. Abbreviations: P (p-value); Q (q-value); A (lifetime alcohol use); AP (lifetime antipsychotic use); D (lifetime drug use); S (suicide); MP (metabolic process); DP (developmental 
process); CC & ST (cell communication and signal transduction); IR (defense/immune/inflammatory response); CP (cell proliferation); NSD (nervous system development). GO terms (left to 
right): GO:0008152; GO:0032502; GO:0007154 and GO:0007165; GO:0006810; GO:0040007 and GO:0008283; GO:0006950; GO:0008219; GO:0006952 and GO:0006955 and 
GO:0006954; GO:0007399; GO:0007268.   
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205308_at ZC2HC1A 
zinc finger, C2HC-type containing 
1A 
0.003 -5.5 0.23 0.29 11.3 2.E-04 0.005 8 
 
 
 
          
201063_at RCN1 
reticulocalbin 1, EF-hand calcium 
binding domain 
0.004 -4.0 0.35 0.42 11.6 6.E-05 0.004 11 
 
 
 
 

        
220925_at NAA35 
N(alpha)-acetyltransferase 35, 
NatC auxiliary subunit 
0.005 -5.0 0.26 0.32 10.6 3.E-04 0.006 9 
 
 
 
    
 
 

   
202255_s_at SIPA1L1 
signal-induced proliferation-
associated 1 like 1 
0.006 -4.1 0.24 0.30 7.6 7.E-04 0.010 14 
 
 
 
     

  
 
 
218390_s_at FAM204A 
family with sequence similarity 
204, member A 
0.010 2.1 0.27 0.33 -3.6 0.002 0.016 10 
 
 
 
          
202621_at IRF3 interferon regulatory factor 3 2.E-04 9.5 0.002 0.016 -3.9 0.026 0.065 19 
 
  
 



  
201219_at CTBP2 C-terminal binding protein 2 3.E-04 10.7 0.004 0.024 -4.6 0.027 0.066 10 
 
  
  

     
207360_s_at NTSR1 
neurotensin receptor 1 (high 
affinity) 
7.E-04 10.2 0.002 0.016 -2.4 0.19 0.24 20 
 
  
  

   

  

202425_x_at PPP3CA 
protein phosphatase 3, catalytic 
subunit, alpha isozyme 
0.002 -13.5 0.008 0.037 5.7 0.087 0.14 4 
 
 S 


 

 

204415_at IFI6 
interferon, alpha-inducible protein 
6 
0.002 -13.5 0.004 0.024 4.8 0.19 0.24 1    
 

 

  
219396_s_at microRNA 631 MIR631 0.002 6.2 0.037 0.081 -4.4 0.010 0.041 15 
 
  
   

    
204844_at ENPEP 
glutamyl aminopeptidase 
(aminopeptidase A) 
0.002 5.5 0.020 0.059 -2.9 0.042 0.084 4    
 

     
210231_x_at SET SET nuclear proto-oncogene 0.002 -7.4 0.035 0.078 5.4 0.017 0.054 3/9 
 
  
  

  

   
213579_s_at EP300 E1A binding protein p300 0.002 8.7 0.015 0.049 -3.7 0.064 0.11 22 
 
  
 

 
216888_at LDB3 LIM domain binding 3 0.003 7.5 0.021 0.061 -3.6 0.051 0.093 10 
 
  
          
204766_s_at NUDT1 
nudix (nucleoside diphosphate 
linked moiety X)-type motif 1 
0.003 8.2 0.024 0.064 -4.2 0.041 0.084 7 
 
  
 

 

    
220814_at SLC30A6 
solute carrier family 30 (zinc 
transporter), member 6 
0.003 -4.8 0.066 0.11 4.5 0.007 0.033 2 
 
  
          
212475_at AVL9 AVL9 homolog (S. cerevisiase) 0.003 5.2 0.029 0.068 -3.5 0.050 0.093 7    
          
218020_s_at ZFAND3 zinc finger, AN1-type domain 3 0.003 -6.4 0.041 0.084 4.6 0.022 0.062 6 
 
  
          
205973_at FEZ1 
fasciculation and elongation 
protein zeta 1 (zygin I) 
0.003 10.5 0.009 0.039 -2.9 0.19 0.24 11 
 
  
          
205064_at SPRR1B small proline-rich protein 1B 0.004 6.1 0.023 0.062 -2.8 0.072 0.12 1 
 
  
        
214191_at ICA1 islet cell autoantigen 1, 69kDa 0.004 -7.7 0.011 0.044 2.5 0.18 0.24 7 
 
  
          
217309_s_at DSCR3 
Down syndrome critical region 
gene 3 
0.004 8.9 0.010 0.041 -2.5 0.20 0.25 21 
 
  
          
205146_x_at APBA3 
amyloid beta (A4) precursor 
protein-binding, family A, member 
3 
0.004 7.0 0.025 0.064 -3.2 0.069 0.12 19 
 
  
     

212182_at LOC100996752 uncharacterized LOC100996752 0.004 8.8 0.13 0.18 -9.7 0.003 0.021 12 
 
 AP 
 

      
217712_at NA NA 0.005 4.2 0.021 0.061 -1.9 0.11 0.16    AP 
          
217218_at WAPAL 
wings apart-like homolog 
(Drosophila) 
0.005 6.8 0.013 0.046 -2.0 0.19 0.24 10 
 
  
          
206609_at MAGEC1 melanoma antigen family C, 1 0.005 4.6 0.042 0.084 -2.6 0.046 0.089 X 
 
  
          
211646_at IGH immunoglobulin heavy locus 0.006 4.5 0.016 0.051 -1.4 0.18 0.24 14 
 
  
          
217442_at CADM3-AS1 CADM3 antisense RNA 1 0.006 -9.0 0.019 0.057 3.5 0.15 0.21 1 
 
  
          
207670_at KRT85 keratin 85 0.006 -5.4 0.064 0.11 4.1 0.026 0.065 12 
 
  
 

        
222079_at ERG 
v-ets avian erythroblastosis virus 
E26 oncogene homolog 
0.006 4.7 0.016 0.051 -1.5 0.19 0.24 21 
 
  
 

     
207511_s_at CNPPD1 
cyclin Pas1/PHO80 domain 
containing 1 
0.006 5.7 0.070 0.12 -4.1 0.023 0.062 2 
 
  
         
218372_at MED9 mediator complex subunit 9 0.006 -5.9 0.041 0.084 3.4 0.062 0.11 17 
 
  
         
221745_at DCAF7 
DDB1 and CUL4 associated factor 
7 
0.007 -8.2 0.025 0.064 3.8 0.12 0.17 17   AP 
        
209350_s_at GPS2 G protein pathway suppressor 2 0.007 4.7 0.075 0.12 -3.5 0.022 0.062 17 
 
  
 

 

    
210683_at NRTN neurturin 0.007 -4.2 0.026 0.065 1.8 0.13 0.18 19 
 
  
     

 
219065_s_at DPY30 dpy-30 homolog (C. elegans) 0.007 8.6 0.048 0.092 -4.7 0.055 0.10 2/6/
 
  
          
  
 
 
 
21 
216148_at NA NA 0.007 5.4 0.034 0.077 -2.4 0.095 0.15  
 
  
          
208748_s_at FLOT1 flotillin 1 0.007 8.3 0.10 0.15 -7.0 0.013 0.046 6 
 
  
 

     

 
214131_at TXLNGY 
taxilin gamma pseudogene, Y-
linked 
0.007 -10.4 0.041 0.084 6.0 0.074 0.12 Y 
 
  
          
207655_s_at BLNK B-cell linker 0.008 10.6 0.075 0.12 -7.2 0.028 0.067 10 
 
 S 
 

 

 

  
212836_at POLD3 
polymerase (DNA-directed), delta 
3, accessory subunit 
0.008 5.0 0.070 0.12 -3.4 0.032 0.073 11 
 
  
   

    
216170_at NA NA 0.008 -4.5 0.070 0.12 3.3 0.032 0.073  
 
  
          
215521_at PHC3 
polyhomeotic homolog 3 
(Drosophila) 
0.008 6.4 0.023 0.062 -2.2 0.18 0.24 3 
 
  
 

        
221183_at LOC100507388 uncharacterized LOC100507388 0.008 7.1 0.044 0.086 -3.6 0.074 0.12 4 
 
  
          
216671_x_at MUC8 mucin 8 0.008 6.5 0.043 0.085 -3.3 0.076 0.12  
 
  
          
201471_s_at SQSTM1 sequestosome 1 0.008 5.8 0.036 0.079 -2.6 0.10 0.15 5 
 
  


   
210739_x_at SLC4A4 
solute carrier family 4 (sodium 
bicarbonate cotransporter), 
member 4 
0.008 -6.5 0.11 0.16 6.5 0.013 0.046 4 
 
  
   

      
218997_at POLR1E 
polymerase (RNA) I polypeptide E, 
53kDa 
0.008 -7.1 0.028 0.067 3.0 0.15 0.21 9 
 
  
         
204640_s_at SPOP speckle-type POZ protein 0.008 -6.4 0.040 0.084 3.4 0.090 0.14 17 
 
  
 

 

   
201802_at SLC29A1 
solute carrier family 29 
(equilibrative nucleoside 
transporter), member 1 
0.008 6.1 0.13 0.18 -5.8 0.011 0.044 6 
 
  


   

203521_s_at ZNF318 zinc finger protein 318 0.008 5.1 0.16 0.22 -5.6 0.006 0.031 6 
 
 D 
         
202400_s_at SRF 
serum response factor (c-fos 
serum response element-binding 
transcription factor) 
0.008 4.4 0.11 0.16 -3.9 0.015 0.049 6 
 
  
 

  

207568_at CHRNA6 
cholinergic receptor, nicotinic, 
alpha 6 (neuronal) 
0.009 6.8 0.051 0.093 -3.6 0.066 0.11 8 
 
  
  

     

200630_x_at SET SET nuclear proto-oncogene 0.009 -6.8 0.042 0.084 3.6 0.090 0.14 3/9 
 
  
  

  

   
210575_at NUDC nudC nuclear distribution protein 0.009 4.9 0.027 0.066 -1.8 0.16 0.22  
 
  
          
202725_at POLR2A 
polymerase (RNA) II (DNA 
directed) polypeptide A, 220kDa 
0.009 6.4 0.066 0.11 -4.0 0.045 0.088 17 
 
  
   

    
211526_s_at RTEL1 
regulator of telomere elongation 
helicase 1 
0.009 3.1 0.071 0.12 -2.3 0.050 0.093 20    
   

   
217280_x_at GABRA5 
gamma-aminobutyric acid (GABA) 
A receptor, alpha 5 
0.009 13.0 0.041 0.084 -7.5 0.11 0.16 15    
 



220462_at CSRNP3 
cysteine-serine-rich nuclear 
protein 3 
0.009 -10.3 0.12 0.17 11.2 0.014 0.048 2 
 
  
     

   
221549_at GRWD1 
glutamate-rich WD repeat 
containing 1 
0.009 6.1 0.025 0.064 -2.0 0.19 0.24 19 
 
  
          
221552_at ABHD6 abhydrolase domain containing 6 0.009 5.4 0.17 0.23 -6.2 0.006 0.031 3 
 

S 
AP 

 

      

217173_s_at LDLR low density lipoprotein receptor 0.010 -6.8 0.031 0.072 2.8 0.16 0.22 19 
 
  
 

      
214164_x_at CA12 carbonic anhydrase XII 0.010 -7.4 0.12 0.17 7.2 0.018 0.056 15 
 
  
  

      
215283_at LINC00667 
long intergenic non-protein coding 
RNA 667 
0.010 6.6 0.050 0.093 -3.3 0.083 0.13 18 
 
  
          
213418_at HSPA6 
heat shock 70kDa protein 6 
(HSP70B') 
2.E-05 25.8 3.E-07 6.E-05 0.8 0.79 0.81 1    
  

    
  
 
 
 
207038_at SLC16A6 solute carrier family 16, member 6 4.E-04 -13.9 4.E-04 0.007 2.5 0.33 0.40 17 
 
  
   

      
220207_at YIF1B 
Yip1 interacting factor homolog B 
(S. cerevisiae) 
6.E-04 -11.5 2.E-04 0.005 0.8 0.69 0.71 19 
 
  
          
213658_at NA NA 8.E-04 -18.7 8.E-04 0.011 3.4 0.36 0.43 15 
 
 S   
          
203802_x_at NSUN5 
NOP2/Sun domain family, member 
5 
9.E-04 10.7 6.E-04 0.010 -1.2 0.49 0.54 7 
 
  
         
212284_x_at TPT1 
tumor protein, translationally-
controlled 1 
0.001 5.6 0.001 0.012 -0.9 0.37 0.43 13 
 
  
 



   
214450_at CTSW cathepsin W 0.002 -12.6 1.E-04 0.004 -0.7 0.75 0.77 11 
 
  
      

  
221135_s_at ASTE1 asteroid homolog 1 (Drosophila) 0.002 -10.5 0.001 0.012 1.0 0.63 0.66 3 
 
  
   

    
218807_at VAV3 
vav 3 guanine nucleotide 
exchange factor 
0.002 -13.6 3.E-04 0.006 -0.4 0.85 0.86 1 
 
 S   
  
210203_at CNOT4 
CCR4-NOT transcription complex, 
subunit 4 
0.002 10.7 1.E-04 0.004 0.9 0.58 0.62 7 
 
  
         
216232_s_at GCN1L1 
GCN1 general control of amino-
acid synthesis 1-like 1 (yeast) 
0.002 10.4 0.002 0.016 -1.6 0.41 0.46 12 
 
  
         
206287_s_at ITIH4 
inter-alpha-trypsin inhibitor heavy 
chain family, member 4 
0.002 -8.7 0.004 0.024 2.0 0.30 0.36 3 
 
  
   

 

  
205599_at TRAF1 TNF receptor-associated factor 1 0.002 9.8 0.002 0.016 -1.4 0.42 0.47 9 
 
  
 

   

   
204506_at PPP3R1 
protein phosphatase 3, regulatory 
subunit B, alpha 
0.003 -19.7 0.003 0.021 4.1 0.37 0.43 2 
 
  
  



  
201854_s_at ATMIN ATM interactor 0.003 -10.9 0.003 0.021 2.0 0.40 0.46 16 
 
  
   

    
221722_x_at LZTS1 
leucine zipper, putative tumor 
suppressor 1 
0.003 -8.0 0.003 0.021 1.2 0.46 0.52 8 
 
  
 

 

 
220858_at SORBS2 
sorbin and SH3 domain containing 
2 
0.003 16.1 1.E-04 0.004 1.4 0.57 0.61 4   D 
          
210370_s_at LY9 lymphocyte antigen 9 0.004 10.1 0.007 0.033 -2.3 0.28 0.34 1 
 
  
          
211287_x_at CSF2RA 
colony stimulating factor 2 
receptor, alpha, low-affinity 
(granulocyte-macrophage) 
0.004 8.9 0.006 0.031 -1.6 0.37 0.43 X 
 
  
  

       
203019_x_at SSX2IP 
synovial sarcoma, X breakpoint 2 
interacting protein 
0.005 -22.8 0.002 0.016 1.7 0.74 0.76 1 
 
  
  

       
217177_s_at PTPRB 
protein tyrosine phosphatase, 
receptor type, B 
0.005 6.5 0.005 0.027 -1.0 0.47 0.52 12 
 
 S 
        
212826_s_at SLC25A6 
solute carrier family 25 
(mitochondrial carrier; adenine 
nucleotide translocator), member 6 
0.006 -9.3 1.E-04 0.004 -1.4 0.41 0.46 X   AP 
 



  
206842_at KCND1 
potassium voltage-gated channel, 
Shal-related subfamily, member 1 
0.006 9.7 0.005 0.027 -1.1 0.57 0.61 X 
 
 AP 
  

     

219358_s_at ADAP2 ArfGAP with dual PH domains 2 0.007 12.5 0.004 0.024 -1.1 0.66 0.69 17 
 
  
        
220652_at KIF24 kinesin family member 24 0.007 -6.4 0.005 0.027 0.7 0.60 0.64 9 
 
  
          
204277_s_at TK2 thymidine kinase 2, mitochondrial 0.007 -6.8 0.013 0.046 1.9 0.27 0.33 16 
 
  
         
214638_s_at CCNT2 cyclin T2 0.007 8.0 7.E-04 0.010 0.6 0.65 0.68 2 
 
  
 

       
209105_at NCOA1 nuclear receptor coactivator 1 0.008 15.1 0.007 0.033 -2.1 0.49 0.54 2 
 
  
  

 

 
205600_x_at HOXB5 homeobox B5 0.008 8.2 0.012 0.046 -1.8 0.34 0.41 17 
 
  
        
204939_s_at PLN phospholamban 0.008 -17.5 0.002 0.016 -0.3 0.94 0.95 6    
      
  
 
 
201819_at SCARB1 
scavenger receptor class B, 
member 1 
0.008 10.7 0.005 0.027 -0.9 0.66 0.69 12 
 
  
 

    
214327_x_at TPT1 
tumor protein, translationally-
controlled 1 
0.008 5.5 0.002 0.016 0.0 0.97 0.97 13 
 
 S 
 



   
217970_s_at CNOT6 
CCR4-NOT transcription complex, 
subunit 6 
0.009 7.4 0.019 0.057 -2.1 0.24 0.30 5 
 
 D 
   

     
216475_at TUBB4BP7 
tubulin, beta 4B class IVb 
pseudogene 7 
0.009 -8.0 0.014 0.048 1.9 0.35 0.42 6 
 
  
          
208885_at LCP1 
lymphocyte cytosolic protein 1 (L-
plastin) 
0.009 14.4 0.003 0.021 0.0 0.99 0.99 13 
 
  
 

   

  
211577_s_at IGF1 
insulin-like growth factor 1 
(somatomedin C) 
0.009 8.8 0.013 0.046 -1.8 0.38 0.44 12 
 
  
 

 
217349_s_at PRICKLE3 prickle homolog 3 (Drosophila) 0.010 8.5 4.E-04 0.007 1.0 0.53 0.58 X    
          
203662_s_at TMOD1 tropomodulin 1 0.010 -11.2 0.010 0.041 1.9 0.49 0.54 9 
 
 S 
 

        
213842_x_at NSUN5P1 
NOP2/Sun domain family, member 
5 pseudogene 1 
0.010 7.0 0.013 0.046 -1.4 0.39 0.45 7 
 
  
         
205396_at SMAD3 SMAD family member 3 0.010 10.0 0.009 0.039 -1.4 0.52 0.57 15 
 
  
  
218737_at SBNO1 
strawberry notch homolog 1 
(Drosophila) 
0.010 -9.6 0.009 0.039 1.0 0.59 0.63 12    
         
  
 
 
 
Figure 6.5. Probe sets with sex-schizophrenia diagnosis interactions with p<0.01. Probes are listed in the same order as in Table 6.8. Black vertical lines separate male-
specific differences, female-specific differences, and qualitative interactions. The log2 ratios of PFC gene expression in patients compared to controls for males (blue) and 
females (pink) were coefficients from the linear regression.
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6.4 Discussion 
6.4.1 Differential PFC gene expression in schizophrenia 
The current work takes a novel approach to genome-wide expression analysis in the PFC by 
comprehensively investigating the effects of sex, diagnosis, and sex-diagnosis interactions in 
a meta-analysis of schizophrenia patients and control subjects. The agreement between 
these results and serum protein concentration in first onset, antipsychotic naive 
schizophrenia patients and controls is also examined. Previous studies have investigated 
differential expression of genes in schizophrenia or sex separately, and have not considered 
interactions.  
This study used a different approach from either Mistry, Gillis, and Pavlidis (2012) (430) or 
Pérez-Santiago et al (2012) (429) to meta-analyse schizophrenia and control PFC gene 
expression data. Although only a subset of the cohorts from the two previous meta-analyses 
was used, 209 differentially expressed genes (229 probe sets) were detected, compared to 
95 differentially expressed genes (125 probe sets) in Mistry, Gillis, and Pavlidis (2012) (430) 
and 144 (160 probe sets) in Pérez-Santiago et al (2012) (429). In particular, the use of array 
weights and robust regression in the presence of regression outliers in this study increased 
the number of differentially expressed genes detected by over 13 fold. Similar to both of the 
previous studies, more downregulated than upregulated probe sets were found. The 
relatively small intersection of findings across all meta-analyses (13 probe sets) suggests 
that different datasets used, pre-processing methods, detection and handling of poor quality 
arrays, modelling, and FDR calculations between the analyses have a considerable impact 
on results. High heterogeneity of the additional cohorts included in the previous meta-
analyses may contribute to the discrepancies and overall smaller number of differentially 
expressed genes found previously. However, after sequentially removing each dataset and 
re-analysing the remaining data, Mistry, Gillis, and Pavlidis (2012) (430) reported that their 
results were robust and not highly influenced by any dataset. They also found a good 
agreement between their results and results found using different methods for pre-
processing, including variations on RMA and MAS5 algorithms (430). Sources of 
discrepancy may therefore arise from other dissimilarities between analyses. Nevertheless, 
a considerable number of the current findings (30% of probe sets) overlapped with findings 
from at least one of the previous meta-analyses. Included in these findings were BAG3, 
C4B, MT1X, NEUROD6, and EGR1, which were confirmed in an independent cohort by 
Pérez-Santiago et al (2012) (429) to be differentially expressed in schizophrenia patients. 
Other findings were consistent with reports from individual cohorts, were a different probe 
set from a reportedly differentially expressed gene, or have been replicated independently or 
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in separate, more specific studies of SMRI or HBTRC brains. For example, NR3C1 
(glucocorticoid receptor) expression was decreased in schizophrenia patients in other 
studies of SMRI samples and in several brain regions, including the dorsolateral prefrontal 
cortex (DLPFC), hippocampus, inferior temporal cortex, and amygdala, and in bipolar 
disorder and depression (444, 445). Reduced BDNF gene expression found in this meta-
analysis confirms previous findings in the DLPFC in an independent cohort (446) and in 
blood levels of the protein (210).  
Several new findings in this meta-analysis yielded novel insight into processes disturbed in 
schizophrenia and provide more evidence for previous lines of inquiry. OXTR gene 
expression was higher in schizophrenia in the present meta-analysis, but was not reported 
as being differentially expressed in any of the individual cohorts or previous meta-analyses. 
Oxytocin acts as a hormone and neurotransmitter, regulates social behaviours and 
cognition, and interacts with gonadal hormones, dopamine, serotonin, and glutamate (447, 
448). Recent studies have found polymorphisms of the OXTR gene to be associated with 
risk for schizophrenia (449), higher plasma oxytocin levels to be negatively associated with 
general and positive symptoms of schizophrenia in females (450), and adjunctive intranasal 
oxytocin therapy in patients to improve Positive and Negative Syndrome Scale (PANSS) 
scores (451). GHR gene expression was also increased in schizophrenia. The growth 
hormone (GH)/insulin-like growth factor (IGF)-1 axis is important in regulating brain function, 
including cognitive functioning (452). Decreased GH has been found in both the pituitary of 
chronic schizophrenia and serum of first onset schizophrenia patients (209, 359). These 
findings provide further support for involvement of GH and oxytocin in schizophrenia. Other 
findings included increased CADM1, which can induce synapse formation (453), and 
reduced SYNDIG1, which regulates the content of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors at synapses and may be involved in synaptic 
plasticity (454).  
A GO term enrichment analysis revealed novel terms associated with schizophrenia and 
consistent with the literature. Disturbed cell signalling has been observed in schizophrenia 
and this study provided further support for this by finding the GO term ‘cellular response to 
cAMP’ enriched. Abnormal activity of cAMP-associated signalling pathways has been 
reported in the DLPFC in schizophrenia, implicating a disturbance in the ability to combine 
information from neurotransmitter receptors and, together with abnormalities in MAPK- 
associated pathways, extensive signalling deficits in schizophrenia (455). GO terms 
involving response to metal ion/transition metal nanoparticle and neuronal apoptosis are 
consistent with a previous pathway-based analysis of genome-wide association study 
(GWAS) data in schizophrenia (456) and with the results of a GO enrichment analysis 
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performed by Narayan et al (2008; GSE21138 cohort) (198) that found enriched terms 
related to metal ion binding and apoptosis. Additional evidence was found here that 
processes controlling the release of cytochrome c from the mitochondria may be involved in 
neuronal apoptosis in schizophrenia (457–460). Indication of mitochondrial dysfunction was 
further found by enrichment of the ‘respiratory electron transport chain’ GO term, which 
supports a parallel transcriptomic, metabolomic, and proteomic study of SMRI brains linking 
disturbed metabolism and oxidative stress to schizophrenia (51). Novel detection of 
differentially expressed genes belonging to these GO terms may provide greater insight into 
pathophysiological mechanisms related to these functions in schizophrenia. Also enriched 
were ‘response to steroid hormone stimulus’ and ‘response to estradiol’ terms. Consistent 
with the Perlman et al (2005) (461) study of estrogen receptor (ER) α mRNA in the DLPFC, 
however, there were no significant differences or sex-dependent differences in ERα or ERβ 
gene expression in schizophrenia patients in the present work. However, pathway analyses 
of GWAS data have previously found the ‘CARM1 and regulation of the estrogen receptor’ 
(BioCarta) pathway (462), ‘androgen and estrogen metabolism’ (KEGG) pathway (462), and 
the ‘estrogen biosynthesis process’ (GO) term overrepresented (463). Furthermore, Weickert 
et al (2008) (464) found an ERα genotype associated with schizophrenia risk and lower 
mRNA levels in the frontal cortex, more novel ERα SNPs in schizophrenia, and more ERα 
splice variants expressed in schizophrenia, one of which reduced gene expression at 
estrogen-response elements. Further work into the role of estrogen in schizophrenia in the 
PFC is warranted to explain the current results in the context of these previous findings. 
Finally, though not specifically enriched, a number of differentially expressed genes were 
also related to metabolic and developmental processes; cell communication and signal 
transduction; transport; growth and cell proliferation; stress response; cell death; defence, 
immune, and inflammatory response; and nervous system development and synaptic 
transmission, which have previously been found to be relevant to schizophrenia.  
Potential confounding effects and heterogeneity between cohorts should be considered 
when interpreting these results. This study showed that differential expression of a number 
of genes including S100A8, C4B, GHR, and others may be caused by exposure to 
antipsychotic medication, lifetime drug or alcohol use, or suicide in patients. Pérez-Santiago 
et al (2012) (429) also found MT1X increased and others (27 of 144 significant genes) 
differentially expressed in fetal brain aggregates treated with haloperidol or clozapine. 
However, their results were based on pooled samples measured on only one Affymetrix HG-
U133 Plus 2.0 chip for each group. S100A8 and S100A9 have also been found to be 
increased in rat frontal cortex after chronic treatment with olanzapine (465). A small fraction 
of probes (14%) showed evidence for heterogeneity across cohorts, including S100A8 and 
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S100A9, C4B, and CADM1. Sources of heterogeneity should be investigated and are 
discussed further in the sections below.     
Finally, seven serum protein with altered concentrations in first onset, antipsychotic naive 
schizophrenia patients also showed differential gene expression in PFC tissue in the same 
direction (p<0.05). This was a surprising finding, given that this post-mortem PFC meta-
analysis was conducted in different subjects, at different stages of illness, with different 
exposures to antipsychotic medication and other confounding factors, and it measured gene 
expression. These findings would need to be validated as some had high q-values and only 
the most significant probe set from a gene was reported. The serum proteins had functions 
in immune/inflammatory response (ferritin, CEA, EN-RAGE, α1-antitrypsin) and apoptosis 
(CA 19-9, HGF, TIMP-1). These findings may suggest that peripheral tissue can reflect 
certain elements of brain dysfunction in schizophrenia. Previous studies have also found 
parallel brain and serum alterations in gene expression and/or protein and small molecule 
concentrations in schizophrenia (213, 214). Harris et al (2012) (213) has proposed that this 
is due to coordination of the brain and periphery through hormones and other regulatory 
molecules.  
6.4.2 Sex-biased gene expression 
Sex-biased genes were largely located on the sex chromosomes. Many of the sex-biased 
genes found here have previously been identified, including XIST, KDM5D, RPS4X, HDHD1, 
ASMTL, RPS4Y1, NLGN4Y, TTTY15, PCDH11Y/PCDH11X, DDX3Y, USP9Y, UTY, ZFY, 
CD99, DDX3X, USP9X, and EIF1AY (436–438, 466). There were no significant sex 
differences in expression of ERα in the PFC, in agreement with Perlman et al (2005) (461). 
ERβ also did not show sex-biased expression here. Several of the genes with higher 
expression in males were X-Y homologous genes. Weickert et al (2009) (437) found that for 
PCDH11Y/PCDH11X this was due to higher PCDH11Y expression in males, suggesting that 
there were no compensatory increases in female PCDH11X expression. Enriched GO terms 
in sex-biased terms included histone demethylation and transcription initiation. Previous 
studies have suggested that abnormal X-chromosome inactivation may occur in psychiatric 
disorders, with higher XIST, KD5MC, and other X-chromosome gene expression found in 
lymphoblastoid cells of female psychiatric patients with mania, psychosis, and major 
depression (467). However, this finding was not replicated here for PFC gene expression in 
schizophrenia. None of the sex-biased genes were differentially expressed in schizophrenia, 
but two (FLOT1 and PLN) had sex-diagnosis interactions with p<0.01. FLOT1 has functions 
in cytoskeletal interactions, endocytosis, and signalling (468), and was male-biased in 
control subjects with reduced expression in male schizophrenia patients compared to 
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controls, relative to female differences. Expression differences in PLN may be due to cross-
hybridization as it is not known to be expressed in the brain (469). Finally, very few of the 
serum analytes with different concentrations between males and females (Chapter 3) were 
also differentially expressed in the PFC. This work and other works examining sex-biased 
gene expression in the PFC contained a limited number of subjects (121 in the current 
study), and here there was a heavy male bias (69%). Subjects in this post mortem study 
were older than in the serum study, and female hormonal status at time of death was not 
available. Tissue was also taken from different regions in the PFC, which potentially 
contributed to the heterogeneity across cohorts found in a large proportion (approximately 
40%) of sex-biased genes.  
6.4.3 Sex-schizophrenia diagnosis interactions in PFC gene expression 
No genes had a significant sex-schizophrenia diagnosis interaction (q<0.1) in this study, 
despite the GO term ‘response to estradiol’ being enriched in differentially expressed genes 
in schizophrenia. The high proportion of males included in each of the cohorts (69%) meant 
the power to detect significant differences between female schizophrenia patients and 
control subjects was reduced, and that the differentially expressed genes detected here 
were based largely on male data. Future studies must recruit more female subjects to 
ensure that the findings presented here and in other publications based on these data 
adequately represent differential gene expression in both sexes. Many of the sex-diagnosis 
interactions examined (p<0.01) had female-specific differences in gene expression in 
schizophrenia (40% of interactions, compared to less than 5% male-specific differences) that 
warrant further investigation in a larger cohort. 
Although there were no significant GO terms arising from genes with sex-diagnosis 
interactions (p<0.01), several of the genes participated in processes previously found to be 
important in schizophrenia. Genes involved in apoptosis included the interferon induced IFI6, 
which was reduced in female schizophrenia patients and plays an important role in 
regulating mitochondrial-mediated apoptosis by inhibiting release of cytochrome c (470). 
Furthermore, expression of PPP3R1 and PPP3CA (protein phosphatase 3, regulatory 
subunit B, α and protein phosphatase 3, catalytic subunit, α isozyme, respectively) were 
decreased in female schizophrenia. High levels of calcineurin (made up of subunits encoded 
by these genes) have been found to induce cytochrome c-dependent apoptosis in neurons 
(471). These may play a role in sex-dependent differences in PFC volume in schizophrenia, 
although these findings vary by study and PFC region (249, 255, 256). Calcineurin also 
plays an important role in immune response, and inhibitors of calcineurin are potent 
immunosuppressors (472). Mice with forebrain-specific calcineurin knockout exhibit impaired 
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working memory (473) and schizophrenia-like behaviours (474). Furthermore, NTSR1 
expression was increased in the PFC of female schizophrenia patients. This is in contrast 
with NTSR1 knockout mice that exhibited similar behavioural and frontal cortex molecular 
abnormalities to the chronic phencyclidine (PCP)-treated mouse model of schizophrenia 
(475). Neurotensin is hypothesized to be an endogenous antipsychotic compound implicated 
in the pathophysiology of schizophrenia (476), which interacts with dopamine systems and is 
regulated by estrogen (477). Important sex differences in the role of neurotensin and 
calcineurin in the pathophysiology of schizophrenia may exist.  
 None of the proteins with significant sex-diagnosis interactions in serum concentration were 
found to have parallel sex-diagnosis interactions in PFC gene expression (p<0.05). In 
addition to limitations described above, sex and gender differences in the course of illness, 
age of onset, and effects of antipsychotic medication (243) may further contribute to 
discrepancies in gene expression findings. However, sex-dependent differences in gene 
expression related to androgen receptor signalling and defence/immune response were 
found in the PFC tissue of schizophrenia patients. This was of particular relevance given the 
increased serum testosterone found in first onset female schizophrenia patients and 
increased immune response markers in male schizophrenia patients found in Chapter 5. 
EP300 and NCOA1 expression was increased in the PFC of female schizophrenia patients 
and are important for the production and operation of the androgen receptor (AR) 
transcription complexes (478). Androgens have been reported to increase EP300, NCOA1, 
and IGF-1 in prostate cancer (478, 479) and were also over-expressed in female 
schizophrenia patient PFC tissue. However, androgen receptor expression itself and ERα 
and ERβ expression were not modified in a sex-specific manner. As discussed above, this is 
consistent with Perlman et al (2005) (461), who also found no significant differences 
between male or female schizophrenia and control subjects in ERα mRNA expression in the 
DLPC. A number of genes, including IRF3, IFI6, PPP3R1, PPP3CA, ITH4, CTSW, and 
BLNK were involved in immune response and may also provide further indication of sex 
differences in immune dysfunction in schizophrenia. However, in contrast to serum results, 
many of these were female-specific.  
A number of limitations must be considered when interpreting results from this study. Gene 
expression was measured in these microarray studies, which may not correlate with protein 
concentration. In addition, a number of different brain areas were used in this meta-analysis, 
including BA9, 10, and 46, which may contribute to heterogeneity in 14%, 39%, and 10% of 
the results for analyses of schizophrenia diagnosis, sex, and sex-diagnosis interaction 
effects, respectively. Different diagnostic instruments/protocols, physicians, 
inclusion/exclusion criteria, experimental procedures, age of subjects and course/length of 
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illness, and confounding factors may also create heterogeneity between cohorts. Lifetime 
substance use, antipsychotic use, and suicide status are confounding variables that can 
influence gene expression and for which little power was available to detect effects. Other 
demographic, health, and lifestyle differences may further confound differences in gene 
expression between schizophrenia and controls, but were unavailable or unrecorded. 
Findings should therefore be validated in a better characterized cohort. As previously 
mentioned, hormonal status was not recorded for female subjects and other differences 
between males and females in course of illness, age of onset, and effects of antipsychotic 
medication (243) may be confounded with sex.  
In summary, the current study used a meta-analysis of five cohorts of microarray data to 
explore the effects of schizophrenia diagnosis, sex, sex-schizophrenia diagnosis 
interactions, and confounding effects of suicide, and lifetime drug, alcohol, and antipsychotic 
medication use on PFC gene expression. The use of array weights and robust regression 
resulted in a greater capacity to detect differentially expressed genes in schizophrenia, 
confirming a number of prior findings and resulting in several novel ones. Findings included 
genes enriched in processes related to neuronal apoptosis, mitochondrial function, and 
response to estradiol and cAMP. Some results may also mirror differences in serum protein 
concentrations between first onset, antipsychotic naive schizophrenia patients and controls. 
Finally, although no sex-diagnosis interactions in gene expression reached significance 
(q<0.10), genes with p<0.01 were involved in mitochondrial-mediated apoptosis and synaptic 
transmission important in schizophrenia and in androgen receptor signalling and immune 
response, which may have sex-dependent roles in schizophrenia. However, as these had 
high q-values, further validation of these results is necessary, together with elucidation of 
their potential role in sex-specific pathophysiological mechanisms and in clinical and 
epidemiological sex and gender differences in schizophrenia. Importantly, more females 
should be included in microarray studies of the PFC and other brain regions in order to have 
more power to detect sex and sex-diagnosis interaction effects in gene expression. 
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Chapter 7 Final discussion 
 
This thesis used serum and brain molecular profiling to investigate sex and female hormonal 
status in controls, schizophrenia, and major depressive disorder (MDD). The aim of this chapter 
is to provide an overview of the major findings resulting from this work, limitations of the studies, 
and implications for future investigations. 
 
7.1 Summary of major findings 
7.1.1 Inflammation and immune response 
Many of the sex-dependent serum biomarkers of MDD found in Chapter 4 were associated with 
increased inflammation, immune, and/or defence response in males. These included C-reactive 
protein (CRP), trefoil factor 3 (TFF3), cystatin-C, fetuin-A, β2-microglobulin, CD5 antigen-like 
(CD5L), and tumor necrosis factor receptor 2 (TNFR2). Similarly, elevated serum levels of 
interleukin (IL)-15, α1-antitrypsin (AAT), IL-8, macrophage derived chemokine (MDC), ferritin, 
intercellular adhesion molecule 1 (ICAM-1), and macrophage inflammatory protein-1 α (MIP-1α) 
involved in inflammation and immune response were found in first onset, antipsychotic naive 
male schizophrenia patients only in Chapter 5. These were accompanied by findings of 
potential sex-dependent differences in expression of genes involved in immune response in the 
prefrontal cortex (PFC) in schizophrenia patients in Chapter 6. Extensive differences in the 
serum levels of proteins involved in these biological processes were observed between males 
and females using oral contraceptives (OCs), after menopause, and with menstrual cycles in 
Chapter 3. These included higher CRP, TFF3, AAT, and fetuin-A in the serum of female OC 
users compared to females with menstrual cycles and higher cystatin-C, MDC, and ferritin in 
males compared to females. Brain and peripheral effects of estrogen, progesterone, and 
testosterone on immune and inflammatory response have also been reported elsewhere (see 
Chapter 1). 
These results require further validation and investigation, but may have implications for the 
current hypotheses of depression and schizophrenia. Immune hypotheses of schizophrenia and 
depression could have a male-specific component that may contribute to sex and gender 
differences in incidence, prevalence, age of onset, and other clinical characteristics. 
Inflammation may contribute to hypothalamic-pituitary-adrenal (HPA) axis dysregulation and can 
affect neurotransmission (143). Pro-inflammatory cytokines can elicit apoptotic activity (480) 
and expression of genes involved in apoptosis was disturbed in the PFC in schizophrenia 
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(Chapter 6). Previous work has already suggested that higher CRP occurs specifically in male 
depression (124, 167–171) and that there are sex differences in the associations between CRP 
and fibrinogen and burnout, depression, and anxiety (169). Other lines of evidence also point to 
potential male-specific disruptions in inflammation in mental disorders. Asperger syndrome in 
adults has been characterized by increased serum concentration of some immune and 
inflammatory molecules in males only (10). A mouse model of early prenatal stress, a risk factor 
for schizophrenia and autism spectrum disorders, causes male-specific alterations in dopamine 
D1 and D2 receptor gene expression, together with indications of placental inflammation and 
stress-induced locomotor hyperactivity that were partly resolved by maternal treatment with 
non-steroidal anti-inflammatory drugs (NSAIDs) (481). Prenatal exposure to valproic acid used 
to produce a rat model of autism has also shown more male behavioural and immunological 
abnormalities (482) and stressor re-exposure in mice produces male-specific sensitized 
expression of IL-1β mRNA in both the PFC and hippocampus (483). Sex differences in immune 
regulation (see also Chapter 1) may be important in understanding these findings. These are 
widespread and were shown in Chapter 3 to involve many of the analytes with sex-dependent 
differences in schizophrenia and MDD. Males may be more prone to dysregulation of acute 
inflammation and proinflammatory immune response, as suggested by the higher prevalence of 
males with autoimmune diseases with these characteristics (380). Androgen activation and 
estrogen suppression of T-lymphocytes have been proposed to account for some of the sex 
differences in schizophrenia in the macrophage-T-lymphocyte theory of schizophrenia (225). 
Sex differences have also been found in microglial cell morphology, function, and number (see 
Chapter 1), including anti-inflammatory effects of estrogen on their activation (55, 56). Three-
way interactions between the HPA and hypothalamic-pituitary-gonadal (HPG) axes and the 
immune system may also contribute to sex-dependent differences in immune and inflammatory 
markers in schizophrenia and MDD (29, 355, 376, 377). Further work is needed to elucidate 
mechanisms for the potential sex differences in immune and inflammatory dysregulation in 
mental disorders. 
Sex differences in response to treatment with anti-inflammatory medication may also be 
expected if these results reflect causal mechanisms of schizophrenia and MDD. However, as 
discussed in Chapter 5, a meta-analysis of 26 trials on anti-inflammatory treatment efficacy in 
schizophrenia did not show results stratified by sex (423), although a lower risk of psychosis 
has also been found specifically in male NSAID (421) and glucocorticoid (422) users. Another 
meta-analysis of 14 trials of anti-inflammatory treatment in depression reported a reduction in 
depressive symptoms compared to placebo, but also did not report results by sex (484). 
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7.1.2 HPG axis 
The HPG axis affects development and function of the nervous system and interacts with other 
components of the endocrine system (see Chapter 1). In this work, alterations in the HPG axis 
were found in schizophrenia and MDD. In schizophrenia, increased FSH, LH, and progesterone 
were found together with female-specific reduction of SHBG and elevation of testosterone in 
serum (Chapter 5). Differentially expressed genes in the PFC of schizophrenia patients were 
enriched in functions related to cellular response to steroid hormone stimulus and response to 
estradiol (Chapter 6) and expression of EP300 and NCOA1 genes, important for production 
and function of androgen receptor transcription complexes, was increased specifically in PFC 
tissue in female schizophrenia patients (Chapter 6). In MDD, comorbid MDD and anxiety 
disorder (s) (CMA), and remitted MDD, elevated testosterone and/or reduced FSH were found 
in females (Chapter 4). These observations were consistent with previous findings indicating 
disturbed sex dimorphisms in schizophrenia (277) and provide support for hypotheses that 
reproductive hormones may be involved in MDD (164).  
Periods associated with fluctuating hormonal levels affect risk for female MDD and 
schizophrenia. While estrogen treatment and periods of high estrogen have been associated 
with improved symptoms of schizophrenia (9, 260–263), periods of low estrogen have been 
linked to psychosis (260). Affective disturbances in females may coincide with rising hormone 
levels during puberty or be cycle-dependent, and perimenopause and postpartum are periods of 
increased risk for depression (156, 160). Together with genetic and environmental factors 
during development, fluctuating hormonal levels that occur throughout female life associated 
with puberty, the menstrual cycle, OC use, menopause, and pregnancy may create 
susceptibility for hormonal dysregulation and vulnerability to mental disorders. The role of 
testosterone in female schizophrenia and depression has been less explored compared to other 
reproductive hormones, but has been shown in this work to be of potential importance to these 
disorders (further discussed in Chapters 4-5). Excess androgens and menstrual disturbance 
are characteristics of polycystic ovary syndrome (PCOS), the most common endocrine disorder 
in reproductive-age women (affects 4-8% of women) (485). A higher prevalence of depression 
and autism spectrum (486), anxiety, bipolar, and eating disorders has been found in females 
diagnosed with PCOS (485). Several common characteristics of PCOS also occur in mental 
disorders, including insulin resistance, increased HPA axis activity, and elevated LH (392–395). 
Although the aetiology of PCOS has not been elucidated, genetic and environmental factors 
have been implicated that may disrupt fetal organization through excess prenatal androgen, 
leading to development of the PCOS phenotype in adulthood (Figure 7.1). Disrupted fetal 
hormonal programming has been linked to MDD (164), schizophrenia (277), and autism 
spectrum disorders (487), which are also characterized by higher serum testosterone in adult 
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females with Asperger syndrome (10). These disorders may share elements of their aetiologies 
and pathophysiologies with PCOS. Further work should explore these links and potential 
treatment options.  
 
Figure 7.1. Model of development of the PCOS phenotype. Genetic and environmental factors may influence fetal 
development to produce an adult PCOS phenotype. Based on Xita and Tsatsoulis (2006) (488) and Crain et al (2008) 
(489). 
7.1.3 Implications for biomarker and microarray studies 
The results of this work have several implications for future biomarker and microarray studies. In 
particular, it was shown that sex and female hormonal status are important factors that should 
be explicitly taken into account in future investigations. Individual chapters discuss these 
implications in more detail, but they are summarized here. 
Results from Chapter 3 showed that biomarker studies should match groups based on both sex 
and female hormonal status. In this work, the presence of extensive differences between males 
and females with menstrual cycles, using OCs, and after menopause in serum concentrations of 
molecules involved in endocrine, immune, metabolic, and other processes was demonstrated. 
These extensive differences had a large impact on the number of false positive results in groups 
with simulated imbalances in the proportions of males or OC users. Group imbalances may 
occur more often in mental disorders, where sex differences in the prevalence of disorders 
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occurs and OC use may be less consistent (366). Random forest classifiers developed in 
Chapter 3 may provide a means of retrospectively investigating group imbalances in previously 
conducted studies. 
Chapters 4 and 5 showed that sex-dependent serum molecular differences were present in 
comparisons between controls and first onset, antipsychotic naive schizophrenia and MDD 
patients. It was demonstrated that only male MDD patients could be classified against controls 
with an accuracy greater than chance using the investigated panel of molecules, though 
performance was still poor. More work is needed to develop a viable set of biomarkers for male 
and female MDD. A previous study also found that sex-specific serum biomarker panels 
classified adults with Asperger syndrome from controls (10). Future biomarker studies of mental 
disorders should consider sex and gender in their design and analysis to improve reproducibility 
of findings.   
Chapter 6 showed that array weights and robust regression could be used to improve the 
capacity to detect differentially expressed genes in a microarray study of PFC tissue in 
schizophrenia patients, resulting in novel findings. Parallels were found between PFC gene 
expression and some of the serum findings in first onset, antipsychotic naive schizophrenia. 
However, the small number of females included in these studies made it difficult to assess sex 
differences and sex-diagnosis interactions in gene expression. Post-mortem PFC studies 
should include more females in order to ensure the extensive microarray findings in 
schizophrenia reported in the literature (discussed in Chapters 1 and 6) are relevant to both 
males and females.  
 
7.2 Limitations and future outlook 
A number of the limitations of this body of work are addressed in this section. In particular, 
these results will need to be validated in independent cohorts. A number of the findings in 
Chapters 4-6 had high q-values (q>0.25), including eight of the sex differences in serum 
analyte associations with log-odds of MDD (Chapter 4), four of the sex-dependent differences 
in serum concentration in schizophrenia patients (Chapter 5), and all sex-dependent 
differences in PFC gene expression in schizophrenia patients (Chapter 6). As these studies 
were not specifically designed to investigate sex, more appropriate planning should occur 
before conducting further investigations of sex-dependent differences and other sources of 
heterogeneity in these disorders. Effort should be taken to recruit adequate numbers of both 
male and female patient and control subjects to serum and PFC studies and to collect and 
assess precise information about female hormonal status, the presence of sex chromosome 
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abnormalities, and diagnostic, health, lifestyle, and socioeconomic variables known to differ 
between genders. Other limitations associated with cohort characterization, the type and 
quantity of molecular data collected from participants, statistical methods, and other more 
fundamental problems that occur in the study of mental disorders are discussed below. 
Individual chapters address limitations of the work specifically covered in them.  
Cohorts used in the schizophrenia serum and post-mortem PFC studies (Chapters 5 and 6) 
included limited demographic and other information. The information that was collected was 
heterogeneous between cohorts. It was therefore not possible to account for variability in serum 
concentration or gene expression associated with these factors in the analyses. Chapter 3 
showed the importance of accounting for female hormonal status and future work should further 
assess the impact of other important variables, including smoking, drug and alcohol use, 
ethnicity, use of psychiatric and other medications (short and long term), history and comorbidity 
with mental disorders and other diseases, body mass index, age, blood pressure, fasting status, 
family history, socioeconomic, and other demographic, health, and lifestyle variables on serum 
concentration and PFC gene expression. This may help to explain heterogeneity in results of 
the meta-analyses and to distinguish between effects of sex and gender. Much of the 
information collected in the Netherlands Study of Depression and Anxiety (NESDA) in Chapters 
2-4 was assessed by self-report, including female hormonal status and lifestyle variables. These 
variables may be inaccurate and in some cases may suffer from social desirability bias (490). 
Furthermore, molecular data for these studies (Chapters 3-6) were collected at a single time 
point. Circadian changes in serum molecular levels and changes associated with other events 
were therefore not evaluated. Disruptions of circadian clocks (491) and response to 
psychological stress (139) have been linked to mental disorders and these may therefore be 
important to examine in future studies. Changes associated with reproductive events throughout 
the menstrual cycle, pregnancy and the postpartum period, transition to menopause, and OC 
use could also not be assessed, some of which may represent a period of risk or remission for 
MDD and schizophrenia. Furthermore, the effects on serum molecular concentrations of 
changes in diagnoses, long term use of psychiatric medication, and course of illness could also 
not be investigated. Future studies should evaluate these in order to gain greater insight into 
potential pathophysiological mechanisms.  
Several limitations were also associated with microarray and multiplex immunoassay data 
collected from participants (see also Chapter 2). The number of molecules investigated in these 
platforms makes individual inspection of each difficult or impossible. Data may consequently be 
modelled inappropriately, resulting in false positive results or in important results being missed. 
Substantial batch effects were also found in both microarray and multiplex immunoassay data 
and several poor quality arrays were present in microarray data (Chapter 6). Use of different 
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methods to find multivariate outliers, determine use of robust regression, transform data, 
account for multiple testing, and impute missing data may affect results from Chapters 3-5 and 
these should be further investigated in future. The Benjamini and Hochberg (1995) (326) false 
discovery rate (FDR) procedure used to control the expected proportion of false positive 
findings in this work assumes independent tests, violated here by the correlations between 
molecular concentrations and expression of genes. Although the procedure has been shown to 
control the FDR in simulated DNA microarray data (492), other procedures including the 
Benjamini and Yekutieli (2001) (493), Storey and Tibshirani (2003) (494), and resampling-based 
procedures (492) should also be tested. These procedures have been reported to control the 
FDR and to improve power for the latter two. In microarray data, poor correlations between 
mRNA and protein levels have been reported and this limits the conclusions reached from these 
investigations. On the other hand, though multiplex immunoassays measure protein and other 
small molecule concentrations, the prohibitive costs associated with incorporating new assays 
into the platform limits the number of measured molecules. Estrogen was not measured in 
serum studies (Chapters 3-5), which would have provided more insight into disruptions of the 
HPG axis and the estrogen hypothesis of schizophrenia. The proteins measured were biased 
toward particular biological processes. These included regulation of cell motility, response to 
stress, regulation of signal transduction, immune response, and others (Table 7.1). Future 
studies should incorporate molecules involved in a broader range of biological functions and 
perform pathway analysis. Furthermore, post-translational modifications, alternatively splicing, 
and cleaved proteins cannot be distinguished in the current panel of molecules. Finally, 
integration of this data with other genomic, metabolomic, and neuroimaging data would provide 
a more comprehensive picture of these disorders.  
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Table 7.1. Over-represented gene ontology (GO) biological process (BP) terms among proteins investigated 
in (A) Chapters 3-4 (NESDA cohort) and (B) Chapter 5 (schizophrenia cohorts). GO BP enrichment analysis was 
carried out as described in Chapter 2. Only the top 20 terms are shown. 
(A) 
 
Term 
Expected 
genes 
Observed 
genes P-value GO BP ID 
GO:0051674 localization of cell 10.7 78 7.E-49 
GO:2000145 regulation of cell motility 5.3 50 2.E-35 
GO:0006950 response to stress 25.7 89 6.E-33 
GO:0042330 taxis 6.3 48 1.E-29 
GO:0006954 inflammatory response 3.2 37 2.E-29 
GO:0051272 positive regulation of cellular component movement 2.8 34 2.E-27 
GO:0010562 positive regulation of phosphorus metabolic process 8.4 50 1.E-25 
GO:1903034 regulation of response to wounding 3.4 34 1.E-24 
GO:0001932 regulation of protein phosphorylation 9.3 50 9.E-24 
GO:0032501 multicellular organismal process 50.9 107 7.E-23 
GO:0042060 wound healing 6.5 42 1.E-22 
GO:0032101 regulation of response to external stimulus 2.9 30 2.E-22 
GO:0031401 positive regulation of protein modification process 8.3 46 3.E-22 
GO:0022610 biological adhesion 10.4 49 8.E-21 
GO:0032879 regulation of localization 8.3 43 5.E-20 
GO:0051247 positive regulation of protein metabolic process 9.0 45 5.E-20 
GO:0001568 blood vessel development 5.2 35 2.E-19 
GO:0009967 positive regulation of signal transduction 10.0 46 4.E-19 
GO:0050790 regulation of catalytic activity 18.6 62 5.E-19 
GO:1902531 regulation of intracellular signal transduction 14.1 54 7.E-19 
 
(B) 
 
Term 
Expected 
genes 
Observed 
genes P-value GO BP ID 
GO:0048584 positive regulation of response to stimulus 8.1 45 5.E-24 
GO:0032101 regulation of response to external stimulus 3.1 31 5.E-23 
GO:0060326 cell chemotaxis 1.1 21 1.E-21 
GO:2000145 regulation of cell motility 2.9 27 2.E-19 
GO:0042327 positive regulation of phosphorylation 4.1 30 1.E-18 
GO:0043207 response to external biotic stimulus 3.7 28 1.E-17 
GO:0006950 response to stress 14.4 48 2.E-17 
GO:0042330 taxis 3.4 27 2.E-17 
GO:0023056 positive regulation of signaling 5.4 32 2.E-17 
GO:0010647 positive regulation of cell communication 5.4 32 3.E-17 
GO:0006955 immune response 1.1 18 3.E-17 
GO:0010562 positive regulation of phosphorus metabolic process 4.6 30 4.E-17 
GO:0051272 positive regulation of cellular component movement 1.6 20 6.E-17 
GO:1903034 regulation of response to wounding 1.9 21 9.E-17 
GO:0018212 peptidyl-tyrosine modification 1.7 20 2.E-16 
GO:0031401 positive regulation of protein modification process 4.6 29 3.E-16 
GO:0009966 regulation of signal transduction 12.7 45 4.E-16 
GO:0001932 regulation of protein phosphorylation 5.1 30 6.E-16 
GO:0002544 chronic inflammatory response 0.1 9 7.E-16 
GO:0009617 response to bacterium 1.1 17 1.E-15 
 
Fundamental problems associated with research in mental disorders include lack of direct 
access to brain tissue, diagnostic criteria and patient heterogeneity, and the observational 
nature of the studies conducted. Ethical considerations prevent many experiments from being 
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conducted on human subjects and consequently human studies are largely observational. Most 
of these investigations, including those conducted in this thesis, assess patients already 
affected by the disorder. Furthermore, only peripheral tissues are easily accessible from 
patients before death, while brain tissue evaluated after death is often confounded by decades 
of psychiatric medication use, course of illness, suicide, and substance use, and sample sizes 
are often very limited. These factors limit the conclusions that can be drawn from the serum and 
PFC investigations. Future studies will be needed to confirm the results of this work and 
determine whether findings are due to pathophysiological or adaptive mechanisms in the 
disorders or a confounding/gender-associated factor. Evidence from animal and cellular models, 
neuroimaging studies, clinical trials, cognitive science, and further large-scale prospective 
and/or longitudinal peripheral and central omics studies will be needed to elucidate male and 
female pathophysiologies in these disorders. Finally, several issues with the diagnostic criteria 
used to classify patients and controls in mental disorders remain unresolved (see also Chapter 
1). Different diagnosing physicians may be a source of heterogeneity across cohorts in 
Chapters 5-6. More fundamentally, however, the use of a dimensional approach in psychiatric 
research as opposed to the categorical one used in this work may be a more fruitful line of 
inquiry into the biological underpinnings of mental disorders. 
 
7.3 Conclusions 
The work carried out in this thesis represents the first large scale molecular profiling 
investigations of serum and brain tissue to comprehensively examine sex and female hormonal 
status in controls, schizophrenia, and MDD patients. Serum concentrations of a number of 
analytes involved in endocrine, metabolic, immune, and other processes varied with sex and 
female hormonal status, many of which were previously been found altered in schizophrenia 
and MDD. These processes may play a role in changing susceptibility and other characteristics 
of mental disorders known to differ between males and females. Male-specific elevations in 
immune and inflammatory molecules were associated with MDD and schizophrenia and these 
may have implications for immune hypotheses of these disorders. Furthermore, alterations of 
the HPG axis in schizophrenia and MDD suggested a potential role for elevated testosterone in 
females with these disorders. However, an investigation of sex-dependent differences in gene 
expression in the PFC of schizophrenia patients was limited by the small female sample size 
and proved inconclusive. Nevertheless, detection of differentially expressed genes was 
improved using robust regression and array weights and these were enriched in biological 
processes involved in cell signalling, neuronal apoptosis and mitochondrial functioning, 
response to estradiol, and others. Based on results of these investigations, future biomarker 
studies should take sex and female hormonal status into account during design and analysis 
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stages to improve reproducibility of these studies in mental disorders. As a whole these findings 
represent a substantial step forward in addressing the potential role of sex in the biological 
underpinnings of schizophrenia and MDD, which may help to explain differences between 
males and females in incidence, prevalence, age of onset, and other characteristics in these 
disorders. These results may also be useful in developing diagnostic technologies and directing 
sex-specific therapies to improve symptoms for patients with these disorders. However, a 
considerable amount of further work remains to be done to understand the aetiologies and 
pathophysiologies of schizophrenia, MDD, and other mental disorders in males and females. 
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Appendix   
Table A.1. Multiplex immunoassay analytes examined in Chapters 3-5.  For each assay, inclusion in the NESDA 
and combined schizophrenia cohorts is reported, together with percentage of missing values.  
 
Analyte name Short name 
UniProtKB 
accession/ 
PubChem 
compound 
identifier C
h
ro
m
o
s
o
m
e
 
C
h
a
p
te
r 
5
 
(S
C
Z
) 
%
 m
is
s
in
g
 
(S
C
Z
) 
C
h
a
p
te
rs
 3
-4
 
(N
E
S
D
A
) 
%
 m
is
s
in
g
 
(N
E
S
D
A
) 
6Ckine 
 
O00585 9 
  
 0 
α-1-Antichymotrypsin AACT P01011 14 
  
 0 
α-1-Antitrypsin AAT P01009 14  0  0.1 
α-1-Microglobulin A1Micro P02760 9 
  
 0 
α-2-Macroglobulin A2Macro P01023 12  0  0.2 
α-Fetoprotein 
 
P02771 4  7.1 
  
β-2-Microglobulin B2M P61769 15  0  0.2 
Adiponectin 
 
Q15848 3  0  0.2 
Aldose Reductase 
 
P15121 7 
  
 0.3 
Angiogenin 
 
P03950 14 
  
 0.2 
Angiopoietin-2 ANG-2 O15123 8  0.3  0.1 
Angiotensin-Converting Enzyme ACE P12821 17  0  0 
Angiotensinogen 
 
P01019 1  3.9  0.1 
Apolipoprotein A-I Apo A-I P02647 11  0  0 
Apolipoprotein A-II Apo A-II P02652 1 
  
 0 
Apolipoprotein A-IV Apo A-IV P06727 11 
  
 0 
Apolipoprotein B Apo B P04114 2 
  
 0 
Apolipoprotein C-I Apo C-I P02654 19 
  
 0 
Apolipoprotein C-III Apo C-III P02656 11  0  0 
Apolipoprotein D Apo D P05090 3 
  
 7.5 
Apolipoprotein E Apo E P02649 19 
  
 0.5 
Apolipoprotein H Apo H P02749 17  0  0.2 
Apolipoprotein(a) Lp(a) P08519 6  0  0.1 
AXL Receptor Tyrosine Kinase AXL P30530 19  0  0 
B cell-activating factor BAFF Q9Y275 13 
  
 0 
B Lymphocyte Chemoattractant BLC O43927 4  15.6 
  
Brain Derived Neurotrophic Factor BDNF P23560 11  0  0.1 
Cancer Antigen 15-3 CA 15-3 P15941 1 
  
 0.1 
Cancer Antigen 19-9 CA 19-9 Q9BXJ9 4  7.8 
  
Carcinoembryonic Antigen CEA P06731 19  2.3  0.2 
Cathepsin D 
 
P07339 11 
  
 0.2 
CD40 antigen CD40 Q6P2H9 20  0.3  0.1 
CD40 Ligand CD40L P29965 X  0.3  0.4 
CD5 Antigen-like CD5L O43866 1 
  
 0.1 
Cellular Fibronectin cFib P02751 2 
  
 28.7 
Chemokine CC-4 HCC-4 O15467 17  0  0 
Chromogranin A CgA P10645 14  2.3  2.2 
Clusterin CLU P10909 8 
  
 0.1 
Collagen IV 
 
P02462 (a1), 
P08572 (a2), 
Q01955 (a3), 
P53420 (a4), 
P29400 (a5), 
Q14031 (a6) 
13/2 
/X 
   0 
Complement C3 C3 P01024 19  0  0.1 
Complement Factor H – Related Protein 1 CFHR1 Q03591 1 
  
 0 
Cortisol 
 
5754   1.3  0.2 
C-Peptide 
 
P01308 11 
  
 0.3 
C-Reactive Protein CRP P02741 1  0.3  1.3 
Creatine Kinase-MB CK-MB 
P12277, 
P06732 
14/ 
19 
 0  6.1 
Cystatin-C 
 
P01034 20 
  
 0 
Endoglin 
 
P17813 9 
  
 0 
Endostatin 
 
P39060 21 
  
 0.1 
EN-RAGE 
 
P80511 1  0  0 
Eotaxin-1 
 
P51671 17  0.6  11.6 
Eotaxin-2 
 
O00175 7 
  
 0.3 
Epidermal Growth Factor EGF P01133 4  1.6  0.3 
Epidermal Growth Factor Receptor EGFR P00533 7  0  0.1 
Epithelial-Derived Neutrophil-Activating Protein 78 ENA-78 P42830 4  0  0 
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E-Selectin 
 
P16581 1 
  
 0.1 
Factor VII 
 
P08709 13  0  0.1 
FASLG Receptor FAS P25445 10  0  4.1 
Fatty Acid-Binding Protein, adipocyte 
FABP, 
adipocyte 
P15090 8 
  
 0.1 
Ferritin FRTN 
P02794, 
P02792 
11/ 
19 
 0  2.2 
Fetuin-A 
 
P02765 3 
  
 0 
Fibulin-1C Fib1C P23142 22 
  
 0.4 
Follicle-Stimulating Hormone FSH 
P01225, 
P01215 
11/6  4.2  2.0 
Galectin-3 
 
P17931 14 
  
 0.1 
Gelsolin 
 
P06396 9 
  
 0.2 
Glucose-6-phosphate Isomerase G6PI P06744 19 
  
 0 
Glutathione S-Transferase α GSTα/GSTA P08263 6  1.6  26.1 
Granulocyte Colony-Stimulating Factor G-CSF P09919 17  5.8 
  
Growth Hormone GH P01241 17  6.8  15.5 
Growth-Regulated α protein GRO-α/GRO-A P09341 4  0  0 
Haptoglobin 
 
P00738 16  0.6  4.5 
Heparin-Binding EGF-Like Growth Factor HB-EGF Q99075 5  0 
  
Hepatocyte Growth Factor HGF P14210 7  0.3  0.3 
Hepatocyte Growth Factor receptor HGF receptor P08581 7 
  
 0 
Hepsin 
 
P05981 19 
  
 0 
Human Epidermal Growth Factor Receptor 2 HER-2 P04626 17 
  
 0 
Immunoglobulin A IgA 
 
  0  0.1 
Immunoglobulin E IgE 
 
  14.3 
  
Immunoglobulin M IgM 
 
  0  0.2 
Insulin 
 
P01308 11  1.0  20.6 
Insulin-like Growth Factor Binding Protein 1 IGFBP-1 P08833 7 
  
 1.4 
Insulin-like Growth Factor Binding Protein 2 IGFBP-2 P18065 2  0  0 
Insulin-like Growth Factor Binding Protein 3 IGFBP-3 P17936 7 
  
 0.1 
Insulin-like Growth Factor Binding Protein 4 IGFBP-4 P22692 17 
  
 0.1 
Insulin-like Growth Factor Binding Protein 5 IGFBP-5 P24593 2 
  
 0.1 
Insulin-like Growth Factor Binding Protein 6 IGFBP-6 P24592 12 
  
 0.1 
Intercellular Adhesion Molecule 1 ICAM-1 P05362 19  0  0.1 
Interferon γ Induced Protein 10 IP-10 P02778 4 
  
 0.6 
Interleukin-1 receptor antagonist IL-1ra P18510 2  1.0  1.6 
Interleukin-2 receptor α 
IL-2 receptor α/ 
IL-2RA 
P01589 10 
  
 0 
Interleukin-3 IL-3 P08700 5  6.8 
  
Interleukin-6 receptor IL-6r P08887 1 
  
 0.1 
Interleukin-6 receptor subunit β IL-6rβ/IL-6rB P40189 5 
  
 0.2 
Interleukin-7 IL-7 P13232 8  1.9 
  
Interleukin-8 IL-8 P10145 4  2.9  13.1 
Interleukin-10 IL-10 P22301 1  0 
  
Interleukin-12 Subunit p40 IL-12p40 P29460 5 
  
 3.5 
Interleukin-13 IL-13 P35225 5  2.9 
  
Interleukin-15 IL-15 P40933 4  5.2 
  
Interleukin-16 IL-16 Q14005 15  0  0.2 
Interleukin-18 IL-18 Q14116 11  0  0.7 
Interleukin-23 IL-23 Q9NPF7 12 
  
 4.8 
Kallikrein 5 
 
Q9Y337 19 
  
 0.8 
Lactoylglutathione lyase LGL Q04760 6 
  
 0.1 
Latency-Associated Peptide of Transforming Growth 
Factor β 1 
LAP TGF-b1 P01137 19 
  
 0 
Lectin-Like Oxidized LDL Receptor 1 LOX-1 P78380 12 
  
 28.7 
Leptin 
 
P41159 7  0  0.2 
Luteinizing Hormone LH 
P01229, 
P01215 
19/6  1.9  28.4 
Macrophage Colony-Stimulating Factor 1 M-CSF P09603 1 
  
 3.8 
Macrophage Derived Chemokine MDC O00626 16  0  0 
Macrophage Inflammatory Protein-1 α MIP-1α/MIP-1A P10147 17  0.3 
  
Macrophage Inflammatory Protein-1 β MIP-1β/MIP-1B P13236 17  0  0.1 
Macrophage Inflammatory Protein-3 β MIP-3β/MIP-3B Q99731 9 
  
 0 
Macrophage Migration Inhibitory Factor MIF P14174 22  0.6  0.1 
Macrophage Stimulating Protein MSP P26927 3 
  
 0.2 
Matrix Metalloproteinase-1 MMP-1 P03956 11 
  
 0.9 
Matrix Metalloproteinase-3 MMP-3 P08254 11  0  0.1 
Matrix Metalloproteinase-7 MMP-7 P09237 11 
  
 0.2 
Matrix Metalloproteinase-9 (total) MMP-9 P14780 20 
  
 0.2 
Matrix Metalloproteinase-10 MMP-10 P09238 11 
  
 0.2 
Mesothelin MSLN Q13421 16 
  
 0.1 
Monocyte Chemotactic Protein 1 MCP-1 P13500 17  0  0.3 
Monocyte Chemotactic Protein 2 MCP-2 P80075 17 
  
 0.4 
Monocyte Chemotactic Protein 4 MCP-4 Q99616 17 
  
 2.0 
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Monokine Induced by γ Interferon MIG Q07325 4 
  
 0.3 
Myeloid Progenitor Inhibitory Factor 1 MPIF-1 P55773 17 
  
 0.2 
Myeloperoxidase MPO P05164 17  0  1.7 
Myoglobin 
 
P02144 22  0  0.2 
Neuron Specific Enolase NSE P09104 12 
  
 0 
Neuronal Cell Adhesion Molecule NrCAM Q92823 7 
  
 2.0 
Neuropilin-1 
 
O14786 10 
  
 0 
Neutrophil Gelatinase Associated Lipocalin NGAL P80188 9 
  
 0 
N-terminal prohormone of brain natriuretic peptide NT proBNP P16860 1 
  
 6.3 
Osteopontin 
 
P10451 4 
  
 16.3 
Osteoprotegerin OPG O00300 8 
  
 0 
Pancreatic Polypeptide PPP P01298 17  0  0.1 
Pepsinogen I PGI O95576 11 
  
 0.2 
Phosphoserine Aminotransferase PSAT Q9Y617 9 
  
 0.1 
Plasminogen Activator Inhibitor 1 PAI-1 P05121 7  0  0.2 
Platelet-Derived Growth Factor BB PDGF-BB P01127 22  0.3  0.1 
Progesterone 
 
5994   1.3  19.9 
Prolactin PRL P01236 6  0  0 
Prostasin 
 
Q16651 16 
  
 0.1 
Prostatic Acid Phosphatase 
 
P15309 3  0 
  
Pulmonary and Activation-Regulated Chemokine PARC P55774 17  0.3  0 
Receptor for advanced glycosylation end products RAGE Q15109 6  0  0.1 
Receptor tyrosine-protein kinase erbB-3 ErbB3 P21860 12 
  
 0.1 
Resistin 
 
Q9HD89 19  0  0.1 
Serotransferrin Transferrin P02787 3 
  
 0 
Serum Amyloid P-Component SAP P02743 1  0  0.1 
Serum Glutamic Oxaloacetic Transaminase SGOT P17174 10  0 
  
Sex Hormone-Binding Globulin SHBG P04278 17  0  0.4 
Sortilin 
 
Q99523 1  0  0.1 
Stem Cell Factor SCF P21583 12  0  0.5 
Stromal cell derived factor 1 SDF-1 P48061 10 
  
 0 
Superoxide Dismutase 1, soluble SOD-1 P00441 21  0  0.8 
Tamm-Horsfall Urinary Glycoprotein THP P07911 16 
  
 0 
T-Cell-Specific Protein RANTES RANTES P13501 17  0  0.3 
Tenascin-C TN-C P24821 9  0  0.1 
Testosterone (total) 
 
6013   0.3  10.0 
Tetranectin 
 
P05452 3 
  
 0.2 
Thrombomodulin TM P07204 20 
  
 0 
Thrombopoietin 
 
P40225 3  0 
  
Thrombospondin-1 
 
P07996 15  0  0 
Thyroglobulin TG P01266 8 
  
 25.5 
Thyroid Stimulating Hormone TSH 
P01215, 
P01222 
6/1  0  0.4 
Thyroxine-Binding Globulin TBG P05543 X  0  0.2 
Tissue Inhibitor of Metalloproteinases 1 TIMP-1 P01033 X  0  0.2 
Tissue type Plasminogen activator tPA P00750 8 
  
 2.8 
TNF-Related Apoptosis-Inducing Ligand Receptor 3 TRAIL-R3 O14798 8  0  0 
Transthyretin TTR P02766 18 
  
 0 
Trefoil Factor 3 TFF3 Q07654 21 
  
 0 
Tumor necrosis factor receptor 2 TNFR2 P20333 1  0  0.2 
Tumor Necrosis Factor Receptor I TNFRI P19438 12 
  
 0 
Tumor Necrosis Factor α TNF α P01375 6  10.4 
  
Tyrosine kinase with Ig and EGF homology domains 
2 
TIE-2 Q02763 9 
  
 0.1 
Urokinase-type Plasminogen Activator uPA P00749 10 
  
 0.1 
Urokinase-type plasminogen activator receptor uPAR Q03405 19 
  
 0.6 
Vascular Cell Adhesion Molecule 1 VCAM-1 P19320 1  0  0.2 
Vascular Endothelial Growth Factor VEGF P15692 6  0  0.1 
Vascular Endothelial Growth Factor C VEGF-C P49767 4 
  
 0.1 
Vascular Endothelial Growth Factor Receptor 2 VEGFR-2 P35968 4 
  
 0 
Vascular endothelial growth factor Receptor 3 VEGFR-3 P35916 5 
  
 1.0 
Vitamin D-Binding Protein VDBP P02774 4 
  
 0.1 
Vitamin K-Dependent Protein S VKDPS P07225 3 
  
 0 
Vitronectin 
 
P04004 17 
  
 0.1 
von Willebrand Factor vWF P04275 12  0  1.1 
YKL-40 
 
P36222 1 
  
 0.2 
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